Stock Code: 688363.SH

2025

Sustainability Report

华熙生物
BLOOMAGE BIOTECH

About This Report

Report Introduction

This report is the third Sustainability Report (hereinafter referred to as "this Report") released by Bloomage Biotechnology Corporation Limited (hereinafter referred to as "Bloomage Biotech", "the Company" or "We") (SSE Stock Code: 688363). It discloses information pertinent to our sustainable development and fulfilment of social responsibilities.

Reporting Scope

This Report covers Bloomage Biotechnology Corporation Limited and its subsidiaries. Unless otherwise stated, the reporting scope is consistent with that of the Annual Report. The reporting period of this Report covers the period from January 1, 2025 to December 31, 2025. To ensure continuity, integrity and comparability, certain content extends beyond the aforementioned reporting period, with detailed explanations provided within the Report.

Basis of Compilation

This Report follows the *Guidelines No. 14 of Shanghai Stock Exchange for Self-Regulation of Listed Companies—Sustainability Report (Trial)*, with reference to the *GRI Sustainability Reporting Standards* (hereinafter referred to as the "GRI Standards") issued by the Global Sustainability Standards Board, the *IFRS S1 General Requirements for Disclosure of Sustainability-related Financial Information*, the *IFRS S2 Climate-Related Disclosures*, the United Nations Sustainable Development Goals (SDGs), the Ten Principles of the UN Global Compact (UNGC) ("the Ten Principles of the UNGC"), key topics for CDP ratings and themes assessed by EcoVadis. This Report contains a detailed index in the appendix for readers' quick reference.

Data Sources

The information presented in this Report is sourced from Bloomage Biotech's internal official documents, statistical reports, third-party surveys, and relevant public sources. Financial data are derived from the Company's Annual Report. Unless otherwise stated, all monetary amounts are denominated in Chinese Renminbi (CNY).

Board Statement

This Report has been reviewed and approved by the Board of Directors of Bloomage Biotech. The Board hereby affirms that this Report contains no falsifications or misleading statements, and takes full responsibility for the truthfulness, accuracy, and completeness of its contents.

Report Release

This Report is published in both Simplified Chinese and English. In the event of any inconsistency, the Simplified Chinese version shall prevail.

Electronic copies of this Report in both languages can be accessed on the websites of the Company and the Shanghai Stock Exchange:

https://www.bloomagebiotech.com/

http://www.sse.com.cn/

Feedback

For inquiries or feedback regarding this Report and its contents, you are welcome to contact us through the following contacts:

Office address: 33/F, Building D, Bloomage International Center, No. A6, Jianguomenwai Street, Beijing, China

E-mail address: esg@bloomagebiotech.com

About Bloomage Biotech

Bloomage Biotech (SSE Stock Code: 688363), founded in 2000, is a synthetic biology-driven biotechnology company, committed to leading the global health and beauty industry through scientific and technological innovation.

Bloomage Biotech pioneered the bio-manufacturing of hyaluronic acid, establishing a globally leading position in the production of carbohydrates and other bioactive substances. With breakthrough technologies in high-end hyaluronic acid research and development, we have become a trusted partner for numerous world-leading universities, research institutions, hospitals, and Fortune 500 companies. Guided by a vision of pure scientific exploration, we are deeply involved in cutting-edge research in glycobiology and cell biology.

Building on this foundation, we continue to deepen our research into bioactive substances closely related to human health, focusing on three key areas - extracellular matrix (ECM), intercellular communication, and intracellular health. We are accelerating the translation of the life science findings and technologies into innovative solutions for anti-aging intervention and tissue regeneration.

These breakthroughs are supported by our globally leading synthetic biology and biomanufacturing platform and its pilot-scale conversion facilities. This platform has become a key industry infrastructure, not only driving our own R&D and innovation but also providing transformation support for global research institutions and industry partners, from laboratory research to commercial application.

Currently, we offer comprehensive solutions across our four major business segments - raw materials, pharmaceuticals & medical aesthetics, skin science, and nutritional science. Our portfolio of brands includes BIOHYALUX, QuadHA, MedRepair, Bio-MESO, Agualuna, and Bloomage Health.

Upholding our corporate mission of "Let every life be alive", we integrate scientific excellence, industrial scale, and a global perspective to continuously advance the future of life sciences, bringing health and beauty to the world.

Chairwoman and General Manager's Message

2025 marks the 25th anniversary of Bloomage Biotechnology Corporation Limited ("Bloomage Biotech"). Reflecting on our development journey, we have always been convinced that corporate vitality stems from sustained scientific and technological innovation capabilities, as well as sound and forward-looking operational capabilities. Amid profound global realignments and continuous industrial transformation, our ability to advance steadily is fundamentally rooted in our unwavering commitment to the mission of "Let every life be alive". We gain insights into global trends with a global vision, while deeply rooted in the Chinese market, steadily advancing toward our goal of becoming "an endogenous growth enterprise with ESG at its core". As a participant of the United Nations Global Compact (UNGC) and a signatory to the Women's Empowerment Principles (WEPs), we actively integrate globally recognized sustainability tenets into our strategy and operations. Therefore, sustainable development serves as a vital pathway for us to align with the tides of the times and reshape our core competitiveness.

As a biotechnology and biomanufacturing enterprise driven by synthetic biotechnology, Bloomage Biotech remains committed to embedding the philosophy of sustainable development into its corporate strategy and operations. We promote technological innovation and green value creation, continuously contributing to the improved public health and quality of life. To foster the overall progress of the industry, we established an open pilot-scale platform for synthetic biology. This platform not only serves our internal innovation needs but also opens its doors to external research institutions and industry partners, providing critical infrastructure for the commercialization of research outcomes. By sharing this key industrialized infrastructure, we have provided essential support for commercializing R&D outcomes across the industry, facilitated synergistic collaboration within the industrial chain, and bolstered the continuous enhancement of China's biomanufacturing capabilities.

In 2025, our practices in the field of sustainability received widespread recognition. We were honored with 12 awards, including the "2025 Best Practice Case of Sustainable Development for Listed Companies" by the China Association for Public Companies and the "China Top 100 ESG Listed Companies" at the 19th China Listed Companies Value Forum. Furthermore, the Carbon Disclosure Project (CDP) awarded us ratings of A- for Climate Change and A for Water Security, both representing leadership-level performance. Additionally, our EcoVadis rating was elevated to the Silver Medal level.

While garnering these honors, we actively amplified our voice as an industry leader, sharing the "Bloomage Experience" with the world. I personally traveled to Geneva to attend the International Cooperation Seminar on Sustainable Brand Building, sharing insights on transforming sustainability concepts into endogenous growth drivers. Furthermore, at the 25th Anniversary Commemoration of the United Nations Global Compact, I emphasized that sustainability must be integrated throughout the entire organizational chain, from Management to frontline employees. Additionally, our executive representatives attended the 2025 China Fragrance and Cosmetics Industry Sustainable Development (ESG) Forum to

deliver keynote speeches and share our management practices. These recognitions provide positive feedback for our continued integration of ESG and business strategy, reinforcing our confidence in long-term steady growth.

Pursuing a governance system featuring compliance assurance and digital empowerment

High-quality development must be founded on a robust and effective corporate governance framework. At Bloomage Biotech, we view corporate governance as an endogenous driver for the long-term growth of corporate value. This year, we fully upgraded our ESG management system by releasing the *Sustainable Development Management Policy* and the *ESG Management System*. These documents cover key sustainability topics, defining development principles, strategic vision, and management requirements. We also established and disclosed specific targets covering carbon reduction, waste management, supplier ESG management, and compliance & business ethics. By integrating key ESG indicators into the organizational performance evaluation system, we achieved deep integration of sustainability goals with daily operations. Besides, our Beijing Headquarters and Jinan Production Base were certified to ISO 37301 Compliance Management System and accepted annual surveillance audits. Furthermore, we commissioned third-party audits for the ISO 37001 Anti-bribery Management System to ensure continuous system operation & optimization. We also conducted a systematic audit of business ethics standards covering major business areas. To better demonstrate our practices, philosophy and achievements to the public in a more transparent manner, the Sustainability section was launched as an independent module on our new official website. These achievements and actions further strengthen our confidence in aligning ESG with business strategy and supporting long-term steady growth.

Concurrently, we continuously refined the collaborative mechanism for risk control, compliance management, and internal audit. By embedding compliance requirements into the entire process of business decision-making and execution, we further solidified the institutional foundation for business ethics and standardized operations. Regarding stakeholder management, we maintained an open, transparent, and responsible attitude, engaging in continuous communication with shareholders, employees, customers, suppliers, partners, and the public to foster long-term, stable, and trust-based relationships. Furthermore, embracing the digital wave, we actively explored the application of AI technology to enhance operational efficiency and empower employees. Leveraging intelligent technology, we enhanced transparent governance and rational decision-making, thereby providing a solid governance foundation for sustainable development.

Driving innovation with synthetic biology and upholding the bottom line of product quality

Innovation is the foundation of our development, underpinned by synthetic biotechnology as our core driving force. Adhering to a vision of scientific exploration, we delve into the frontiers of glycobiology and cell biology. We focus on three key R&D directions - extracellular matrix (ECM), intercellular communication, and intracellular mechanisms. Leveraging a world-leading synthetic biology and biomanufacturing platform, we accelerate the transformation of research findings into products and systematic solutions, providing essential support for global research and industry partners in bridging the gap from laboratory to commercialization.

In 2025, we intensified R&D investment to refine an innovation system that spans basic research, pilot conversion, and industrialization, thereby driving synergistic development across raw materials, medical terminals, skin science, and nutritional science. Leveraging our globally leading pilot conversion platform for synthetic biology, we achieved technological breakthroughs in core substances such as Polydeoxyribonucleotide (PDRN), Micro-crosslinked Hyaluronic Acid (Micro-crosslinked HA), and Non-animal Chondroitin Sulfate (Non-animal CS). From the extracellular matrix (ECM) to intracellular energy metabolism and intercellular communication, we continuously optimized our R&D layout regarding aging intervention mechanisms. While pursuing innovation, we upheld the principle that quality remains paramount. This year, our hyaluronic acid raw material plant passed the on-site audit for current Good Manufacturing Practice (cGMP) from U.S. Food and Drug Administration (FDA) with "zero defects", demonstrating our enduring commitment to quality management and product responsibility.

Building upon stringent quality management, we integrated sustainable supply chain management into its product responsibility system and established the Supplier ESG Management System 1.0. We promoted the signing of the *Supplier Code of Conduct* and conducted ESG operational training. We also established carbon data collection mechanisms and distributed ESG self-assessment questionnaires (covering greenhouse gas, labor, human rights, environmental, and governance dimensions) to suppliers. With these actions, we extended sustainability requirements to the upstream supply chain. Moreover, recognized for exceptional low-carbon transition practices, we received the "Pioneer Supplier in Carbon Reduction" award from clients, marking substantive recognition of our sustainability capabilities by core customers.

Adhering to green and low-carbon operations to promote circular and symbiotic development

Facing the long-term global challenges of climate change and resource constraints, we have deeply integrated green and low-carbon philosophies into our overall corporate development. Following the first full value-chain greenhouse gas accounting and verification in accordance with international standards in 2024, we continued to advance full value-chain carbon accounting and verification in 2025. By continuously improving data quality and management capabilities, we solidified the practical foundation for comprehensive carbon management. Driven by synthetic biotechnology, we replaced traditional energy-intensive and highly polluting production methods with advanced biomanufacturing, thereby enhancing resource efficiency at the source. During the reporting period, we achieved phased progress in its low-carbon transition. In terms of carbon emissions, our key production bases have achieved a significant reduction. Regarding product carbon footprint, several key products have seen a significant decrease compared with the base year, and the effectiveness of renewable energy application has gradually become evident.

We have integrated low-carbon requirements into the early stages of product R&D and process design, steadily advancing toward the goal of "reducing total carbon emissions by 50% by 2030 compared to 2023". Regarding the circular economy, we have purchased FSC-certified eco-friendly paper to upgrade our green packaging system. Moreover, we have normalized the year-round operation of the BIOHYALUX Single-use Empty Tube Recycling Program, facilitating the efficient conversion of waste packaging into renewable resources. In 2025, we recycled a total of 21,276,700 disposable empty tubes from the BIOHYALUX brand and 3,852,700 of other brands, promoting packaging recycling and public engagement in low-carbon practices. Furthermore, we embedded sustainability into our corporate culture by organizing the first "carbon neutrality" anniversary celebration, fulfilling our green responsibilities with tangible actions to safeguard a sustainable future.

Adopting a people-centric approach to create long-term value with society

We adhere to a people-oriented development philosophy, continuously refining a diverse, equitable, and inclusive talent development system. We offer employees competitive career paths and growth opportunities while refining multi-channel promotion mechanisms to stimulate organizational vitality and innovation potential. Regarding employee well-being, we not only offer comprehensive statutory and supplementary benefits but also safeguard employee rights through digital communication channels and democratic management mechanisms, creating a supportive and resilient organizational atmosphere. Safety and health are our solemn commitments to employees. We continuously optimize our Environmental, Health, and Safety (EHS) management system, with production bases in Jinan, Tianjin, and Dongying certified to ISO 45001. In terms of social responsibility, 2025 marked the fifteenth year of our "In Cloud" public welfare campaign. Over the past fifteen years, we have prioritized both cultural heritage and industrial empowerment. Leveraging synthetic biotechnology to tap into the potential of unique resources in remote regions, we have transformed scientific achievements into high value-added industries that benefit the populace, contributing to rural revitalization with technological strength and demonstrating the warmth of corporate responsibility.

Looking ahead, we will continue to prioritize technological innovation, underpinned by synthetic biotechnology. We remain dedicated to the long-term track of aging intervention and life health, seeking certain growth amidst an uncertain environment. With firm resolve, we will drive the synergistic evolution of ESG and business strategies, striving for the mutual enhancement of corporate, social, and environmental values, and contributing lasting strength to human health and sustainable development.

01

Corporate Governance and Sustainable Development

A robust governance system serves as the cornerstone of an enterprise's enduring success. In 2025, Bloomage Biotech continued to optimize its corporate governance and sustainable development management framework, while simultaneously optimizing and upgrading its risk control, compliance, and audit systems. By strengthening compliant operations, business ethics, and information security management, we continuously refined our governance mechanisms and enhanced operational resilience. In this way, we safeguarded the fundamental rights and interests of stakeholders, and steadily increased the overall corporate value.

Corporate Governance

In strict accordance with the *Company Law of the People's Republic of China* and the latest regulatory requirements of the China Securities Regulatory Commission and the stock exchanges, Bloomage Biotech continuously improves its corporate governance system. During the year, the Company revised its *Articles of Association* in accordance with the *Guidelines for the Articles of Association of Listed Companies* and other regulations. Concurrently, it revised over 20 internal management policies, including the *Rules of Procedure for General Meeting of Shareholders*, the *Rules of Procedure for the Board of Directors*, and the *Working System for Independent Directors*. Additionally, it abolished the policies related to the Board of Supervisors in accordance with the law. It also ensured that the corporate governance structure remained consistent and effectively aligned with the latest laws and regulations.

The Company continues to deepen the fiduciary duties of directors and executives by explicitly defining conflict of interest prevention mechanisms in the *Articles of Association*. It strictly prohibits the misuse of authority for improper gains and refines regulatory requirements concerning commercial bribery, related-party transactions, and horizontal competition. Valuing the supervisory, checks-and-balances, and advisory functions of independent directors, it improves relevant provisions in the *Articles of Association* to enhance their performance capabilities and fully leverage their roles. Meanwhile, it continuously optimizes standardized information disclosure processes, elevating governance transparency and compliance standards in all aspects.

The Company has established a corporate governance structure comprising the General Meeting of Shareholders, the Board of Directors, and the senior management, characterized by clearly defined powers and responsibilities, and standardized operations. The distinct yet collaborative roles of these governing bodies provide a solid guarantee for the science-based formulation and compliant execution of major decisions, as well as the improvement of operational quality and efficiency. The General Meeting of Shareholders, composed of all shareholders, serves as the supreme authority responsible for deliberating and approving major corporate matters. The Board of Directors acts as the core governance body, exercising core functions of strategic decision-making and supervisory management. The senior management is responsible for organizing and implementing specific production and operational activities. During the year, the Company successfully completed the reform of the Board of Supervisors system. To be specific, it integrated the original functions of the Board of Supervisors into the Audit Committee, Remuneration and Assessment Committee, and Special Meetings of Independent Directors, all under the Board of Directors, thereby streamlining the governance structure and enhancing operational efficiency.

The Board of Directors has established six specialized committees - the Strategy Committee, Audit Committee, Nomination Committee, Remuneration and Assessment Committee, Environmental, Social and Governance (ESG) Committee, and Risk Management Committee. These committees assume supervisory, evaluative, and advisory functions in their respective fields, systematically supporting the Board in scientific decision-making and effective governance to ensure the standardized and efficient operation of the corporate governance mechanism.

The Company places high importance on the diversity of the Board's composition. When confirming director candidates, multiple factors are considered on all fronts, including gender, age, cultural and educational background, professional experience, skills, and knowledge structure. In 2025, the Company re-elected the new Board of Directors and appointed the senior management. In this case, the Board members selected possess profound backgrounds in diverse fields with complementary professional capabilities, facilitating more rational, comprehensive, and forward-looking decisions in an increasingly complex and volatile market environment.

Composition of the Board of Directors	Convocation of Three Types of Meetings
The Board consists of 9 directors, including 3 independent directors and 2 female directors.	Shareholders' Meetings: 2 sessions Board Meetings: 8 sessions Special Meetings of Independent Directors and Specialized Committee Meetings: 14 sessions

During the year, the Company organized multiple special training sessions for directors and senior management. The curriculum covered key areas such as independent directors' performance of duties, Audit Committee supervision, compliant disclosure of annual reports, and corporate governance practices, continuously reinforcing the compliance awareness and governance capabilities of the core management team.

Sustainable Development Management System

Sustainable Development Management Framework

Bloomage Biotech has established an ESG governance structure and management mechanism characterized by top-level leadership and tiered implementation. This mechanism empowers the Company with the capability to advance ESG management practices through multi-faceted, multi-form, and multi-departmental collaboration.

Board of Directors	The Board of Directors is responsible for overseeing and coordinating all ESG-related matters. It reviews and approves relevant recommendations from the ESG Committee, ensuring that the Company implements sustainable development principles from top to bottom while integrating ESG management into business decision-making processes
ESG Committee	An ESG Committee is established under the Board of Directors, with Independent Director Yao Yang serving as Chairman. The committee operates under the supervision of the Board of Directors. Aiming to achieve high-quality sustainable development, it is responsible for deliberating on ESG-related matters and reporting to the Board.
ESG Management Department	The ESG Management Department is responsible for the Company's ESG management, including tasks of building the ESG management system, assessing ESG risks, formulating ESG strategic plans, driving the implementation of key ESG projects, evaluating and optimizing key ESG indicators, and managing ESG communication and information disclosure. The department reports annually to the ESG Committee on work achievements and future plans, operating under its guidance and supervision.
ESG Working Group	ESG Working Groups have been established across all business lines, production bases, and functional departments, with dedicated teams and designated personnel responsible for coordinating and implementing ESG-related tasks.

In 2025, both the Board of Directors and the ESG Committee each reviewed ESG matters once, while the Chairwoman and General Managerreviewed these matters once. The review covered major achievements regarding the ESG management system, sustainability strategy, low-carbon transition planning, supplier ESG management system, ESG digital management, sustainable corporate culture development, and information disclosure. Meanwhile, the Management reviewed and approved the 2025 Annual Plan for Key ESG Projects, covering supplier ESG management, life cycle assessment (LCA) management for products, organizational capacity building for sustainable development, and ESG management system optimization.

Sustainability Strategy

In 2025, the Company upgraded its sustainable development policy framework in all fronts and officially released the *Sustainable Development Management Policy* and the *ESG Management System*. These policies cover key sustainable development topics, defining development principles, strategic visions, and management requirements to continuously enhance operational resilience and innovation capabilities, as well as the adaptability to future market changes. At the implementation level, the Company integrated key ESG indicators into the organizational performance assessment system, driving the deep alignment of sustainable development goals with daily operations. This year, the achievement rate of relevant targets reached 100%, effectively validating the effectiveness of strategic execution.

Guided by its strategy, the Company deeply practiced a high-quality development model that balances diverse interests, integrates green concepts, and enhances social welfare. We continued to focus on three core pillars - sustainable operations, sustainable society, and sustainable products. Centered on six key areas - corporate governance, ESG risk

management, sustainable innovation, environmental impact management, employee rights protection, and social empowerment & public welfare, we steadfastly implemented various management indicators and targets. The Company consistently adhered to a systematic, evidence-based, and rational approach, dedicated to strengthening operational resilience and continuously elevating the capacity for future development.

Sustainable Operations	We continuously optimize corporate governance and ESG risk management, identifying, assessing, and managing key risks. We establish a sound, transparent, and equitable corporate governance mechanism to support the Company's long-term and sound operation.
Sustainable Products	We focus on innovation to develop more efficient and environmentally friendly technologies and products. We optimize procurement, production, and other processes to reduce emissions, energy consumption, and resource consumption, achieving sustainability across the product lifecycle.
Sustainable Society	We prioritize employees' rights and interests and strive to create a diverse, inclusive, and equitable working environment. We engage in social empowerment and public welfare activities, leveraging technology and resources to create greater value for society.

Bloomage Biotech Sustainable Development Framework



As a member of the Supplier Ethical Data Exchange (Sedex), the Company benchmarks against internationally recognized responsible supply chain standards. We conduct Sedex Members Ethical Trade Audits (SMETA) or equivalent audits and improvement activities based on business needs. These activities aim to enhance the management level and transparency of the supply chain in terms of labor and human rights, health and safety, business ethics, environment and other aspects.

Sustainability Culture Development

The Company is dedicated to enhancing employees' awareness and practical capabilities regarding sustainable development. We formulated and implemented annual plans for ESG training and corporate culture, integrating ESG concepts into specialized training to ensure that employees at all levels understand and fulfill relevant requirements. To establish a long-term learning mechanism, we launched an online ESG knowledge base this year, providing all staff access to core ESG documents and creating a digital resource platform for ready access and learning. Additionally, the corporate website was revamped to feature a "Sustainability" section, showcasing our philosophy, actions, and performance in environmental, social, and governance aspects, thereby improving the efficiency and transparency of internal, external ESG information communication.

During the year, the Company organized eight special sharing sessions centered on ESG concepts, policies, industry trends, and professional skills. These sessions covered over 20 departments across the front, middle, and back offices, attracting nearly 400 participants. Concurrently, we innovated our communication approaches by launching four themed campaigns on our internal platform, "Little Horn", aligning with occasions such as World Earth Day, International Day for Biological Diversity, World Environment Day, and World Food Day. These initiatives continuously advocated green office practices and low-carbon lifestyles.

In terms of cultural practice, the Company held its first-ever carbon neutrality anniversary celebration. A total of 99 employees participated in small-sum donations to help offset the 82 tons of carbon emissions generated by the event. Additionally, we collaborated with our brand, BIOHYALUX, on an empty tube recycling program to create eco-friendly souvenirs, vividly integrating sustainability into our corporate culture and achieving a synergy between concept dissemination and practical action.

In terms of digital management, the Company successfully launched the ESG Data Management Platform 2.0 this year. This upgrade enhanced capabilities ranging from data collection, verification, and analysis to report generation on all fronts, effectively strengthening the precision of ESG management and the efficiency of decision support.

Sustainability Performance Management

In 2025, Bloomage Biotech continued to consolidate the long-term mechanism linking ESG performance to compensation, ensuring the effective extension of the sustainability strategy from top-level design to the execution level. Throughout the year, the Company integrated ESG Key Performance Indicators (KPIs) into the organizational performance assessment system. These indicators were incorporated into the annual personal performance commitments of the senior management, heads of core functional departments, and personnel in key positions, maintaining the established weight of ESG indicators in the comprehensive assessment. Assessment results were directly linked to annual performance ratings and served as a key basis for salary adjustments and bonus distribution. This clear incentive and constraint mechanism actively drives the Management to fulfill their sustainable development responsibilities.

Stakeholder Engagement and Double Materiality Assessment

Stakeholder Engagement

Bloomage Biotech places high importance on the ESG concerns of all stakeholders and listens to the opinions and suggestions of regulatory bodies, shareholders, employees, clients, partners, communities, and other parties. Through normalized communication, the Company fosters internal, external understanding and consensus, integrating key expectations into business management and strategic decision-making processes. Furthermore, it regularly discloses progress through channels such as annual reports, continuously enhancing information transparency and stakeholder trust.

Stakeholder Engagement Mechanism of Bloomage Biotech

Stakeholders	Expectations and Demands	Engagement and Response
Government and Regulatory Agencies	·Compliant operations ·Tax compliance ·Economic development ·Anti-corruption · ·Product responsibility	·Supervision and inspection ·Daily management ·Meetings and exchanges ·Public consultation
Shareholders and Investors	·Corporate governance ·Risk management ·Shareholders' rights and interests ·ESG performance ·Business ethics ·Information transparency	·General Meeting of Shareholders ·Investor exchange meeting ·Information disclosure ·Field investigations ·Teleconferencing ·Email and online engagement platforms
Employees	·Employee rights protection ·Employee compensation and benefits ·Employee training and development ·Employee safety and health	·Employee roundtables ·Staff training ·Employee satisfaction surveys ·Performance assessments
Clients and Consumers	·Product responsibility ·Excellent services ·Client Privacy Protection	·Client satisfaction surveys ·Customer service hotlines ·Social media platforms

Stakeholders	Expectations and Demands	Engagement and Response
		·Client follow-up
Suppliers and Partners	·Honorable fulfillment of contracts ·Sustainable procurement ·Green products ·Product responsibility ·Intellectual property protection	·Supplier assessments ·Supplier training ·Supplier meetings and exchanges ·Strategic cooperation
Communities	·Public welfare and charity undertakings ·Environmental protection ·Rural revitalization ·Community development	·Public welfare activities ·Community events ·Media communication ·Public consultation
Industry Associations and Chambers of Commerce	·Scientific and technological innovation ·Industry development ·Product responsibility	·Industry exchanges ·Formulation of industry standards ·Field visits
Media	·Product responsibility ·ESG performance ·Response to climate change ·Business performance	·Press conference ·Social media platforms ·Public opinion monitoring ·Field interviews
Universities and Research Institutes	·Scientific research innovation ·Talent development	·University-enterprise cooperation ·Academic research ·Technology cooperation

Double Materiality Assessment

In 2025, Bloomage Biotech conducted a double materiality assessment in accordance with the *Guidelines No. 14 of Shanghai Stock Exchange for Self-Regulation of Listed Companies—Sustainability Report (Trial)* (hereinafter referred to as the "Guidelines"), relevant international standards, and mainstream information disclosure frameworks. The specific assessment steps are as follows:

Assessment Process of Double Materiality Issues

Step 1	Identification of Material Issues	Bloomage Biotech referenced international standards and disclosure frameworks, capital market rating indicators, peer performance, national policies, and its business development. As a result, 24 sustainable development issues were identified, which formed a repository for material issues.
Step 2	Survey on Material Issues	**Impact Materiality:** Internal and external stakeholders were invited to assess the materiality through online questionnaires. The questionnaire survey covered 10 categories of stakeholders, including the management team, employees, government or regulatory agencies, shareholders or investors, clients or consumers, suppliers or partners, universities or research institutions, industry associations or chambers of commerce, the public, and sustainable development industry experts.
		Financial Materiality: Interviews were conducted with the management team to evaluate financial materiality of each issue from various dimensions, including impact on costs and revenues, industry context, business mode, operational features, and key concerns of investors.
Step 3	Analysis of Material Issues	**Ranking Material Issues:** Survey data and interview results were analyzed to perform a comprehensive quantitative assessment. Issues were ranked based on two dimensions: "materiality to the Company's financial performance" and "materiality to economic, social, and environmental impacts"
		Review of Material Issues: External experts provided feedback on the identified material issues and their rankings. Subsequently, the management team reviewed these findings

Based on the principles of "Double Materiality", Bloomage Biotech assessed 26 ESG issues, identifying 24 issues with impact materiality and 2 issues with financial materiality, thereby determining the key content of this Report.



Double Materiality Matrix of Bloomage Biotech

Impact Materiality		
Environmental Compliance Management Water Management Corporate Governance Compliance and Risk Management Business Ethics Intellectual Property Protection Information Security	Employee Rights and Interests Employee Development Occupational Health and Safety Responsible Marketing Customer Service Industrial Cooperation and Development Pollutant and Waste Management Supplier Management R&D Innovation	Response to Climate Change and Energy Management Product Quality
Product Environmental Impact Environmental Permits and Certifications Circular Economy Biodiversity Ethics in Technology Rural Revitalization and Social Contributions Anti-Unfair Competition Due Diligence Investigation		Medium
Unimportant	Important	Financial Materiality
Environment Issues	Social Issues	Governance Issues

Financially Material Issues

For those financially material issues identified, we have summarized their impact areas along with associated potential risks and opportunities, as well as their potential financial impacts. In accordance with the Guidelines from the Shanghai Stock Exchange, we have disclosed relevant management measures and progress within this Report.

Response to Climate Change and Energy Management	
Impact Areas	Upstream value chain; company operations; downstream value chain
Potential Risks	**Physical Risks:** • Extreme weather events (such as typhoons, rainstorms, and floods) may damage production facilities and infrastructure, and disrupt supply chains and logistics, thereby resulting in production suspension losses, asset impairment, and a decline in operating revenue. • Long-term temperature rise and climate anomalies may drive up energy demand for cooling and exacerbate water scarcity and intake difficulties, leading to increased operating costs related to energy and water resources. **Transition Risks:** • Domestic and international carbon pricing and climate regulatory policies are becoming increasingly stringent, potentially driving up carbon emission compliance costs and export-related expenses. • Clients are continuously raising the entry barriers for low-carbon products and green supply chains. If the transition to energy structure adjustment and emission reduction lags behind, the Company may face risks such as order loss, market share decline, and weakened competitiveness.
Potential Opportunities	• **Energy Security**: Optimize the energy mix and increase the utilization of renewable energy to reduce dependence on fossil fuels, thereby mitigating operational risks arising from energy price fluctuations and changes in supply policies. • **Cost Reduction and Efficiency Improvement**: Leverage process improvements and digitalized energy efficiency management to enhance energy utilization efficiency, reducing energy consumption per unit of product and energy costs. • **Revenue Growth**: Develop climate-resilient products and low-carbon raw materials to respond to green consumption trends and premium demands, cultivating new business growth drivers. • **Value Drive**: Meet customer requirements for low-carbon and green supply chains, deepen collaboration on emission reduction and green procurement, and consolidate market share while enhancing differentiated competitive advantages.
Potential Financial Impacts	**Risks**: ·Asset impairment or losses related to production suspension. ·Low-carbon technology R&D and equipment upgrades will increase capital expenditure. Procuring green power or renewable energy and adjusting the power structure may temporarily drive up energy unit prices and related operating costs, while also increasing operational expenses such as carbon management. **Opportunities**: ·Through energy efficiency improvements, process optimization, and digital management, the Company aims to reduce energy consumption and operating costs. ·Enhanced capabilities in low-carbon products and green supply chains can drive order acquisition and market expansion, promoting operating revenue growth.
More Management Content	Please refer to the "Green Operations and Climate Response" section and the ESG Key Performance Tables.

Product Quality	
Impact Areas	Company operations; downstream value chain
Potential Risks	·**Increased Compliance Costs**: With the continuous tightening of domestic and international regulatory requirements for pharmaceuticals, medical devices and cosmetics, the Company may face increased investments in product safety assessments, testing and verification, registration and filing, as well as quality system maintenance, which will in turn drive up R&D and compliance costs. ·**Recall and Compensation Risks**: Major quality incidents could trigger product recalls, returns and exchanges, compensation claims, and penalties. This would lead to inventory write-offs and losses in channels and customers, resulting in cash outflows and brand asset impairment.

Product Quality	
Potential Opportunities	·**Operating Cost Savings**: Through stability studies and the optimization of formulations and packaging technologies, the Company aims to improve logistics compatibility and warehouse turnover efficiency while ensuring product quality and safety. This reduces hidden costs such as breakage and return & exchange, thereby lowering logistics and warehousing expenditures. ·**Market Premium and Share**: Higher levels of quality stability and product experience help strengthen brand reputation and customer loyalty, enhancing market competitiveness and premium pricing capabilities. This supports entry into high-barrier channels and expansion into new markets.
Potential Financial Impacts	**Risks**: ·Increased investments in quality control, testing & verification, and compliance may drive up operation and management costs. ·Major quality incidents may lead to inventory write-offs and asset impairment, as well as non-operating expenses such as recalls, compensation, and penalties. **Opportunities**: ·Quality improvements and process/packaging optimization are expected to reduce operating costs associated with rework & repair, complaint handling, returns & exchanges, and logistics & warehousing. ·Enhanced brand and channel capabilities can drive sales growth and market expansion, promoting an increase in operating revenue.
More Management Content	Please refer to the "Innovation-Driven Development and Product Responsibility Management" section and the ESG Key Performance Tables.

Key Honors in Sustainable Development

In 2025, the Company maintained communication and collaboration with stakeholders including the government, clients, capital markets, industry associations, research institutions, and the media, jointly promoting the positive development of the industry and society.

International Commitments and Participation ·Bloomage Biotech officially joined the United Nations Global Compact (UNGC) in 2025. ·Bloomage Biotech continued participation as a global signatory of the UN Women's Empowerment Principles (WEPs).
Improvement in International Ratings ·**EcoVadis**: Awarded the Sustainability Silver Medal, with a comprehensive score ranking in the top 13% of global assessed companies, achieving a leap from Bronze to Silver Medal. ·**CDP**: The CDP Climate Change rating upgraded from B to A- and Water Security rating upgraded from A- to A, both reaching the global leadership level.
Honors Related to Sustainable Development The Company received recognition in multiple authoritative selections, garnering a total of 12 ESG and sustainability-related honors in 2025, including the following: ·Selected as the "2025 Best Practice Case of Sustainable Development for Listed Companies" by the China Association for Public Companies ·Named in the "China Top 100 ESG Listed Companies" at the 19th China Listed Companies Value Forum ·Won the 3rd Guoxin Cup · ESG Golden Bull Award

▶ Case: Bloomage Biotech Attends UNGC Annual Meeting and Shares Chinese Approach to ESG Governance

On December 2, 2025, Bloomage Biotech was invited to attend the 25th Anniversary Commemoration of the United Nations Global Compact (UNGC). At the roundtable forum themed "Beyond Social Responsibility: Driving Corporate Resilient Growth with Sustainable Leadership", Zhao Yan, Chairwoman and General Manager, shared the Company's practical experience and governance philosophy in sustainable development with global attendees. Her speech focused on topics such as ESG governance framework development, strategic integration pathways, and sustainable leadership.

Bloomage Biotech was invited to attend the UNGC's 25th Anniversary Commemoration

▶ Case: Bloomage Biotech Signs the "Creating Sustainable Brands" Vision Initiative

On September 4, 2025, Bloomage Biotech participated in the High-Level Dialogue on "Building Sustainable Business and Brands". The event was jointly organized by the United Nations Conference on Trade and Development (UNCTAD), the United Nations Forum on Sustainability Standards, and the China Association for Standardization in Geneva. As one of the first signatories, the Company officially signed the "Creating Sustainable Brands" Vision Initiative (also known as the "Geneva Vision Initiative"), further enhancing its global influence and recognition as a responsible Chinese brand.

Investor Rights Protection

Bloomage Biotech consistently upholds the principles of "authenticity, accuracy, completeness, timeliness, and fairness" in information disclosure, viewing transparent and efficient investor relations management as a crucial component of corporate governance. This year, the Company revised its *Information Disclosure Management System* and *Investor Relations Management System*, optimizing disclosure and communication standards to effectively safeguard the legitimate rights and interests of investors and other stakeholders.

To protect investors' rights to information and participation, the Company has established a multi-level, regular investor communication system and maintained frequent interactions. In 2025, we successfully held three high-quality earnings presentation meetings via online interaction on the SSE e-Interaction Platform. Additionally, through a combination of online and offline channels, we hosted nearly 100 investor research activities and conference exchanges. Key communication mechanisms include, but are not limited to the following:

- **Regular and Thematic Exchanges:** We organized annual, semi-annual, and third-quarter earnings presentation meetings to provide timely interpretation of operating results and strategic layouts.
- **One-to-Many and One-to-One Communication:** We actively participated in brokerage strategy conferences and maintained efficient communication with investment institutions and analysts through on-site research and conference calls.
- **Normalized Interactive Platforms:** We made efficient use of the SSE e-Interaction Platform, the special email address for investor relations, roadshows and other channels to respond to investor inquiries in a timely and standardized manner.

Key Performance Table for Investor Rights Protection in 2025
Total announcements released throughout the year: 109 (comprising 52 announcement texts and 57 attachments)
Earnings briefings held during the year: 3
Investor exchange activities launched (including roadshows, reverse roadshows, and strategy conference participation): Nearly 100

Compliance and Internal Control Risk Management

Bloomage Biotech consistently upholds laws and regulations, adheres to lawful operations and tax compliance, and actively fulfills its corporate citizenship responsibilities. This year, the Company improved its governance structure, sound institutional system, deepened risk prevention and control, and promoted integrity culture. By introducing the *Internal Audit System* and optimizing the *Internal Control Management System*, it further refined the professional, digital compliance management framework. Existing regulations were categorized into three major types - "compliance management system, anti-bribery management system, and comprehensive compliance and anti-bribery system", enhancing the systematic nature and applicability of the institutional framework.

During the year, the Company integrated the functions of legal affairs, risk management, audit & supervision, and compliance management, establishing the new Risk Control, Compliance, and Audit Center. Through the integration of functions, it built a risk prevention & control and compliance management system that features "comprehensive coverage, clear responsibilities, and efficient coordination". This initiative achieved resource sharing among risk control, compliance operations, and audit supervision, thereby improving the overall efficiency of the risk management system.



Compliance Management

Bloomage Biotech consistently views compliance management as a vital safeguard for steady corporate operations. In accordance with laws and regulations applicable to the places of operation and industry regulatory standards, it advances the establishment of a compliance management system, the cultivation of a compliance culture, and full-process compliance control in all aspects. This comprehensive approach prevents operational compliance risks and ensures the sustained, sound development of all business operations.

Compliance Management System

Aiming to continuously strengthen compliant operations, prevent major penalties, and empower business development, Bloomage Biotech has constructed a standardized, normative, intelligent, and efficient compliance management system. The Company upholds the philosophy of "law-abiding compliance and integrity" among all employees and continuously conducts compliance awareness activities to promote effective implementation.

In terms of institutional development, the Company has formulated and updated relevant policy documents centering on the core requirements of the compliance management system. It has also refined departmental responsibilities in line with the latest organizational structure to ensure that policies are executable and aligned with business scenarios. Furthermore, it integrated specific compliance and anti-bribery policies to form a comprehensive institutional framework, achieving synergistic alignment between these two core policy categories.

Regarding management system certification, the Company has obtained ISO 37301 Compliance Management System certification and accepts regular annual surveillance audits. Currently, the operational sites certified under this management system cover the Beijing Headquarters and the Jinan Production Base, ensuring the continuous and effective operation of our compliance management system across major operational bases.

On the foundation of refined compliance management system, we aim to continuously strengthen lawful compliance management capabilities and prevent regulatory penalty cases. We are dedicated to building daily management capabilities, translating compliance requirements into internal management & control measures and standards. Furthermore, leveraging artificial intelligence tools, we integrate management requirements with operational workflows to promote compliance in daily operations and decision-making processes.

More Efforts in Compliance Culture Development

The Company upholds the philosophy of "law-abiding compliance and integrity" among all employees and normalizes compliance training and awareness activities. We have built a compliance training matrix that covers all staff, focuses on key areas, and integrates internal and external coordination. By designing differentiated training content tailored to different positions and risk scenarios, we have continuously enhanced employees' compliance awareness and execution capabilities.

In terms of internal employee training, the Company implements precise, stratified, and categorized education. For all employees (including new hires), it launches general compliance training sessions centered on the *Compliance (Anti-Bribery) Management Regulations* and the *Employee Compliance and Anti-Bribery Handbook* to popularize compliance policies and personal codes of conduct. Notably, new employees receive training within 30 days of onboarding to strictly enforce the "entry gate", serving as the "first lesson in compliance reinforcement" of their career and solidifying their foundation in compliance cognition. For personnel in key positions in important areas such as marketing, engineering, and procurement, we conduct special risk prevention training on topics such as "advertising and publicity, contract risk control management, and common disputes in engineering and equipment procurement", with typical cases combined. This initiative aims to prevent compliance risks on the business front line and resolve practical issues.

Regarding the development of an external compliance ecosystem, the Company extends compliance management to

partners, actively conveying Bloomage Biotech's compliance values and cooperation consensus to suppliers, distributors, and other business associates. For instance, led by business departments, the Company conducts due diligence investigations on key business partners and guides them to operate in compliance with laws by signing compliance agreements or requiring compliance commitments, thereby jointly building a clean, transparent, compliant cooperation ecosystem.

To ensure the effective implementation of the compliance culture, the Company has formulated the *Implementation Measures for Compliance Training* and the *Implementation Measures for Compliance Performance*. Compliance training and examination results are incorporated into the performance assessment system of all business departments and individual employees, with clear reward and penalty measures implemented. Simultaneously, the Company has utilized multiple channels, such as the intranet, social media, and meetings, to promote the culture and organized all employees to sign the *Compliance Commitment Letter*. This year, the signing rate of employees reached 100% for the *Compliance Commitment Letter*.

In 2025, Bloomage Biotech conducted 9 special compliance training sessions, achieving a 100% training coverage rate for personnel in key positions. Throughout the year, the online Training on Code of Conduct for Employee Compliance (Anti-Bribery) remained available to build a strong ideological defense for integrity in operations among all employees. Regarding professional capability enhancement, we provided in-depth empowerment to core staff in legal affairs, audit and supervision, and business lines, improving the professional ability of key personnel to identify risks and translate compliance obligations into practice.

Key Performance
Special compliance training sessions held: 9
Training coverage rate for personnel in key positions: 100%
Signing rate of Compliance Commitment Letter by employees: 100%

Internal Control and Risk Management

Bloomage Biotech is dedicated to building a resilient internal control and risk prevention & control system to cope with the increasingly complex business environment and external challenges, ensuring the steady achievement of strategic objectives.

Internal Control and Risk Management System

In 2025, the Company publicly disclosed the *Rules of Procedure for the Risk Management Committee*, optimizing the deliberative rules to strengthen the Board of Directors' functions in the overall decision-making and supervision of major risks. In the same year, we launched an upgrade of the risk control system. While clarifying the management structure and responsibilities, we optimized communication mechanisms and appointed a Risk and Compliance Liaison in secondary business departments to effectively strengthen the implementation of various tasks. Regarding system documentation, we issued the *Internal Control Management System* and three process documents. To be specific, the three documents are the *Establishment of Internal Controls, Policies, and Procedures*, the *Execution and Monitoring of Internal Control Policies and Procedures*, and the *Processes for Reporting Internal Control and Compliance Matters*, detailing specific requirements for the execution and monitoring of internal controls.



Risk Management Structure of Bloomage Biotech

The Company continuously strengthens the collaborative operational mechanism of the "Three Lines of Defense". Each department collaborates according to its designated responsibilities to build a multi-tiered, cohesive, and mutually constrained operational mechanism, ensuring continuous monitoring and management of various risks.

First Line of Defense: Business/Operation Departments	As the first line of defense in risk management, business/operation departments are required to proactively identify, assess, control, and report risks within their scope of responsibilities during daily operations, implementing risk prevention and control measures within specific business processes.
Second Line of Defense: Risk Control and Compliance Department	As the second line of defense for risk management, the department is responsible for organizing group-wide risk management, daily monitoring, and rectification follow-ups. Its tasks include establishing risk management systems, defining risk rating criteria, and driving the digital risk management.
Third Line of Defense: Audit and Supervision Department	As the third line of defense for risk management, the department, under the supervision of the Audit Committee of the Board, conducts reviews and evaluations of the Group's risk management status, and periodically reports the review results and rectification recommendations to the Audit Committee.

Risk Identification and Assessment

The Company has established a risk identification mechanism covering the entire business process. In 2025, we led all departments in conducting regular business risk assessments and updating the *Risk Management Matrix*. During the process, we strictly followed a closed-loop process ranging from risk identification and assessment to the formulation of control measures and continuous monitoring. We focused on identifying core risk factors in key areas such as strategic target decomposition & achievement, partner management, brand reputation maintenance, customer churn, and technological iteration, laying the foundation for subsequent risk responses. This year, we held risk management activities across the entire business scope and formulated special response measures for major risk items.

To deepen the closed-loop risk management, the Company initiated a program on "Matching and Integrating Compliance Obligations and Internal Control Standards" this year. This program facilitates the translation of external compliance requirements into internal, manageable, and traceable risk control points, thereby achieving the goal of proactive risk and compliance management.

To enhance the efficiency and foresight of risk management, the Company actively advanced the development of a digital, intelligent risk control system, focusing on elevating the level of refinement and intelligence in risk management. In terms of top-level planning, we formulated a digital and intelligent risk control blueprint, promoting the structuring of business rules and the effective accumulation of risk data. We also achieved intelligent scenario applications for compliance and risk control in multiple key business areas. As to tool application, we independently developed and launched a tool for intelligent contract risk review. Utilizing AI models to automatically identify and analyze contract terms and partner qualifications, the tool can provide revision suggestions, significantly improving the efficiency of legal review and the accuracy of risk identification. Furthermore, we deployed AI Compliance Assistants in areas such as quality, regulatory affairs, and safety & compliance. These assistants enable intelligent interpretation of regulatory requirements, comparison of new and old versions, and intelligent Q&A. They provide business departments with real-time and precise compliance guidance, enhancing the proactivity and response capability of risk prevention and control.

Risk Management and Response

To address major risks, the Company established a robust risk reporting mechanism. By regularly collecting documents such as the *Quarterly Risk Monitoring Report*, *Annual Risk Management Report*, and *Risk Management Matrix*, we tracked potential risks and incidents. To enhance control efficiency, we built an automated collection platform to achieve online summary and centralized management of risk events, significantly improving the efficiency of information aggregation and traceability.

Regarding risk management, the Company established a risk early warning mechanism, identified Key Risk Indicators (KRIs) in critical business areas, and launched these indicators in the digital mechanism. We prioritized the clear visualization and management of operation-related indicators to enable effective early warnings of risks. During process control, we continuously monitored business workflows to promptly alert on potential operational risks, and proactively initiated special audits for identified high-risk areas, driving the optimization of process rules and control tools. Addressing specific risk points identified during monitoring and audits, we strictly implemented a rectification tracking mechanism. This involved not only proposing requirements for scenario-based rule refinement but also promoting the formulation or revision of corresponding management systems. In this way, these actions ensured the effective implementation of every risk control

measure and the formation of a complete management cycle comprising identification, early warning, control, and institutionalization.

In terms of risk response, each business unit organized the systematic formulation of special emergency response plans in accordance with our *Emergency Management Measures*. For major or severe emergency events, a group-wide Emergency Response Leadership Team led by General Manager was established to coordinate command efforts. This team formulated specific response plans and established corresponding reward and penalty schemes to ensure orderly emergency responses and the fulfillment of responsibilities.

Development of Risk Management Culture

In terms of development of risk management culture, the Company has established a tiered training mechanism and held special training sessions for directors, supervisors, senior management, managers at all levels, and operational execution personnel in a targeted manner. The training sessions adopted a model combining course learning with project practices, to enhance the risk control competency and practical capabilities of all employees. In 2025, the Company launched a total of 16 special training sessions on risk management, achieving a 100% coverage rate for risk management personnel and department heads.

Business Ethics

Bloomage Biotech strictly complies with the laws and regulations applicable to its places of operation, including the *Anti-Monopoly Law of the People's Republic of China*, the *Anti-Unfair Competition Law of the People's Republic of China*, and the *Anti-Money Laundering Law of the People's Republic of China*. Upholding the principle of integrity, it maintains a "zero tolerance" stance toward corruption, fraud, and other violations. This year, the Company continued to refine its anti-bribery management system, solidifying the foundation for compliant operations through improved regulations, risk controls, and the cultivation of a culture of integrity.

Anti-Bribery

To regulate the conduct of group-wide employees and business partners, the Company formulated and revised the *Anti-Bribery Management System*, the *Code of Anti-Bribery Conduct*, and the *Due Diligence Management Regulations* in accordance with requirements of the anti-bribery management system. We also issued the *Conflict of Interest Management System for Employees* to clarify behavioral guidelines regarding anti-corruption, anti-fraud, and conflict of interest management. All our employees have been required to sign the confirmation form for the *Code of Professional Ethics*, imposing corresponding penalties ranging from verbal warnings and written warnings to termination of employment for violations of relevant professional ethics regulations.

This year, the Company integrated anti-bribery management into its overall compliance system. It refined the anti-bribery responsibilities of each department based on the latest organizational structure, establishing a comprehensive institutional framework supported by "specific and general regulations". In conjunction with the integrated series of compliance management system frameworks this year, it formulated the *Management Regulations for Employee Business Conduct* and the *Employee Disciplinary Management Regulations*. These documents clarify requirements for employees regarding anti-bribery and anti-corruption across internal business, external business, and personal conduct. They also detail penalties for violations of relevant business conduct, guiding employees to build an open and transparent business environment together with the Company.

The Company has established an anti-bribery governance structure with the Board of Directors as the supreme leading body overseeing the overall picture, the General Manager as the primary person in charge, and the Chief Compliance Officer authorized to assume full responsibility. We have entrusted a third-party certification body annually to conduct an audit of the ISO 37001 Anti-Bribery Management System to ensure continuous and effective system operation. This year, we conducted one systematic review of business ethics standards, achieving 100% coverage in business audits.

The Company remains steadfast in its commitment to upholding high standards of business ethics. It prioritizes the prevention of corruption, bribery, unfair competition, conflicts of interest, and other fraudulent activities. To this end, it continuously strengthens its business ethics system, enhances its complaint and reporting mechanism, and rigorously oversees matters related to business ethics, such as integrity in operations, anti-corruption initiatives, and complaint handling. This comprehensive approach ensures that any form of corruption and unfair competition is avoided. Maintaining a "zero tolerance" stance toward all forms of corruption and violations, the Company has formulated clear, strict behavioral norms and approval procedures for high-risk areas such as product sales, recruitment, interactions with government and healthcare professionals, and third-party cooperation. By establishing "red lines" for conduct, it embeds anti-fraud requirements into daily operational processes.

Conflicts of Interest	The Company requires regular declaration of personal conflicts of interest from all employees. Background checks are conducted for new hires, focusing on conflicts of interest and bribery records. Strict restrictions apply to hiring government officials and their relatives to prevent illicit benefit transfer. In 2025, Bloomage Biotech achieved 100% coverage in employee declarations for conflict of interest.
Management of Gifts and Hospitality	The Company strictly standardizes the exchange of gifts and business hospitality in commercial activities. It prohibits the offering or acceptance of any gifts, cash, or entertainment that may compromise the impartiality of business decisions. Strict due diligence and approval procedures are implemented for charitable donations and sponsorship activities to prevent them from being used for bribery purposes.
Business Partner Management	The Company extends compliance requirements to the upstream and downstream of the value chain. It conducts anti-bribery due diligence on key third-party business partners, such as suppliers and distributors. Furthermore, compliance commitment letters contain clauses on good-faith cooperation, financial compliance, and anti-commercial bribery. These letters have been incorporated into all procurement contracts to strengthen third-party risk constraints.
Anti-Unfair Competition	The Company incorporates anti-unfair competition into its compliance management system. Through institutional development and specialized controls, it effectively mitigates risks associated with unfair competition, including false advertising, commercial disparagement, trade secret infringement, and monopolistic practices. In 2025, Bloomage Biotech had no lawsuits or major administrative penalties resulting from its own unfair competition practices, ensuring overall compliance in market practices.

Integrity Culture Development

The Company has established a normalized integrity training system to continuously enhance employees' integrity awareness with methods such as case promotion and online learning, covering all employees. We have held targeted training sessions for core management personnel and high-risk business departments such as sales and procurement, combining specific job responsibilities with practical cases. Integrity training is incorporated as a mandatory component of new employee orientation. New employees are required to sign both the *Labor Contract* and the *Anti-Bribery Compliance Commitment* upon joining, ensuring that they master basic anti-bribery requirements before assuming their posts. In 2025, the Company conducted six special inspections on integrity in operations and reviewed key processes through various audits. Additionally, two company-wide integrity awareness sessions were conducted, covering compliance requirements, management responsibilities, and risk cases. These sessions reached all core managers, totaling over 1,000 participants.

Key Performance
Number of concluded embezzlement lawsuits filed against Bloomage Biotech or its employees: 0
Number of company-wide anti-bribery risk assessments conducted: 1
Number of special anti-bribery training sessions for the management team and employees: 2
Training coverage rate for personnel in key positions: 100%
Percentage of directors receiving anti-commercial bribery and anti-corruption training: 100%
Percentage of the management team receiving anti-commercial bribery and anti-corruption training: 100%
Percentage of employees receiving anti-commercial bribery and anti-corruption training: 100%

Regular Assessment of Commercial Bribery Risks

The Company has established a rational and systematic system for assessing commercial bribery risks. Centered on key processes such as partner admission, business agreement signing, third-party management, sponsorship & donations, and expense reimbursement, it has regularly identified, analyzed, evaluated, and addressed risks to dynamically manage potential corruption and bribery risks. A comprehensive assessment has been conducted at least annually. In response to early warning signs such as regulatory policy changes, whistleblower reports, or industry risk incidents, the Company has immediately initiated targeted assessments to ensure the agility of risk control. In 2025, we conducted one corruption risk assessment, achieving 100% coverage of all operating sites.

Whistleblower Protection Mechanism

Committed to building an honest and transparent business environment, the Company has formulated the *Management Measures for Compliance Reporting, Investigation and Handling*, and established a normalized mechanism for fraud prevention, reporting and investigation. We encourage stakeholders, including employees, customers, and suppliers, to supervise and report violations such as breaches of laws and regulations, fraud, corruption, unfair competition, violations of business ethics and other violations that may impair our interests. We strictly maintain the confidentiality of whistleblower

information and prohibit any form of retaliation. Personnel with direct interest in the reported matters are required to proactively recuse themselves to avoid conflicts of interest, thereby protecting the privacy and safety of whistleblowers and their close relatives.

We have established multiple complaint and reporting channels, including a hotline, dedicated email, physical mail, and on-site reception. These channels are publicized to all employees, distributors, and suppliers via intranet announcements, contract terms, and brochures. In 2025, adhering to the principle of timely handling, the Company properly addressed all reporting responses and special investigations, achieving a 100% handling rate for reported matters.



Whistle-blowing Workflow

Reporting Channels
E-mail address: jubao@bloomagebiotech.com
Tel.: 010-85670099-1503

For verified reports that recover losses for the Company, we will grant material or honorary rewards to the whistleblowers in accordance with relevant policies, thereby upholding our compliance baseline.

Network Information Security and Data Privacy

Information security and privacy protection are the fundamental prerequisite for the Company to establish long-term trust and conduct sustainable cooperation with business partners, customers, and employees. In 2025, building upon the continuous improvement of the information security management system, we enhanced our active defense and intelligent control capabilities on all fronts by taking robust safeguard measures. This constructed a solid barrier for steady business operations and the information security of all stakeholders. During the reporting period, Bloomage Biotech had no information security incidents.

Data Security Management System

The Company strictly complies with laws and regulations such as the *Cybersecurity Law of the People's Republic of China*. This year, it officially released and implemented the new version of the *Information and Network Security Management System*. This updated the management framework in all aspects to cover the entire process of network construction, operation, and maintenance for the Company and all subsidiaries. We continuously advanced the graded protection system for network security and fulfilled security protection obligations. We also met relevant compliance requirements such as annual information security system audits and classified protection assessments.

We have established a governance structure with the Information Security Management Committee at our core, implementing the information security management system across five dimensions - organization, management, technology, training, and supervision. In terms of compliance, we were certified to the ISO 27001 Information Security Management System in 2025. Additionally, our anti-counterfeiting traceability system and the raw material portal system completed annual re-evaluations, both passing the Level 2 assessment of the National Information Security Classified Protection, thereby ensuring the security and continuity of business data.

The Company has established an information security risk management mechanism covering prevention, monitoring, and response, and systematically advances it around three pillars: risk assessment, emergency response, and full-staff supervision. Key initiatives included the following:

Risk Assessment and O&M Monitoring	The Company established a normalized risk assessment mechanism and conducted regular security reviews of network infrastructure and data transmission processes. For outsourced third-party operation and maintenance services, it strictly enforced supplier qualification reviews and signed confidentiality agreements to ensure the security and controllability of external services.
Emergency Response and Security Audit	The Company formulated detailed emergency response plans for cybersecurity incidents, with the Integrated Operation & Digital Center coordinating the handling of security events such as system vulnerabilities and cyber-attacks. Access logs for all application systems were retained for a minimum of six months to ensure traceability of operations and support audits and accountability determination.
Security Awareness Development and Closed-Loop Supervision	The Company strictly implemented an annual security training plan, continuously promoting key data security protection points among all employees. Meanwhile, it established a closed-loop supervision process. To be specific, it opened a dedicated reporting mailbox and committed to respond to reports of behaviors endangering network security within five working days while maintaining strict confidentiality. This process also included appeals and review stages to enhance the fairness and transparency of the process.

Data and Privacy Security Assurance

The Company places high importance on customer privacy protection and data compliance, strictly adhering to the requirements regarding information collection, use & retention, and individual rights stipulated in its internal *Privacy Policy*. To ensure standardized and secure data usage, it has established a unified master data standard and governance system. It has also built the Group's "Data Lakehouse Integration" architecture, and implemented the "Principle of Least Privilege Access" to establish refined control mechanisms.

Policy Standardization	The Company compiled the *Permissions and Security Operations Manual* and the *Change and Version Management Manual*. These documents cover core processes such as user management, sensitive data desensitization, code change approval, and usage guidelines for version management tools (Git/SVN).
Permission Classification	The Company implemented a strict hierarchical management system for information system permissions, classified as Top Secret, Confidential, and Secret. This ensures that users are granted only the data and functional permissions necessary to fulfill their duties. Furthermore, passwords for critical systems were stored using non-plaintext secondary encryption to strengthen identity authentication and access control.
Tool Control	The Company established the Indicator Management Center and the Data Asset Ledger System. These initiatives implement data permission control at the system control level, achieving hierarchical and classified management.

In terms of technical assurance, the Company employs multi-layered technical measures to safeguard network security in all aspects, ranging from infrastructure to application deployment:

Network Isolation and Hardening	The Company separated internal and external application deployments, with critical applications restricted to internal network access only. Physically isolated measures were applied to systems involving confidential information, and all connected terminals were required to install antivirus software. Furthermore, the Company actively reduced the network attack surface and engaged third-party service providers for network traffic monitoring services, utilizing real-time traffic analysis to precisely detect malicious activities and potential security risks.
Vulnerability and Encryption Management	Leveraging the Alibaba Cloud Security Center and internal monitoring mechanisms, the Company implemented dual control over system vulnerabilities. Encryption measures were taken for both data transmission and storage to ensure data integrity and confidentiality.
Application Development Security	When introducing technologies such as low-code platforms and Robotic Process Automation (RPA), permission controls were synchronously integrated during the design

	phase. For the cloud deployment of Business Intelligence (BI) tools, a full-process monitoring system was established covering report development, release, and permission management.

To further enhance the information security awareness of all employees and strengthen its information security management, the Company invited professional lecturers to produce an online recorded course - Network Security Training 2025 of Bloomage Biotech, enabling employees to conduct self-directed learning via the online platform. Additionally, in response to the widespread application of artificial intelligence technology, it specifically enhanced safety education within this new technological context. To be specific, it organized eight special empowerment training sessions, including AI Security and Internal Applications, focusing on elevating employees' awareness of AI security risk prevention. These sessions have ensured that data security baselines are maintained while embracing technological innovation.

Intelligent Technology Empowerment and AI Security

Bloomage Biotech adheres to a strategy that places equal emphasis on digital drive and security governance, viewing AI as a profound transformation in research and production methods. This year, we actively applied AI technologies to enhance operational efficiency and empower employees. By establishing a standardized and convenient AI service ecosystem and security norms for technology application, we ensured a balance between technological innovation and data security.

The Company has developed an ecosystem for intelligent office practices and a culture of innovation, establishing an AI service platform accessible to all employees. Adopting a "local + cloud" dual-engine model, the platform integrates dozens of the latest domestic and international large models and tools. It provides services such as intelligent data analysis and automated workflows, lowering technical barriers and enhancing cross-departmental collaboration efficiency.

▶ Case: Bloomage Biotech Holds the First "Smart Bloomage - AI Navigation" AI Innovation Competition with Feishu

To further stimulate innovation vitality among all employees, Bloomage Biotech, in partnership with Feishu, hosted the inaugural "Smart Bloomage - AI Navigation" AI Innovation Competition. The event attracted over 70 teams to develop innovative AI application solutions addressing core business pain points. Through the approach of promoting learning and application through competition, the Company sparked an internal upsurge of learning and applying AI, accelerating the overall digital transformation process.

Concurrently, Bloomage Biotech attaches great importance to the application and development of digital-intelligent innovation technologies, dedicated to reducing costs and enhancing efficiency with digital means. The Company continuously advances system upgrades, digital management of production processes, and automation transformation of production lines, consolidating the foundation for intelligent manufacturing on all fronts. On this basis, it integrates various types of software and hardware facilities to break down data barriers. In this way, it achieves the interconnection and deep integration of multiple core systems within the industrial park. In this case, key scenarios are included, such as intelligent supply chain, intelligent manufacturing, and digital integrated marketing.

Honors Related to Digital-Intelligent Innovation

Bloomage Biotech has received repeated recognition in the field of digital-intelligent innovation, garnering a total of two sustainable innovation awards in 2025:

- Four scenarios (Digital-Intelligent Lean Management, Quality Traceability & Analysis Improvement, Digital-Intelligent Supplier Management, and Human-Machine Collaborative Operation) were recognized as Shandong Provincial Excellent Intelligent Manufacturing Scenarios.
- The Smart Factory for High-end Pharmaceutical Devices and Functional Skincare Products was rated as an Advanced (Provincial-level) Smart Factory.

While expanding intelligent applications, the Company continuously strengthens data security governance. In 2025, we updated AI usage norms and data management systems, reinforced the technical protection architecture, and defined security boundaries for technology applications. A comprehensive defense system was established, covering management norms, technical protection, operational monitoring, and security culture. It serves to continuously address cybersecurity challenges and protect the information security of employees, customers, and partners.

02

Innovation-Driven Development and Product Responsibility Management

Bloomage Biotech focuses on four core pillars, "R&D, quality, product services, and supply chain". It is committed to building a full-process value creation system that spans from source innovation to end-user delivery. It also adheres to an innovative-driven development approach, leveraging technological advancement to enhance its R&D efficiency and industrialization capabilities, while promoting green and low-carbon development and digital-intelligent transformation. With responsible products and services, it contributes to the high-quality and sustainable development of the biotechnology industry.

R&D Innovation

R&D Innovation Management

R&D innovation represents the starting point of Bloomage Biotech's value creation. Through systematic innovation management, cutting-edge technological breakthroughs, sustainable R&D concepts, rigorous scientific ethics, and open industry collaboration, the Company continuously strengthens its technological barriers and drives industry advancement.

Innovation Management System

To effectively implement its innovation strategy, Bloomage Biotech has established a tiered and coordinated R&D management structure in compliance with relevant laws and regulations, including the *Law of the People's Republic of China on Promoting the Application of Scientific and Technological Advances* and the *Administrative Measures for the Safety of Biotechnology Research and Development*. By introducing internal policies such as the *Management System for Grade Evaluation of Raw Material R&D Projects* and the *Management System for Technical Review of Raw Material R&D Projects*, and by optimizing existing policies including the *Implementation Rules for the Project-Based Incentive Mechanism of the Skin Science Innovation R&D Center*, the Company ensures that its R&D design activities are conducted in a standardized, orderly, traceable and regulatable manner throughout key stages such as project initiation, development, and review. This system effectively strengthens the governance of scientific achievements and talent incentive standards, and has vigorously promoted the efficient transformation of scientific achievements as well as their commercialization and market application.



R&D Management Structure of Bloomage Biotech

With respect to incentives and research achievements management, we have established scientific standards for the evaluation of research achievements and talent rewards. During the reporting year, we revised the *Patent Incentive Measures*, and optimized the reward mechanism based on both technological innovation results and patent commercialization performance. We also encouraged team collaboration. These actions further stimulate the company-

wide innovation vitality and enthusiasm for the commercialization of research results, and promote the efficient translation of scientific achievements and their market applications.

Technology Innovation-Driven Development

During the reporting year, Bloomage Biotech focused on innovation in bioactive substances, advancing technological upgrades and the restructuring of its R&D system, with the aim of building a full-chain innovation ecosystem spanning from basic research to market application. Supported by eight major R&D platforms, we further strengthened the collaborative R&D and green manufacturing of bioactive substances. By leveraging AI technologies, we have achieved functional integration and intelligent upgrades, continuously making breakthroughs in key technologies while optimizing its patent portfolio. On this basis, we have established an integrated innovation pathway from scientific research to product commercialization. Through optimized evaluation and technology transfer mechanisms, we have accelerated the effective transformation of R&D achievements into commercial products, forming an integrated industry chain spanning bioactive materials, medical final products, skin science innovation and translational products, and nutrition science innovation and translational products. In this way, we have significantly enhanced our innovation competitiveness and industry influence.

▶ Case: Bloomage Biotech's Breakthroughs in Innovative PDRN Technology

Bloomage Biotech's invention patent for Specific-Sequence Nucleic Acid Molecules and Their Application as PDRN has been published by the China National Intellectual Property Administration. This technology overcomes the traditional limitations of animal-derived PDRN, and produces multiple confirmed PDRN molecules with defined sequences and proven efficacy, offering the cosmetics and pharmaceutical industries new active ingredients for skin care and repair. The technology provides three core advantages, "sequence controllability, safety and non-toxicity, and enhanced efficacy", expanding applications in high-end skin repair and clinical scenarios such as medical wound healing.

▶ Case: Bloomage Biotech's Next-Generation Micro-cross-linked Technology Wins the Science & Technology Innovation Award at the 3rd China Plastic Surgery Innovation and Transformation Competition

In the central region finals of the 3rd China Plastic Surgery Innovation and Transformation Competition, Bloomage Biotech won the Science & Technology Innovation Award for its project titled Application and Transformation of Next-Generation Micro-cross-linked Hyaluronic Acid Technology in Perioral Skin Anti-Aging. In response to key clinical challenges, the Company leveraged its proprietary micro-cross-linked technology to overcome the difficulties in precise anti-aging treatments, effectively translating life science research achievements into high-quality products with clinical value.

Bloomage Biotech Wins the Science & Technology Innovation Award

▶ Case: Bloomage Biotech's Pilot-Scale Platform Wins the National Five-Star Certification, Setting a Global Benchmark for Transformation

Bloomage Biotech's "Biomanufacturing Pilot-Scale Achievement Transformation Platform" stood out in the selection jointly released by the Ministry of Industry and Information Technology and the National Development and Reform Commission, becoming one of the first national-level certified biomanufacturing pilot-scale platforms in China. The platform has obtained "Five-Star" service certifications in key fields such as cosmetics, food additives, and biopharmaceuticals, fully demonstrating its leading position in the field of biomanufacturing.

Bloomage Biotech is among the only five companies to receive this honor in the country, signifying that its transformation capabilities in cosmetics, food additives, and biopharmaceuticals have reached the highest national standards. The platform's 64 flexible production lines now serve as a critical bridge between basic research and industrialization, providing support for the practical application of technology and industry collaboration.

Bloomage Biotech's Biomanufacturing Pilot-Scale Achievement Transformation Platform Is Among the First to Receive National-level Certification

▶ Case: Leading in glycobiology, Bloomage Biotech Wins the AMA Best Ingredient Award

In August 2025, Bloomage Biotech participated in the AMA 2025 Aesthetic Medicine Asia Summit & 2nd Aisa Beauty Injection Medical Aesthetics Summit in Chengdu, showcasing eight core products and providing cell-level scientific solutions that support the entire process of plastic and aesthetic medicine. Through breakthroughs in technological innovation and applied research, we received the Best Ingredient Award at the summit. This recognition highlights our core technological strengths in glycobiology and cell engineering, as well as our comprehensive operational capabilities spanning raw-material R&D, process innovation, quality management, global regulatory registration, and technical services.

▶ Case: Advancing Industry Development Models to Enable High-Quality Development in Biomanufacturing

In August 2025, Bloomage Biotech participated in the academic symposium titled the Economic and Social Value of the Hyaluronic Acid Effect. At the symposium, Zhao Yan, Chairwoman and General Manager of Bloomage Biotech, delivered a keynote presentation. Using Bloomage Biotech's development journey as a case study, she provided an in-depth analysis of the evolving development pathway of China's biomanufacturing industry. She emphasized that companies should achieve breakthroughs in manufacturing technologies through applied research and ultimately reinvest the funds from transformation into both basic and applied research, thus helping enterprises generate new technological breakthroughs in basic and applied research to achieve transformative growth.

Bloomage Biotech participated in the Academic Symposium on the Hyaluronic Acid Effect

Sustainable Innovation

Bloomage Biotech has established a multi-layered sustainable innovation system spanning ingredients, technologies, and development philosophy, integrating the green and low-carbon principle into the entire value chain from product R&D and process innovation to value delivery.

Ingredient Sustainability

In the development of raw material products, the Company consistently adheres to a source-substitution strategy and green process route. Rather than obtaining raw materials through the direct harvesting of rare plants, animals, or marine organisms, Bloomage Biotech leverages technologies such as metagenomics, metabolomics, and synthetic biology to identify functional genes from microorganisms, and further applies synthetic biology to construct cell factories, achieving the large-scale green manufacturing of functional ingredients. This approach not only addresses the difficulties in sourcing functional ingredients but also reduces its reliance on wild biological resources, and minimizes the harvesting pressure at the source, thus contributing to ecological protection.

In 2025, the Company achieved several technological breakthroughs in multiple fields by applying synthetic biology,

microbial fermentation, and gene editing technologies. For instance, it realized the large-scale production of Tricholoma matsutake mycelium, eliminating its dependence on wildlife harvesting. It became the first company in China to achieve compliant fermentation-based production of sodium chondroitin sulfate, replacing traditional animal-derived extraction. It developed high-purity recombinant collagen (Types III, IV, and VII) and other extracellular matrix (ECM) components. It realized the green, large-scale production of (S)-equol and other precisely configured bioactive compounds. At the same time, it made advances in several key technologies, including multi-targeted delivery, natural preservation, and biomimetic ECM synthesis, while establishing a proprietary intellectual property right portfolio to strengthen the foundation for new quality productive force.

In addition, the Company selected low-toxicity, harmless, and environmentally friendly reagents and materials according to a strict standard. Several of its bioactive products, including Hyaluronic Acid (HA) and Ergothioneine Pro (EGT Pro), have obtained internationally recognized green certifications, including the COSMetic Organic and Natural Standard (COSMOS) and certifications issued by the French ecological certification body Ecocert, ensuring the purity and environmentally friendly attributes of these raw materials.

Technology Sustainability

Leveraging cutting-edge technologies such as synthetic biology, the Company continuously strengthens its technical capabilities to support sustainable innovation. We focus on green manufacturing and biomanufacturing. Through R&D and improvement work such as production process optimization, process parameter adjustment, and structural modification, we improve our resource and energy utilization efficiency, and strive to meet the quality and production capacity requirements while progressively reducing pollutant generation and carbon emission intensity, thereby exploring low-carbon and sustainable technological pathways.

Efficient Microbial Manufacturing	Relying on the synthetic biology platform, the Company conducts high-throughput screening and engineering of high-yield microbial strains and promotes green microbial fermentation processes to achieve efficient and low-pollution manufacturing of key bioactive substances.
Raw Material Source Substitution	Fermentation-based production methods are adopted to replace traditional extraction from animal and plant sources, thereby reducing the Company's reliance on animal-derived materials and rare plant resources while lowering carbon emissions and wastewater pollution.
Deep Clean Production Processes	Green technologies such as membrane filtration and enzymatic hydrolysis are introduced to replace traditional high-pollution chemical treatment methods. In particular, enzymatic hydrolysis is used instead of acid hydrolysis, which significantly reduces the use of acids and alkalis, helping to establish a clean production system that converts renewable biomass into high value-added active ingredients.
Synergy between AI and high-throughput technologies	Through integrated systems such as high-throughput automated screening, enzyme transformation and evolution, and AI-based data analysis, the Company applies AI to design gene sequences and predict molecular structures, helping to accelerate the R&D cycle, improve precision, and reduce the costs of consumables.
Deepening Mechanism Research	By utilizing both in vitro and in vivo research models to analyze the signaling pathways and targets associated with the action of active substances, the Company enhances the precision of application solutions while reducing resource consumption.
Technology Platform Upgrading	The Company continues to enhance its application research platforms and refine the application scenarios of active ingredients in fields such as skincare, food, and pharmaceuticals, thereby improving the development efficiency and product quality while reducing redundant R&D investment.

▶ Case: Bloomage Biotech's Registration of Fermentation-Based Pharmaceutical-grade Sodium Chondroitin Sulfate

The raw material for sodium chondroitin sulfate independently developed by Bloomage Biotech using a fermentation-based process has successfully completed the master file registration with the Center for Medical Device Evaluation (CMDE) of the National Medical Products Administration (NMPA), making the Company the first enterprise in China to achieve compliant registration of fermentation-based sodium chondroitin sulfate production. This breakthrough marks a transformation in the resource sourcing model for sodium chondroitin sulfate production, shifting from traditional animal extraction to microbial fermentation-based manufacturing. The innovation reduces the immunogenicity risks and environmental burdens and is expected to be applied in ophthalmology, orthopedics, and medical aesthetics.

▶ Case: Bloomage Biotech's Synthetic Biology Innovation Reduces Reliance on Animal-Derived Sources

Through its subsidiary - Bloomage GAG Biotechnology Co., Ltd., Bloomage Biotech is leveraging synthetic biology to drive the transformation of heparin production from traditional animal extraction to biomanufacturing. The fully enzymatic synthesis process developed by the company has increased the anticoagulant activity of heparin to more than ten times that of animal-derived products while establishing a comprehensive non-animal-derived industry chain platform covering glycoengineering reagents, active pharmaceutical ingredients, and final products. This innovation can reduce the dependence on animal resources and promote the sustainable transformation and technological advancement of the industry.

▶ Case: Green and Intelligent Manufacturing of Rare Matsutake Active Ingredients

The Tricholoma matsutake mycelium fermentation lysate filtrate independently developed by Bloomage Biotech has successfully completed the new cosmetic ingredient registration with the National Medical Products Administration, with intended uses as a skin-protecting agent and antioxidant. This development overcomes the long-standing reliance on wild harvesting of Tricholoma matsutake, known as the "king of mushrooms". By applying advanced microbial fermentation technologies and cell lysis processes, Bloomage Biotech has successfully addressed the challenges of low yield, instability, and ecological disruption associated with the traditional sourcing methods. The innovation achieves large-scale, standardized production of this rare natural resource while protecting biodiversity and promoting the sustainable and inclusive utilization of scarce natural resources through technological advancement.

Bloomage Biotech Completes the NMPA Registration for a New Cosmetic Ingredient

Honors for Sustainable Innovation

The Company has received broad recognition through multiple authoritative innovation awards. In 2025, Bloomage Biotech received a total of four sustainable innovation awards, including:

- Recombinant Type III Collagen and Sodium Surfactin products received the Allē Award from the authoritative journal Cosmetics & Toiletries.
- The hyaluronic acid derivative technology was recognized as one of the Top Ten Technological Advances in China's Cosmetics Industry in 2025 by China Association of Fragrance Flavor and Cosmetic Industries.

Philosophy Sustainability

Through institutional guarantee and value-driven communication, the Company promotes the integration of sustainable development principles throughout the entire value chain of corporate development. From the perspective of management, it embeds sustainability requirements into its R&D and production processes. During the raw material development stage, an Environment, Health and Safety (EHS) review mechanism is incorporated to ensure that green and safety standards are controlled at the source of the technical route. At the same time, the Company has established a carbon footprint evaluation methodology for active ingredient products. By obtaining carbon footprint certifications, the Company enhances the green index of its products, and uses the evaluation results to guide scientific research and innovation, thereby systematically advancing the low-carbon product optimization.

From the perspective of consumers, the Company returns to the intrinsic value of products and provides precise and long-lasting solutions based on dermatological science. It advocates rational consumption and aims to reduce unnecessary resource consumption. At the same time, through science-based communication, it promotes the green consumption philosophy and encourages the adoption of healthy and sustainable consumption concepts.

▶ Case: White Tea Hand Care Series of Bloomage Biotech: Caring for Your Hands While Protecting the Planet

Bloomage Biotech consistently integrates sustainable development deeply into product innovation. It has successfully launched the White Tea Aromatic Hand Cream and White Tea Hand Cleanser. In terms of raw materials, the products prioritize naturally derived ingredients, with more than 80% of ingredients sourced from natural origins. White tea extract serves as the core active ingredient, while the remaining ingredients are carefully selected from plant-based oils, natural moisturizing factors, and biodegradable surfactants. This has reduced its reliance on chemically synthesized ingredients that may pose potential risks to the ecological environment and human health, embodying the principles of purity, safety, and sustainability from the source. The entire R&D and production process strictly follows the principles of green chemistry. The Company optimizes its production

processes to reduce energy consumption, adopts environmentally friendly packaging to minimize plastic usage, and ensures that production waste is properly treated, achieving environmental friendliness in the entire value chain from raw material purchasing and manufacturing to final products. Testing and validation show that the products are gentle and non-irritating to the skin, and demonstrate good biodegradability in natural environments, which can reduce the potential environmental impacts.

Science and Technology Ethics

The Company strictly upholds the ethical boundaries of scientific research and rigorously complies with applicable regulations and guidelines, including the *Ethical Review Measures for Life Science and Medical Research Involving Human Subjects*, the *Good Clinical Practice (GCP) for Drug Clinical Trials*, and the *Declaration of Helsinki*. By adhering to the 3R principles, "Replace, Reduce, and Refine", it has established the internal specification titled *Technical Guidelines for Cosmetic Consumer Usage Testing* to ensure that both internal and external testing activities are conducted in compliance with laws and regulations. From the perspective of governance structure, it has established an ethics management system with clearly defined roles and responsibilities. The R&D Management Committee is responsible for overseeing the development of technology ethics on the global R&D platform, while the Cosmetic Efficacy Evaluation Ethics Committee provides dedicated oversight of relevant evaluation procedures. Leveraging a dynamic risk assessment framework, the Company continuously evaluates and updates product safety based on the latest developments in toxicology, scientific assessment methodologies, and regulatory requirements. In 2025, the Company incurred no regulatory penalties related to violations of technology ethics standards.

Test Ethics and Clinical Alternative Approaches

Guided by the core principles of science, humanity, and responsibility, Bloomage Biotech continuously explores advanced technologies and alternative approaches in the evaluation of product safety and efficacy, aiming to reduce its reliance on both human and animal testing. The Company has successfully established and applied a series of advanced in vitro model technologies, which are widely used in safety and efficacy evaluations such as skin irritation and phototoxicity assessments. In addition, it has developed a multidimensional efficacy evaluation system to ensure product safety while continuously reducing its dependence on traditional testing methods.

The Company regards human efficacy and safety verification as a cornerstone of compliance and trust. For finished products, we collaborate with qualified clinical testing institutions to conduct rigorous human efficacy tests, ensuring that all data withstand both scientific and ethical scrutiny. During the clinical trial process, we first assess the feasibility of clinical trial exemption through methods such as comparison with equivalent products. For trials that must be conducted, we strictly implement informed consent procedures to fully protect the rights and interests of subjects and ensure the scientific rigor of the trials.

In terms of animal testing, the Company strictly complies with the *Guiding Principles for the Registration Review of Animal Testing Studies for Medical Devices*, and always prioritizes animal welfare and ethical principles. Alternative methods such as cell-based experiments are adopted first to avoid unnecessary animal testing.When animal testing is indeed required for product safety assessment, the Company conducts strict screening of partner institutions, prioritizing research organizations and medical institutions with sound animal ethics review mechanisms. Cooperation agreements clearly stipulate compliance with nationally and internationally recognized animal ethics principles and relevant regulations, so as to protect laboratory animal welfare, optimize experimental designs to reduce animal usage, and minimize animal suffering to the greatest extent.

In 2025, focusing on core functional ingredients and products such as salidroside and hyaluronic acid (HA) derivatives, the Company established an in vitro acute toxicity evaluation model based on human keratinocytes, reducing or replacing animal toxicology tests and animal cell tests to ensure animal welfare. In addition, we developed a highly biomimetic in vitro three-dimensional dermal tissue model to simulate the real skin microenvironment, enabling rapid evaluation of skin cell responses, biocompatibility and functionality of raw material or product candidates. This model has been pioneeringly applied in pharmaceutical and medical device R&D projects.

Artificial Intelligence and Information Ethics

Bloomage Biotech abides by relevant standards on artificial intelligence (AI) ethics and information ethics. In product R&D, the Company applies AI technologies in a responsible manner. In particular, when adopting generative AI solutions, active human oversight is implemented, and comprehensive evaluation and assessment are conducted on final outputs. In terms of information ethics, the Company regards data as a key asset, coordinates the requirements of information confidentiality and integrity, and ensures compliant management and control throughout the entire data lifecycle.

Collaborative Development

Bloomage Biotech actively builds an open R&D ecosystem, extensively sharing its technological expertise and industry chain resources. In 2025, by deepening industry–university–research collaboration, leading the development of high-standard industry norms, and expanding its strategic partnerships, the Company broke down industry barriers and, together with its partners, drove industry-wide innovation.

Cooperation Among Industries, Universities and Research Institutes

Deepening University-Enterprise Collaboration	·The Beijing Key Laboratory of Intelligent Carbohydrate Manufacturing and Functional Applications, jointly established by the Company and Peking University, was officially approved. As Beijing's first provincial- and ministerial-level key laboratory dedicated to precision manufacturing and applications in carbohydrate science, it fills a gap in specialized platforms within the Beijing International Center for Science and Technology Innovation. The laboratory focuses on three core research directions—carbohydrate biosynthesis, chemical synthesis, and functional applications—while actively supporting China's 15th Five-Year Plan to drive innovation in biomanufacturing technologies and industrial upgrading. ·The Company continues to deepen collaboration with universities including Jiangnan University and Southwest University. Guided by the "Three Reductions and Three Health Initiatives" concept, these partnerships advance both fundamental research and translational development of active ingredients in areas such as joint health, lipid metabolism, and gut health.
Building Academic Platforms	·Together with leading domestic research and medical institutions, the Company has initiated the establishment of the Skin Pharmacology Committee under the Chinese Pharmacological Society. This initiative aims to build a comprehensive academic platform spanning the full value chain and to address common challenges in the industry.
Research Outputs	·In 2025, the Company published multiple high-impact SCI papers in fields including functional sugars, flavonoids, and probiotics. Notably, its research team published a study on N-acetylneuraminic acid in npj Science of Food, a Nature portfolio journal. The study systematically elucidates its roles in immune regulation and gut microbiota modulation, providing robust scientific support for the Company's proprietary BLOOMNEST® product line.

▶ Case: Bloomage Biotech Co-Initiates the Establishment of the Skin Pharmacology Committee to Promote Collaboration among Industries, Universities and Research Institutes

In November 2025, at the 2025 Academic Conference on Skin Pharmacology and Medical-Engineering Translational Research, Bloomage Biotech cooperated with leading domestic research and medical institutions to initiate a proposal for establishing the Skin Pharmacology Committee under the Chinese Pharmacological Society. This initiative aims to build a comprehensive academic platform spanning the entire value chain from basic research to clinical validation. Leveraging Bloomage Biotech's research strengths in the Extracellular Matrix (ECM) and anti-aging science, the collaboration focuses on addressing common industry challenges, particularly in efficacy evaluation and delivery technologies.

Bloomage Biotech attended the 2025 Academic Conference on Skin Pharmacology and Medical-Engineering Translational Research

Standard Setting

Sodium Hyaluronate Testing Standards	·During the reporting year, the Company participated in the development of several national and industry standards for sodium hyaluronate. The industry standard developed under the Company's leadership, *Determination of Sodium Hyaluronate Content in Oral Cleaning and Care Products by High-Performance Liquid Chromatography*, successfully passed review. In addition, it actively contributed to the development of national standards including the *Determination of Sodium Hyaluronate in Food*, the *Methods for Determining the Purity and Molecular Weight of Sodium Hyaluronate*, and the *Methods for Determining the Degree of Modification and Cross-Linking of Cross-Linked Sodium Hyaluronate*, providing key methodological support for quality control of related products.
Raw Material and Product Standards	·During the reporting year, the Company led the development of group standards including the *Ectoin for Medical Device* and the *Sodium Acetylated Hyaluronate for Cosmetic Use*. It

	also participated in the formulation of several group standards, such as the *DNA Sodium as a Cosmetic Ingredient* and the *Guidelines for the Export of Collagen Raw Materials for Use in Medical Devices*. In addition, it also participated in the development of the industry standard, *Recombinant Collagen Dressings*, systematically improving the technical standard framework in these related fields.
Frontier Technology Guidelines	·During the reporting year, the Company's brand QuadHA, in collaboration with the Chinese Research Hospital Association and other institutions, released the *Expert Guidelines on Cellular-Level Anti-Aging*, providing technical leadership and normative reference for the emerging field of cellular-level anti-aging.

▶ Case: Official Release of the Group Standard - Ectoin for Medical Device Developed under the Leadership of Bloomage Biotech

Led by Bloomage Biotech and jointly drafted with multiple industry partners, the group standard - *Ectoin for Medical Device* (T/CSBM 0061-2025) was officially released and will come into effect on March 1, 2026. The establishment of this standard aims to address the current inconsistent quality issues of Ectoin (Tetrahydromethylpyrimidine Carboxylic Acid) used in medical devices, and to provide a unified industry benchmark to ensure the safety and efficacy of raw materials.

Group Standard - *Ectoin for Medical Device*

Industry Empowerment

Expanding Global Collaboration	The Company has established strategic partnerships with Xcell, LG Household & Health Care, and COSMAX NBT in Korea. With a focus on areas such as cell culture media, skin longevity, and oral anti-aging agents, they develop products and introduce technologies jointly to promote international collaborations and localized applications.
Sharing Innovative Expertise	The Company actively participates in leading international academic conferences. As a key contributor to global scientific collaboration and knowledge sharing, it continuously shares its cutting-edge R&D achievements and innovative expertise with the global scientific community. Through open and professional academic dialogues, it transforms innovation into shared scientific consensus that drives the collective advancement of the industry.

▶ Case: Bloomage Biotech's Presence at the 2025 International Hyaluronic Acid Conference

In June 2025, Bloomage Biotech participated in the 5th International Hyaluronic Acid Conference hosted by the International Society for Hyaluronan Sciences (ISHAS), where it presented a range of scientific research and innovation achievements in the field of hyaluronic acid. Professor Shi Haining, Chief Scientist of Functional Foods at Bloomage Biotech, delivered a keynote speech demonstrating that hyaluronic acid has protective effects on the joint health of physically active populations based on scientific experimental data, providing theoretical support for the emerging field of sport nutrition. In addition, Dr. Sun Xin, an applied research scientist, introduced a supramolecular hyaluronic acid-ectoin complex (HA-ECT) developed by Bloomage Biotech. Through molecular design, it can enhance the skin permeability and cellular activity, and help to alleviate skin inflammation and aging caused by external factors, offering new directions for skincare product development.

Keynote Speech Delivered by Professor Shi Haining, Chief Scientist of Functional Foods at Bloomage Biotech

▶ Case: Bloomage Biotech's Presence at the 35th IFSCC Congress with Nine High-Quality Papers

In September 2025, the 35th IFSCC Congress was successfully held at the Palais des Festivals et des Congrès de Cannes. Bloomage Biotech presented nine high-quality research papers at the congress, demonstrating the global scientific influence and competitiveness of China's beauty and cosmetics research community. At the congress, Bloomage Biotech delivered a speech on its cutting-edge research titled Ectoin in Addressing Chronic Stress under a 3D Skin Model, and shared its latest research findings, injecting new scientific momentum into the technological innovation in the cosmetics industry.

Bloomage Biotech at the 35th IFSCC Congress

Intellectual Property Protection

Bloomage Biotech integrates intellectual property (IP) management into the entire process of product operations management. By establishing clear management policies and objectives, optimizing organizational structures and resource elements, and strengthening full lifecycle IP management, the Company implements the Plan-Do-Check-Act (PDCA) cycle to build and continuously improve a standardized and effective IP management system. During the reporting year, the Company obtained certification for its intellectual property management system and upgraded the system in accordance with GB/T 29490-2023 standard.

The Company strictly complies with the latest laws and regulations. With reference to standards such as the *Requirements of Enterprise Compliance Management Systems for Intellectual Property*, it has developed and continuously refined the IP protection management policies and procedures tailored to its business development needs, and effectively implemented them in its IP management activities. It clearly defines the principles and division of responsibilities for managing various types of intellectual property rights, including patents, trademarks, copyrights, and trade secrets, and regulates the processes of IP application and registration, utilization, management, transfer, and protection. In addition, IP management documentation is managed in a scientific and well-organized manner.

Strengthening the Evaluation Mechanism before Patent Application	·The Company formulates the patent portfolio strategies, defines clear portfolio objectives and principles, and designs differentiated filing approaches according to different technical solutions.
Enhancing Trademark and Brand Development	·The Company adheres to the principle of "trademarks precede market entry". To be specific, it conducts comprehensive searches and analyses prior to product launches, and completes trademark registrations for multiple classes in different regions to build a trademark portfolio covering key global markets. At the same time,

	it strengthens its routine monitoring of the external use of the "Bloomage Biotech" brand. It has also established supporting internal audit specifications to ensure the lawful and compliant use of brand marks.
Advancing Digital Management Upgrades	·The Company further optimizes its intellectual property data system, and enhances its capabilities for rapid data retrieval, multi-dimensional analysis, and real-time monitoring of critical nodes. Digital tools are leveraged to replace the repetitive manual work, significantly improving its operational efficiency.
Expanding External Collaboration and Exchange	·The Company actively broadens its external communication and collaboration channels and proactively participates in industry standard development and legislative research. It has participated in activities such as the revision of the *Guidelines for the Cultivation of High-Value Patents* organized by Shandong Provincial National Intellectual Property Protection Center, and legislative research for the *Regulations of Jinan Municipality on the Protection and Promotion of Intellectual Property Rights* led by Jinan Municipal Coordination Task Force for Quality City Development, thereby contributing to the standardized development of the intellectual property sector.

The Company has established a mechanism for resolving intellectual property disputes and formed a dedicated emergency response team comprising IP professionals, legal personnel, external attorneys, and technical experts. In case of an intellectual property dispute, the team will conduct investigations, obtain evidence for infringement cases, and take differentiated response measures. In 2025, the Company was not subject to any penalties or liabilities arising from infringement of third-party intellectual property rights, nor were there any material IP infringement litigation cases.

In terms of capability development, the Company's IP team maintains a biweekly knowledge-sharing mechanism and delivers annual IP training programs. During the reporting year, a total of seven specialized training sessions covering patents, trademarks, and copyrights were conducted for business units, with 310 participants in total. These sessions effectively enhanced employees' IP awareness and practical competencies.

Quality Management

We define quality management as a double materiality issue: it is not only a core focus of the company's sustainable development, but also has a material impact on the company's financial performance. The Company strictly adheres to national laws, regulations, and technical guidelines, including the *Pharmacopoeia of the People's Republic of China*, the *Guidelines for Self-inspection Verification of Medical Device Registration*, and the *Technical Guidelines for Cleaning Validation*. It continuously implements and refines internal regulatory documents such as the *Quality, Food Safety and HACCP Management Manual* and the *Product Monitoring and Measurement Control Procedure*. By establishing a clearly defined, full-process quality management system, it conducts quality and safety controls covering product design and development, R&D innovation, manufacturing, warehousing and logistics.

Governance

Bloomage Biotech has established a three-tiered quality management structure comprising the Board of Directors, Supply Chain Platform, and Quality Center, employing a vertical management model to implement quality management. The Company conducts management reviews and internal audits in accordance with system requirements to ensure the effective operation of its quality management system. It also cascades quality objectives down to organizational and individual performance levels, continuously monitoring and evaluating them through key quantitative indicators. This drives the implementation of quality responsibilities at every level.



The Company proactively collaborates with external regulatory bodies, certification agencies and customers to conduct various audit activities. By establishing an internal quality inspection and audit team, we routinely conduct internal system audits and product tests to ensure management compliance. In 2025, we completed a total of 55 factory inspections by clients and third-party audits organized by clients, with no major quality risks identified. For general deficiencies identified during audits, we developed corrective action plans according to requirements and completed closed-loop processing timely, ensuring effective operation and continuous improvement of the quality management system.

Quality Audit Overview

- For pharmaceutical and medical device: Brazil MDSAP, EU MDR audits, BSI unannounced inspections, etc.
- For active pharmaceutical ingredient (API): FDA audits, inspections of Ukraine State Administration of Medicines
- For personal care: ISO 22716 & GMPC audits and Watsons audits

Quality Certifications

- ISO 13485 Medical Device Quality Management System Certification
- ISO 9001 Quality Management System Certification
- ISO 22716 & GMPC (US) Certification
- EFfCI GMP (Good Manufacturing Practice Certification by the European Federation for Cosmetic Ingredients)
- HACCP System Certification
- FSSC 22000 Food Safety System Certification
- ISO 22000 Food Safety Management System Certification
- Kosher Certification
- Halal Certification

▶ Case: Bloomage Biotech Successfully Passes FDA Audit

In March 2025, the Company received a notification of compliance following the U.S. Food and Drug Administration (FDA) on-site cGMP inspection, along with the Establishment Inspection Report (EIR), confirming that the relevant facility passed the on-site GMP audit with "zero-deficiency". As one of the world's primary pharmaceutical regulatory authorities, the FDA conducts audits covering critical elements such as quality systems and data integrity. This audit was conducted in accordance with requirements including ICH Q7, covering six major systems (i.e., quality systems, facilities and equipment, materials systems, production systems, laboratory systems, packaging and labeling), with additional verification of computerized systems and electronic records integrity. The "zero-deficiency" result of this audit marks that the Company's Good Manufacturing Practice (GMP) system for pharmaceutical production meets international high-standard requirements.

Strategy

Bloomage Biotech integrates quality management into its corporate strategy, clearly defining a quality strategy centered on "Customer Centricity, Compliance Competitiveness, and Quality and Inheritance ". By benchmarking against international advanced standards, it has established a comprehensive quality management system, promotes a culture of quality across all employees, and consistently delivers products and services with market competitiveness.

Product Lifecycle Quality Assurance

Bloomage Biotech implements quality control throughout the entire product lifecycle, continuously enhancing its quality management system covering supplier quality, R&D management, production management, product recalls, and other processes. The Company conducts comprehensive product safety reviews across all segments of the industrial chain and maintains ongoing quality management and supervision of products. During the reporting year, the Company conducted 12,326 group-wide full-chain product quality and safety tests, and completed the rectification and closed-loop of problems identified after review.. In 2025, none of the Company's products, including pharmaceutical/non-pharmaceutical raw materials, cosmetics and medical devices, were found non-compliant.

Supplier Quality	·The Company adheres to internal regulations such as the *Material Classification Management Procedure* and the *Group Supplier Quality Management Procedure*, strictly conducting supplier qualification audits, controlling incoming material quality and performing regular quality assessments. For detailed information on supplier quality management, please refer to the Section "Sustainable Supply Chain Management".
R&D Quality	·**Quality Benchmarking:** During the product development process, product critical quality attributes are defined by packaging development engineers, formulation R&D engineers, professional efficacy evaluation institutions and safety testing organizations to ensure quality and safety are controlled from the very beginning of product R&D. ·**R&D Evaluation:** Through formulation design, compatibility studies, and stability testing, the

	Company conducts safety assessments and quality reviews during the R&D phase, ensuring that product development is both science-based and quality-controlled.
Production Quality	·**Source Control:** Leveraging the proprietary R&D technology platform, the Company conducts in-depth research on the efficacy mechanisms, safety, and stability of various bioactive substances. Through rigorous source screening, compositional analysis, purity test and allergenicity assessment of raw materials, we strictly enforce quality standards and production compliance at the sourcing stage, ensuring safety, efficacy, and batch stability. ·**Process Control:** An analytical testing system for product manufacturing has been established to carry out multiple key safety tests, including accelerated stability studies, packaging material compatibility research, and preservative efficacy test. Through rational risk assessment and multi-dimensional test methods, potential risks such as prohibited ingredients, excessive levels of restricted substances, and microbial contamination are identified and controlled. All test items are executed in accordance with national standards, industry regulations and international regulatory requirements, providing a solid technical foundation for product quality. ·**Process Standards:** We have enhanced process standards by introducing advanced manufacturing technologies and refined process controls to achieve high-efficiency production in sterile environments. Through rational raw material compatibility, the synergistic effects of the formulation system are optimized. Process validation is conducted to comprehensively verify equipment, production procedures and test methods for commercial manufacturing. ·**Finished Product Test:** A dual testing mechanism is implemented before finished products are launched. On one hand, a comprehensive full-specification test is conducted in accordance with product standards to ensure that product quality meets specified requirements. On the other hand, production and testing records are reviewed to confirm that all deviations have been effectively addressed and closed, with no outstanding issues remaining. Products are released only after passing this comprehensive evaluation.
Daily Operational Management	·**Routine Prevention:** Based on product positioning, order cycles, and historical demand fluctuation trends, the Company establishes rational safety stock levels, and defines replenishment triggers and upper and lower inventory limits, thereby achieving precise replenishment and optimized inventory structure. ·**Emergency Response:** An interdepartmental coordination mechanism has been established to rapidly identify urgent order requirements and conduct comprehensive assessments of the availability of finished goods, semi-finished products and packaging materials. By flexibly responding through methods such as reallocating available stock and accelerating the conversion of semi-finished products, the Company enhances its response speed. Timely post-event reviews are conducted, and the findings are simultaneously updated into the production scheduling process. ·**Continuous Monitoring**: After a product is launched, it enters a phase of active monitoring and continuous optimization, and a "Post-marketing Product Safety Monitoring System" is established.. Regular data reviews are conducted, with corresponding adjustments simultaneously made to inventory and production plans, thereby achieving a dynamic balance between supply and demand and ensuring efficient resource allocation.
Product Traceability and Recall	·**Recall System:** The Company has established and improved system documents including the *Non-conformance Control Procedure*, the *Product Recall Management Procedure* and the *Medical Device Recall Management Standard Operating Procedure.* These procedures cover the entire chain from risk identification and rapid response to traceability and disposal, effectively achieving closed-loop management of quality risks. ·**Traceability System:** A digital smart QR code traceability system has been established, recording key information at each stage, including raw material warehousing, production, packaging, and shipment. This enables point-to-point traceability from the product to its corresponding container. The traceability system covers key stages including new product introduction management, supplier traceability and management, raw and auxiliary material certification, production and manufacturing control, laboratory management and warehousing and transportation management. Annual forward and backward traceability simulation tests are conducted to ensure product traceability throughout its entire lifecycle, from production through the post-market phase. ·**After-sales System:** We participate in return/refund guarantee programs on major e-commerce platforms (e.g., Tmall, Douyin, JD.com, Xiaohongshu), while deploying dedicated customer service personnel to proactively collect consumer feedback on product quality, usage methods and skin concerns to drive continuous improvement of products and services. ·**Recall Drills:** At least one simulated recall drill is conducted annually to test and enhance the Company's recall capabilities and response speed. No actual recall incidents occurred during the reporting year.

Risk Management

Bloomage Biotech has established a routine mechanism for quality risk identification and communication. The Quality Center is responsible for identifying and analyzing quality-related risks and opportunities, formulating response measures to reduce risks to acceptable levels, and ensuring the effective operation of the quality management system. In the meantime, the Quality Center prepares risk management reports and conducts quarterly quality risk reviews and reports to achieve dynamic monitoring and rapid response. Each production base formulates and implements the *Risk and Opportunity Control Procedure* to identify, assess, control and track improvements related to quality risks and opportunities.

Based on its own business characteristics and industry research findings, the Company conducts a comprehensive identification of quality management risks and opportunities. Following this identification, it performs an integrated assessment focusing primarily on the type, level, potential impact and countermeasures for each risk and opportunity.

Risk Type	Risk Description	Risk Level	Potential Impact	Response Measures
External Factors	Regulatory requirements	High	Adjustments in regulations and compliance requirements may render products, processes or quality systems non-compliant, leading to increased rectification costs and compliance risks.	·Main functional departments reinforce collection of and evaluation on laws and regulations as required. ·All departments shall implement strict process controls in accordance with requirements.
	Customer demand	High	Changes in customer quality standards, delivery timelines and cost expectations may increase alignment difficulties, elevate delivery risks and reduce customer satisfaction.	·Reinforce communication with customers about formulating quality standards, and unify standards and test methods of the two parties. ·The Marketing Department enhances communication and interaction with customers to promptly collect and understand their needs.
	Technology	High	Lagging iteration of processes and equipment may compromise quality stability and efficiency, increase costs, and undermine product competitiveness and market responsiveness.	·Develop technology breakthrough and equipment upgrade plans based on current technical capabilities.
	Competition	Moderate	Industry competition and demand fluctuations may impact order stability and pricing, increasing operational uncertainty and complicating strategy implementation.	·Intensify efforts to explore new markets, assess trends in mature markets and promptly provide the Company with new market opportunities.
Internal Factors	Resources	Low	Inadequate operation and maintenance management of facilities and equipment may lead to downtime, deviations, or quality fluctuations, increasing production risks and operational costs.	·Strictly implement equipment upgrades and maintenance according to the Company's plans to enhance equipment stability.

Opportunity	Opportunity Type	Description	Response Measures
Opportunity	Policy	Adjustments in the regulatory environment and policy orientation may create opportunities for enhancing the Company's compliance capabilities, product registration and market	·Dynamically monitor laws, regulations and regulatory requirements while intensifying policy learning. ·All departments strictly implement relevant work in accordance with the

Opportunity	Opportunity Type	Description	Response Measures
		expansion.	Company's rules and regulations.
	Market	Intensified industry competition is driving customers to raise their requirements for quality, delivery, and compliance capabilities. This presents an opportunity for the Company to acquire new customers and secure higher-value business by upgrading its management capabilities.	·Actively expand the market to create new opportunities for development and transformation.
	Technology	Introduction of new equipment and processes can enhance technological proficiency, reduce product costs, and strengthen market competitiveness.	·Actively carry out technological research and equipment modification to continuously guarantee product quality.

Metrics and Targets

Bloomage Biotech has established the operational target of building and implementing a comprehensive quality management system that covers the "entire process, full chain, and all employees". Building upon this foundation, it sets quality management goals tailored to its own business characteristics. It also conducts regular management reviews and evaluations of established product quality and safety targets to ensure they are effectively implemented as planned and successfully achieved. This year, all its bases met all annual quality targets. The Company had no major liability accidents related to product and service safety & quality, with no significant quality risks identified.

Quality Management Targets	**Medical Devices, Pharmaceutical Raw Materials, Non-pharmaceutical Raw Materials**
	Target: A customer satisfaction rate of over 93%, and a first-pass yield rate of finished products of over 99%. **Progress:** 100% first-pass yield rate for finished products
	Cosmetics
	Target: 100% ex-factory pass rate of cosmetics 98% first inspection pass rate On-time delivery rate exceeding 99% **Progress:** 100% ex-factory pass rate of cosmetics 100% first inspection pass rate 100% on-time delivery rate

To achieve its quality management targets, Bloomage Biotech has developed key implementation pathways and specific action plans in a systematic and comprehensive way. It has established a product quality assurance system and continuously improved its quality safety and culture training content, driving its product quality and safety management level towards industry excellence benchmarks.

Quality Safety Culture and Training

The Company adheres to the principle that "quality is the lifeline of an enterprise", and continuously promotes the communication and implementation of this quality philosophy. Through initiatives such as "Quality Month," quality knowledge competitions, and QC group activities, it enhances employees' understanding and engagement with quality requirements and improvement methodologies, transforming quality awareness from regulatory requirements into daily practices. Additionally, leveraging platforms including quality culture walls, the *Quality White Paper*, and internal training, it consolidates and shares quality philosophies, standard requirements and exemplary cases to facilitate knowledge transfer.

The Company conducts annual quality safety training for all employees. During the reporting period, quality and safety culture training covered topics including quality and safety laws and regulations, and internal system audit. This training reached personnel in quality-related positions at the production bases. Through special lectures, industry exchanges, and professional skills competitions, the Company enhanced employees' quality knowledge and practical abilities, strengthening their capacity for problem analysis and resolution. Besides, it integrated quality awareness, tools and methods into business units and operational processes, fostering organization-wide participation in quality creation, quality control and continuous improvement.

▶Case: Bloomage Biotech Quality Month: Improving Quality Through Innovation

In September 2025, Bloomage Biotech organized Quality Month activities centered on the theme "Improving Quality Through Innovation". During the event, the Company officially released a quality white paper *The Ark of Life*: *Hoisting the Sails toward the Stars and Seas - Exploration, Heritage and Warmth*. This paper elaborates on core topics such as quality culture and ecological foundation, competitiveness building, quality improvement and heritage innovation, and the expression of quality insights. This fully demonstrates Bloomage Biotech's pursuit of excellence in quality and its implementation pathway. Simultaneously, Bloomage Biotech released its corporate quality declaration: "Quality is the lifeline of our enterprise, and safeguarding this lifeline is the code of conduct for every employee. Everyone is a creator and guardian of quality". This further clarifies quality responsibilities for all employees and strengthens their commitment and accountability. To implement these principles, the Company prioritized quality safety culture training with full staff participation. Through specialized lectures, case studies, on-the-job practices and other diverse activities, quality concepts were integrated into daily operations, effectively enhancing employees' focus on quality compliance and risk prevention.



Quality White Paper - *The Ark of Life: Hoisting the Sails toward the Stars and Seas - Exploration, Heritage and Warmth*

Pharmacovigilance and Adverse Reactions

Pharmacovigilance

Bloomage Biotech strictly complies with national, local, and international regulations and guidelines related to pharmacovigilance, and closely tracks changes in these regulations. This year, it continuously revised and improved internal systems and management methods, including the *Procedures for the Detection of Pharmaceutical Safety Indicators* and the *Operating Procedures for the National System for Monitoring Adverse Events of Medical Devices*, thereby establishing a pharmacovigilance system covering pharmaceuticals, medical devices and cosmetics. In 2025, it focused on revising several pharmacovigilance procedures, strengthening the construction of its adverse drug and device reaction monitoring system, and continuously enhancing its quality management and control standards.

The Company has established a comprehensive pharmaceutical safety management system structure. The Drug Safety Committee is led and coordinated by the Chairman of the Board, with members including the heads of key functional departments such as Pharmacovigilance Department, Quality Assurance Department, Production Management Department, Marketing and Sales Department, R&D and Innovation Department and Regulatory Compliance Department, ensuring that management efforts cover all aspects of the process. The Drug Safety Committee focuses on its core responsibilities, including the assessment of major safety risks, the management of significant or urgent drug safety incidents, decision-making on risk control and the monitoring of drug safety. It promotes cross-departmental collaboration to achieve efficient response and closed-loop management across all stages from R&D and production to the post-marketing phase.

Through dedicated internal audits & self-inspections for pharmacovigilance, product testing, specialized investigations, and external reviews by clients and regulatory bodies, the Company ensures data integrity and traceability throughout product lifecycles. In 2025, we completed one dedicated internal audit of our pharmacovigilance system and one company-level

GMP self-inspection for pharmaceuticals. We underwent 14 audits related to adverse event monitoring, which were conducted as part of official, client, and company-level medical device inspections. Additionally, we completed four self-inspections and external audits of our cosmetic quality system. These efforts achieved full coverage of critical processes, ensuring the compliance and safety of all product categories.

To continuously enhance the pharmacovigilance awareness and capabilities of all employees, the Company conducted diverse training sessions covering pharmacovigilance, medical device vigilance and cosmetic adverse reaction monitoring. In 2025, we organized 25 training sessions, including regulatory briefings, policy interpretation, technical courses, and practical exercises, with a total of 188 participants.

Furthermore, the Company actively collaborates with external industrial partners to build a pharmacovigilance collaboration network, empowering employee growth and the sustainable development of the enterprise. In 2025, we engaged in in-depth cooperation with clients and institutions such as the Jinan Food and Drug Inspection and Testing Center, Jinan Adverse Drug Reaction Center. Focusing on key topics including cosmetic adverse reaction monitoring, development of medical device vigilance system, and investigations into the current status of manufacturing enterprises, we conducted eight exchange and practice activities. These took various forms, such as enterprise research, joint research projects, and participation in provincial and municipal pharmacovigilance professional knowledge competitions, thereby promoting the sharing of pharmacovigilance experience and capability enhancement.

▶ Case: Promoting Learning Through Competition to Build a Robust Pharmacovigilance Knowledge System

In the 2025 Jinan City Pharmacovigilance Knowledge Competition in Shandong Province, the team representing the Pharmacovigilance Center of Bloomage Biotech was awarded the Second Prize for group. Bloomage Biotech is committed to strengthening employees' expertise in drug safety and quality standards through learning exchanges and professional competitions, leveraging contests as educational tools to deepen mastery of pharmacovigilance regulations and practices.

▶ Case: Government-Enterprise Collaboration Enhances Cosmetic Safety Monitoring

To better implement the *Regulations on Supervision and Administration of Cosmetics* and the *Measures for the Administration of Cosmetics Adverse Reaction Monitoring,* while promoting corporate safety accountability and monitoring efficacy, Jinan Food and Drug Inspection and Testing Center conducted technical guidance sessions at Bloomage Biotech on June 25, 2025. Bloomage Biotech introduced its monitoring mechanisms and operational status, focusing on key areas including monitoring system development, personnel allocation, information collection, analysis and evaluation, risk management and control, and the monitoring of new cosmetic ingredients. Drawing on regulatory requirements and practical experience, experts from the center provided guidance and recommendations on strengthening monitoring awareness, optimizing reporting procedures, improving information collection, and enhancing risk prevention and control capabilities. This exchange further deepened government-enterprise collaboration, enabling Bloomage Biotech to refine its monitoring mechanisms and enhance its risk identification and response capabilities, thereby continuously ensuring consumer safety in cosmetic use.

Adverse Reaction Management

The Company places great importance on adverse reaction management for pharmaceuticals, medical devices, and functional skincare products. It has formulated and issued procedural documents including the *Management System for Reporting and Monitoring of Adverse Drug Reaction*, the *Control Procedures for Monitoring and Re-evaluation of Adverse Event of Medical Device*s, and the *Management Regulations for Monitoring of Cosmetics Adverse Reaction*. In the meantime, by integrating these with processes such as customer complaint handling and product recalls, it ensures that measures including reporting, investigation, customer reassurance, and product disposal for adverse reaction events are carried out within the required timeframes.

In 2025, the Company reported 183 adverse drug reactions, 66 adverse events related to medical devices, and 1 adverse reaction related to cosmetics, continuously enhancing its capacity for quality and safety risk prevention and control.

Adverse Reaction Handling Process	
Information Collection and Assessment	·The Company collects adverse reaction information reported by relevant parties, including medical institutions, distributors, and individual consumers. Relevant internal departments then complete adverse reaction feedback forms for individual cases. ·A preliminary assessment is conducted on the authenticity and completeness of the collected information. For cases where information is incomplete or questionable, a follow-up procedure is initiated to further verify the details.
Report Analysis and Submission	·Based on the complete information, a report analysis is conducted, with a focus on identifying serious adverse reaction events and potential risk signals that could lead to significant social impact. ·An evaluation is performed on the causality between the adverse reaction and the product, leading to a determination of the causal relationship and risk level.
Investigation and Decision-Making	·For events assessed as posing potential quality or safety risks, reports are escalated to higher management through the designated channels. ·Relevant business units lead cross-departmental investigations to comprehensively assess potential contributing factors across product usage, storage, transportation, manufacturing, quality control, R&D design and regulatory compliance. ·The investigation findings from all departments are consolidated to assess the nature and scope of impact of the event. Subsequently, corresponding risk control measures (such as product improvement, label revision, or partial recall) are formulated and implemented, thereby achieving closed-loop management.

Chemical Ingredient Management

Bloomage Biotech has established a chemical ingredient assessment and management system covering the entire process from raw material access to finished product disclosure. This system balances compliance baselines, risk assessment, and consumer rights to know and is managed with reference to the "4M" methodology.

The Company continuously refines its chemical ingredient management framework, establishing a framework that includes compliance-based screening and quantitative risk assessment mechanisms.

Compliance-based Screening: It is ensured that raw materials and finished products of Bloomage Biotech comply with regulatory requirements, such as the *Safety and Technical Standards for Cosmetics*, and that restrictions or substitutions are implemented for ingredients with potential controversy.

Quantitative Risk Assessment: Bloomage Biotech conducts exposure level and risk assessments based on product usage scenarios. It continuously optimizes formulations to control chemical exposure at a reasonable and as-low-as-reasonably-practicable level. It also completes necessary human efficacy and safety testing before all products are launched, thereby strengthening the defense line of ingredient management.

Furthermore, the Company implements dynamic management of prohibited, restricted and high-risk ingredients, including the following:

Strict Control of Prohibited and Restricted Ingredients	·The Company conducts mandatory screening for prohibited ingredients in accordance with national laws and regulations, such as the *Safety and Technical Standards for Cosmetics*, to ensure "zero addition" of prohibited substances.
Proactive Restriction and Substitution of Controversial Ingredients	·For ingredients not legally prohibited but with potential safety risks, the Company establishes specialized assessment and substitution mechanisms, implementing restrictions proactively based on industry research advancements and health requirements. ·The Company prioritizes the use of safe, recognized green ingredients in the industry as substitutes, and reduction of the use of additives such as preservatives at optimized raw material ratios.
Chemical Phase-out Program	·A dynamic chemical phase-out list management mechanism has been established. This involves regularly reviewing the list of chemicals in use. Based on factors such as updates to the latest laws and regulations, safety risk assessment results and advancements in industry technology, it formulates a phased phase-out plan for chemicals that are high-risk, low-efficiency, or have poor environmental performance. ·During the phase-out process, supporting measures such as alternative solution validation, compliant disposal of existing chemicals and employee training are simultaneously developed to ensure the phase-out is carried out smoothly

	and orderly, without impacting production operations or product safety.

The Company provides complete labeling of product ingredients in accordance with regulatory requirements and completes the necessary filings on regulatory platforms. Consumers can access ingredient information through product packaging and relevant filing information channels, ensuring their right to know and supporting transparent consumption.

In terms of internal management, the Company has established comprehensive ingredient safety training and risk control mechanisms. Specialized ingredient safety training is regularly provided for personnel in key positions such as R&D, production, and quality control, continuously strengthening employees' understanding and execution capabilities regarding regulatory requirements, lists of prohibited and restricted substances, and the management of sensitive ingredients. This year, we successfully organized company-wide training sessions focused on core ingredients such as gradient molecular weight hyaluronic acid (INFIHA) and extracellular matrix (ECM) biomimetic technology. This promoted the management awareness of ingredient risk across all business areas. Through systematic capacity building, we make sure that all employees possess standardized capabilities in ingredient identification, assessment, and management, providing a solid foundation for product safety and compliant operations.

Customer Service and Rights Protection

Bloomage Biotech adheres to a customer-centric approach, building long-term, mutually trusting relationships through responsible marketing, reliable privacy protection, efficient complaint resolution and continuous service optimization.

Responsible Marketing

The Company places great emphasis on the scientific accuracy and regulatory compliance of its external communications. It strictly adheres to responsible marketing-related laws and regulations, including the *Law of the People's Republic of China on the Protection of Consumer Rights and Interests* and the *Advertising Law of the People's Republic of China*. To ensure compliance, it has formulated the *Code of Conduct for Advertising Release,* and the *Compliance Guidelines for Live Streaming Promotional Activities*, and has revised the *Sensitive Term Base for Cosmetics and Daily Chemical Products*. Through these institutional constraints and process controls over marketing and communication activities, it safeguards the legitimate rights and interests of consumers on all fronts. In 2025, the Company was not involved in any legal proceedings related to false marketing claims.

Enhanced Product Information Disclosure

The Company has established an open, transparent and verifiable product information disclosure system, implementing information review mechanisms and completing statutory filings to prevent misleading information. Product labels and public documentation disclose information including Chinese name, responsible entity, executive standard number, full ingredient list, net content, shelf life, usage instructions and necessary warnings. Additional required information is supplemented according to the product type. The Company concurrently discloses information through its official website and e-commerce platforms, and enhances consumers' accurate understanding of product ingredients and usage methods through explanations by R&D experts, science communication content, and customer service consultations.

In 2025, the Company initiated a product label upgrade program, adding internationally recognized certifications such as COSMOS Natural, NATRUE Certification, and Vegan label. Biodegradability test results and safety assessment data for key substances (particularly biomacromolecules and polymers) were disclosed to enhance supply chain transparency and verifiability.

Empowering Compliance Marketing

In terms of internal management, the Company has established a systematic framework for compliance marketing, implementing a standardized review process involving multiple departments. It has utilized digital tools for preliminary reviews and established mandatory review stages at key milestones such as new product launches and efficacy claims. Through external expert training and regular learning mechanisms (covering key regulatory points, compliance of sensitive terms, case study reviews, and updates of risk lists), it has continuously enhanced the compliance awareness and practical skills of personnel in key positions such as e-commerce live streaming and operations. This has established a long-term compliance management mechanism integrating four key elements - "institutional constraints, process control, training empowerment and case study inspiration."

In its external collaborative marketing efforts, the Company has established a risk control mechanism that spans the entire process: before, during, and after collaboration. During the contracting phase, the Company incorporates marketing risk clauses into its contracts and explicitly requires partner agencies and influencers to strictly adhere to all relevant laws, regulations and platform rules. In the pre-execution phase, the Company conducts rigorous background and access checks on potential collaborators, including celebrities, influencers, and streamers. It also provides compliance training to these potential partners and strictly reviews all external communication content. During live broadcasts, the Company deploys a multi-platform manual monitoring system to track live dynamics and public feedback in real time, ensuring that marketing activities remain compliant and under control. If any instances of non-compliant marketing are identified, it will promptly conduct reviews and traceability analysis and establish a record of violations. It will also optimize control processes and update training content. This continuous improvement of the long-term mechanism reinforces institutional binding force.

Client Privacy Protection

Placing great emphasis on the client privacy protection, Bloomage Biotech has constructed a multi-dimensional protection system that integrates institutional constraints, technical safeguards, process controls and third-party management. The Company requires employees to strictly manage documents and materials, prohibiting any form of unauthorized disclosure. For personnel in supervisory roles, their duty of confidentiality is explicitly defined regarding personal information and privacy accessed during the execution of their duties. They are strictly prohibited from disclosing, selling or unlawfully providing customer information. The Company conducts irregular training on trade secrets and privacy protection to reinforce employees' compliance awareness and accountability requirements.

Regarding technology and processes, the Company employs measures such as transmission encryption to ensure the confidentiality, integrity and accuracy of sensitive or critical business data during transmission, thereby reducing information leakage risks. Furthermore, it has digitized the approval process for external technical documents, standardizing the approval pathways for internal access to, borrowing of, and external provision of materials. All B2B cooperation contracts incorporate confidentiality clauses, prohibiting disclosure of customer information without informed consent. For B2C consumers (end users), the Company strictly adheres to the *Personal Information Protection Law of the People's Republic of China* and platform rules, implementing the principle of notice and consent, and processing personal information within the scope of legality and compliance. For customer data involving third-party collaboration, the Company implements access reviews and manages confidentiality agreements. For third-party system operation and maintenance services, the Company conducts qualification and credit assessments and signs confidentiality agreements to prevent risks related to external access and data leakage.

In 2025, the Company had no customer privacy breaches and received no confirmed complaints regarding infringement of customer privacy or data loss. It also had no customer complaints arising from inadequate customer data security management.

Enhancing Customer Service

Customer Feedback and Complaints

Bloomage Biotech adheres to a customer-centric approach, having established a complaint management system guided by the Group and implemented at its production bases. At the Group level, the *Guiding Document for Complaint Handling Procedures* is formulated. Each production base, based on its specific business characteristics, develops its own *Customer Complaint Operating Procedures* and corresponding management rules, ensuring unified standards and adapted implementation.

The Company has established a customer complaint handling process through its unified online OA system. This process clearly defines the responsible parties and processing standards for each stage, including complaint acceptance, classification, response, investigation, resolution, and feedback. Access and operations are restricted to authorized personnel, ensuring processing efficiency while strictly controlling information security. The Company has established a standardized closed-loop process for complaints, encompassing eight key stages. Through the system, work order routing and timeliness monitoring are achieved, ensuring clear responsibility assignment, explicit processing standards and prompt and efficient responses at each stage.



Complaint Closed-Loop Process

The Company commits to strictly maintaining the confidentiality of complainants and whistleblowers. It publicly discloses complaint and reporting channels through avenues such as its official website, product instructions and service agreements, and assesses customer awareness through customer satisfaction surveys. For different types of complaints, it initiates differentiated handling processes, forming a closed-loop mechanism with clear classification and defined pathways:

Product Quality Issues	Initiate the quality traceability and corrective and preventive action mechanism.
Adverse Reactions during Use	Transfer to the adverse reaction monitoring and support process.
Experience and Functionality Suggestions	Incorporated into the needs assessment and R&D improvement system.

For complex complaints involving multiple stages, the Company has established a cross-departmental joint meeting and joint investigation mechanism. It coordinates departments including Quality Department, R&D Department, Production Department, Regulatory Affairs Department, and Marketing Department to conduct root cause analysis. Through technical review, batch traceability, and process audits, it develops systematic improvement plans to prevent recurrence of the issue. Besides, it regularly conducts structured analysis of B2B and B2C complaint data, utilizing the results for product optimization and service standard iteration. In 2025, the Company handled 35 quality-related complaints with a 100% closed-loop resolution rate. For end user complaints, it enhanced service experience through differentiated response strategies. To be specific, it strengthened communication and emotional support for subjective experience feedback. It implemented escalated responses and transparent tracking for after-sales issues. In 2025, it received 9 end user complaints with 100% response and resolution rates.

Improvement of Customer Satisfaction

Bloomage Biotech formulated documents including the *Operating Procedures for Customer Satisfaction Survey and Analysis*, establishing service quality inspection and assessment standards linked to customer service performance, while continuously conducting customer service capability training. Through regular online and offline satisfaction surveys, we evaluate complaint mechanisms, service processes and product experience. Digital tools are leveraged to expand survey coverage and enhance data analysis capabilities, with results used for product iteration and service optimization.

The Company has built a tiered training system covering internal employees and partner institutions, focusing on compliance requirements, product knowledge, service process standards, and smart tool applications. Online courses, offline bootcamps and specialized training improve service professionalism and response efficiency.

▶ Case: Training System Upgrade Enhances Professional Capabilities in Consumer Service

In 2025, Bloomage Biotech upgraded the training system within its Business Unit for Commercialization of Skin Science Innovations, shifting focus from "knowledge transfer" to "capability building", and transitioning from one-way instruction to interactive, practice-oriented learning methodologies. Through systematic, sound communication training, the Company continuously elevates skin consultants' professional competence and communication skills, transforming them from product presenters to skin health solution providers. This expertise is embedded throughout the service cycle to further enhance consumer experience. At the same time, for key milestones such as new product launches and employee onboarding, the Company conducts regular training and specialized drills to ensure more accurate content delivery and more professional service.

▶ Case: BIOHYALUX Enhances Customer Satisfaction With a Closed-loop Service System

To continuously improve customer satisfaction and safeguard rights, BIOHYALUX (a Bloomage Biotech brand) optimized its service system. Focusing on the principles of "faster response, more accurate resolution, more reliable delivery and stronger protection", it has built a full-process service loop including care outreach, issue handling and feedback-driven improvement. The team continuously iterates service quality by upgrading the member experience, standardizing service processes, strengthening information security and implementing satisfaction surveys and "gray release" test mechanisms. Through the aforementioned initiatives, the key service indicators for the BIOHYALUX have shown improvement. To be specific, the first-contact resolution rate for consumer issues increased to 95%. The delivery time has been reduced to within 48 hours. The complaint rate has been lowered to below 0.05%. Leveraging its excellent service quality and professional capabilities, the customer service team for Bloomage Biotech's brand BIOHYALUX on the Tmall platform was honored with the "Golden Wangwang" Customer Service Team awarded by Tmall for its efficient response speed and superior service experience. The experience score of its Douyin store has consistently remained above 4.9 points.

Sustainable Supply Chain Management

A stable, responsible, and resilient supply chain is a critical foundation for ensuring the high-quality delivery of innovation achievements. Bloomage Biotech collaborates closely with upstream and downstream partners to co-create value and drive collaborative innovation, fostering a transparent, green, and efficient sustainable supply chain ecosystem.

Supplier Management and Evaluation

The Company has established a full lifecycle supplier management system covering supplier registration and admission, merit-based selection, partnership establishment, performance evaluation and management, exit management, and continuous improvement, thereby enhancing supply chain management transparency.

Supplier Admission Management

Bloomage Biotech strictly complies with applicable laws and regulations, including the *Law of the People's Republic of China on Tenders and Bids*. It has established a rigorous supplier admission mechanism for supplier selection, and conducted multi-dimensional evaluations:

Qualification Review	·For new suppliers, the Company collects and reviews their business qualifications and product documentation, and assesses their quality management systems. ·For existing suppliers, it conducts on-site, on-line, and written audits to verify the effective operation of their quality systems and regularly updates supplier qualification records.
On-site Review	·Through necessary site visits and on-site reviews, the Company verifies the authenticity of suppliers' production environments and management levels, and selects qualified suppliers for inclusion in the annual *Qualified Supplier List*.
ESG Performance	·In addition to traditional evaluation criteria, the Company also incorporates suppliers' compliance performance in areas such as environmental management, energy management, occupational health and safety, and labor rights protection into its assessment framework. ·Additional credit is granted to excellent suppliers that have obtained relevant international or national management system certifications.

Through phased evaluations and ongoing monitoring and verification, the Company ensures that the supplier admission process is standardized, consistent, and risk-controlled.



Supplier Admission Process

Dynamic Supplier Management and Evaluation

Bloomage Biotech places strong emphasis on supplier review and has established a sound supplier evaluation system. We have formulated the *Quality Management Procedures for Group Suppliers* and the *Management Procedures for Supplier Quality Review*. We have also updated the *Supplier Code of Conduct* and the *Performance Evaluation Form for Suppliers of Production Materials*. We implement a normalized supplier performance evaluation mechanism, conducting comprehensive assessments of suppliers in four key dimensions (i.e., quality, cost, delivery, and service). We classify suppliers into four categories (i.e., excellent, good, qualified, and unqualified) in terms of assessment results. Based on the evaluation results, differentiated supplier management strategies are applied:

- For suppliers with remarkable performance, the Company allocates greater procurement share and prioritizes them in new product development, fostering strategic partnerships with them.
- For underperforming suppliers, targeted performance improvement programs are initiated. Through corrective action notices and performance review meetings, suppliers are required to complete root cause analysis and implement corrective measures within a defined timeframe.

Supplier Quality Management

To continuously ensure product quality and supply chain reliability, the Company has established a systematic, full-lifecycle closed-loop supplier quality management system. In addition to defining standards and responsibilities upfront through quality agreements, it implements refined management practices in daily operations and dynamic monitoring. Clear and quantifiable supplier quality targets are established, including a minimum incoming inspection pass rate of 98% for raw and auxiliary materials and no less than 97% for packaging materials. At the same time, the Company strengthens the full-process traceability for suppliers and materials and standardizes the inspection and acceptance criteria. During incoming material inspections, particular attention is given to verifying the consistency between labels, storage conditions, and specifications, and the applicable standards and Qualified Supplier List. Where necessary, suppliers are required to issue formal declarations to ensure material traceability, stable quality, and compliance with production and regulatory requirements.

Supplier Quality Management	
Source Control	·The Company manages suppliers from the source and implements a classified management system based on the criticality of materials. ·Strict review and admission procedures are implemented for key suppliers. ·The Company defines both parties' responsibilities, technical standards, and liability for breach of contract through quality agreements, establishing a standardized foundation for ongoing collaboration.
Daily Management	·Relying on the annual quality agreements and continuous monitoring mechanisms, all incoming materials are strictly inspected and accepted. ·Upon detecting any quality deviation, an immediate investigation and feedback process is initiated, requiring suppliers to implement corrective and preventive actions. ·Cause-based audits are conducted to verify the effectiveness of corrective measures, ensuring issues are fully closed.
Quality Audits	·A Qualified Supplier List and an annual audit plan have been established. ·On-site audits and unannounced spot checks are conducted for key raw material suppliers, and batch-by-batch inspections are implemented for critical materials. ·The Company collaboratively develops corrective action plans for identified audit issues, tracks progress, and performs follow-up reviews to continuously enhance the supply chain quality management capabilities. ·In 2025, a total of 220 supplier quality audits were completed (including over 160 audits for active pharmaceutical ingredients and medical devices, and more than 60 audits for personal care materials).

Supply Chain ESG Management

The Company incorporates ESG requirements into its supply chain management. It establishes a supplier ESG management system, requiring suppliers and their subcontractors to comply with laws and regulations, social responsibility standards, and sustainability commitments. It has defined clear compliance and management requirements from the following five dimensions to ensure that all aspects of the supply chain meet the sustainable development standards:

Labor Rights and Human Rights Protection	Suppliers are required to safeguard employees' legal rights and interests, prohibit forced labor and child labor, and provide a fair and dignified working environment.
Health and Safety	Suppliers are required to establish occupational health and safety management systems, prevent workplace accidents, and protect employees' physical and mental well-being.
Environmental Responsibility	Suppliers are required to comply with environmental regulations and commit to energy conservation, emission reduction, pollution prevention, and resource recycling.
Business Ethics	Commercial bribery, corruption, and unfair competition are strictly prohibited, and suppliers are expected to operate with integrity.
Management System	Suppliers are required to establish effective internal management systems to ensure the continuous and effective implementation of the above ESG requirements.

The Company has established a supplier ESG self-assessment mechanism to dynamically identify and manage the ESG risks among key suppliers, and facilitate the capability enhancement of suppliers simultaneously. In 2025, the Company successfully achieved its annual target of conducting ESG assessments "covering over 20% of the production material suppliers". At the same time, it attached great importance to the training on ESG management awareness and capacity building for both internal procurement teams and suppliers. During the reporting year, ESG-related training was provided for internal procurement staff and external suppliers, continuously strengthening the ESG competencies of both internal and external personnel.

Supplier Performance Evaluation and Exit Management

The Company provides targeted improvement feedback to suppliers based on the annual performance evaluation results. Suppliers with critical non-conformities or rated as "Unqualified" are removed from the Qualified Supplier List. Any future cooperation with these suppliers requires re-assessment through the new supplier admission process, thus establishing a closed-loop management system that safeguards the overall supply chain quality.

In the reporting year, Bloomage Biotech had a total of 489 production suppliers, distributed by region as follows:

Key Performance
• Mainland China: 480
• Hong Kong, Macao, and Taiwan, China: 1
• Overseas countries or regions: 8

Resilience-oriented Supply Chain Risk Management

Regarding material supply stability as one of the key risks within its supply chain, the Company has established "dual sourcing" as a core strategy. By developing alternative suppliers, introducing competitive mechanisms, and advancing domestic substitution, it has reduced its single-source dependency risks and enhanced both the supply chain resilience and the cost control capabilities.

Supplier Risk Management and Mitigation Measures of Bloomage Biotech

Risk Type	Specific Risk Description	Response Measures
Material Stability Risk	Insufficient continuity and stability of material supply directly affect production and delivery schedules.	·Cross-functional Collaboration: Front-, mid-, and back-office departments jointly develop the demand forecasts and procurement plans, and establish an integrated information-sharing and early warning mechanism.
		·Classified Management of Materials: Identify critical materials, implement multi-dimensional classified management, and establish annual demand forecast and supply plans.
		·Dynamic Procurement Optimization: Increase procurement planning and monitoring frequency for new product demand, and adjust the procurement cycles based on stock levels.
		·Strategic Cooperation: Enter into strategic cooperation agreements with key primary packaging material suppliers and establish safety stock.
External Environment Risk	External uncertainties such as geopolitical conflicts and changes in cross-border trade regulations hinder the cross-border flow of materials.	Optimization of Global Supply Chain Layout: Building on existing nodes in the United States, South Korea, and Hong Kong, China, the Company plans to add new supply chain nodes in Singapore and New Zealand in 2026 to diversify regional risks.
Supply Chain Structure Risk	Dependence on a single supplier may lead to supply disruptions in the event of capacity fluctuations or operational crises of the supplier.	Dual Sourcing and Domestic Substitution: Take measures like dual sourcing and domestic alternatives for key categories such as film bags, membrane fabrics, paper boxes, and prefilled syringe plungers to mitigate supply disruption risks.
		Strategic Supplier Coordination: Establish long-term strategic partnerships with core suppliers, share demand forecasts, and promote upstream alignment in delivery mechanisms and strategies.

Delivery and Logistics Risk	Long-distance transportation and disruptions in logistics networks may delay material delivery and impact the production schedules.	Optimization of Logistics Solutions: Adopt a combined transportation model of "sea freight for raw materials + air freight for finished goods" to ensure delivery stability.
		Safety Stock and Alert Threshold Management: Set safety stock levels and alert thresholds for high-risk materials, and regularly review deviations between the inventory plans and actual levels to balance the supply security and inventory turnover efficiency.

The Company manages its stock through an ERP system and, based on a "one item, one code" approach, achieve full lifecycle data recording from production to distribution. This not only provides consumers with anti-counterfeiting and traceability services, but also enables the Company to quickly identify, trace, and control risks in the event of quality concerns or market anomalies. In conjunction with the client feedback mechanism, the Company can promptly initiate the Corrective and Preventive Action (CAPA) process, driving continuous improvement of products and services.

Sustainable Procurement Practices

Bloomage Biotech adheres to the principles of sustainable procurement. From the perspectives of low carbon, environmental protection, and circularity, the Company enhances the sustainability performance of its products through collaborative innovation and procurement optimization. It prioritizes suppliers with strong sustainability capabilities, building a sustainable supply chain from the source. It has obtained Forest Stewardship Chain of Custody (FSC-COC) certification, enabling it to procure the packaging materials certified by the Forest Stewardship Council (FSC). The certification covers all external packaging materials for its functional skincare products.

Supplier Integrity Management

To build stable and healthy partnerships, Bloomage Biotech actively safeguards the legitimate rights and interests of both itself and its partners, practices transparent procurement, and requires suppliers to sign the *Anti-Commercial Bribery Agreement* during the admission stage, maintaining zero tolerance for commercial misconduct. The Company implements a supplier negative list and a "one-vote veto" mechanism: Suppliers involved in bid rigging or collusion, violations of transparent procurement agreements, or major safety or environmental incidents with significant adverse social impact are blacklisted and permanently disqualified from cooperation. In 2025, all suppliers signed the Company's *Anti-Commercial Bribery Agreement*, achieving a 100% execution rate.

Incorporating green and low-carbon development philosophy into corporate operation management, Bloomage Biotech continuously improves its environmental management system, and drives multiple production bases to obtain international management system certifications. As a result, we earned international recognition such as EcoVadis Silver Medal, CDP Climate Change rating A- and Water Security rating A. Besides, we actively respond to climate change, identify and manage climate-related risks and opportunities, and set greenhouse gas (GHG) emission reduction targets. Following the first full value-chain GHG accounting and verification in accordance with international standards in 2024, we continued to advance full value-chain carbon accounting and verification in 2025. By improving data quality and management capabilities, we solidified the practical foundation for comprehensive carbon management. Through the deployment of renewable energy, the company's key production bases have achieved a reduction in carbon emissions, validating the scientific rigor and practical feasibility of our low-carbon transition, thereby providing practical support for full value-chain carbon management. In terms of pollution prevention & control, we strictly implemented national emission standards and strengthened the whole-process management of exhaust gases, wastewater, and waste. Meanwhile, we are committed to efficient resource utilization and circular economy. To be specific, we continuously reduced our environmental footprint through multiple initiatives such as retrofits for energy saving, renewable energy adoption, green packaging, and empty bottle/tube recycling programs, while regularly conducting biodiversity assessments to steadily advance sustainable development.

03

Green Operation and Climate Response

Incorporating green and low-carbon development philosophy into corporate operation management, Bloomage Biotech continuously improves its environmental management system, and drives multiple production bases to obtain international management system certifications. As a result, we earned international recognition such as EcoVadis Silver Medal, CDP Climate Change rating A- and Water Security rating A. Besides, we actively respond to climate change, identify and manage climate-related risks and opportunities, and set greenhouse gas (GHG) emission reduction targets. Following the first full value-chain GHG accounting and verification in accordance with international standards in 2024, we continued to advance full value-chain carbon accounting and verification in 2025. By improving data quality and management capabilities, we solidified the practical foundation for comprehensive carbon management. Through the deployment of renewable energy, the company's key production bases have achieved a reduction in carbon emissions, validating the scientific and practical feasibility of our low-carbon transition, thereby providing practical support for full value-chain carbon management. In terms of pollution prevention & control, we strictly implemented national emission standards and strengthened the whole-process management of exhaust gases, wastewater, and waste. Meanwhile, we are committed to efficient resource utilization and circular economy. To be specific, we continuously reduced our environmental footprint through multiple initiatives such as retrofits for energy saving, renewable energy adoption, green packaging, and empty bottle/tube recycling programs, while regularly conducting biodiversity assessments to steadily advance sustainable development.

Environmental Compliance Management

Committed to green manufacturing, Bloomage Biotech follows the management principle of "accident prevention, compliance with regulations, environmental protection, and continuous improvement". It continuously improves its environmental management system to ensure operational compliance and reduce environmental risks and impacts.

Environmental Management System

Strictly following laws and regulations including the *Environmental Protection Law of the People's Republic of China* and the *Law of the People's Republic of China on Environmental Impact Assessment*, Bloomage Biotech has continuously advanced and optimized its ISO 14001 Environmental Management System for operation. In terms of institutional development, all its production bases have updated multiple environmental protection regulations based on their own specific risks and regulatory requirements. Jinan Production Base added seven regulations including the *Management Regulation on Legal Disclosure of Environmental Information* and the *Management Regulation on Hazardous Waste*, while Dongying Production Base updated 20 environmental management regulations, continuously enhancing lower management.

The Company has established a three-tier environmental management network featuring oversight by the headquarters, primary responsibilities of production bases, and participation by all employees. Its Safety and Environmental Protection Management Center coordinates corporate environmental management and supervises all production bases. Each production base, as the executive body, identifies and assesses environmental factors, sets targets, and formulates and implements management plans. Environmental protection personnel are assigned at workshop levels to implement regional environmental responsibilities and ensure the execution of measures. In 2025, Hainan Production Base obtained the ISO 14001 Environmental Management System certification following the production bases in Jinan, Dongying, and Tianjin.

As part of its efforts to strictly implement the "three simultaneous" system for environmental protection in construction projects, the Company conducts environmental impact assessments in accordance with the law throughout the project construction process, and organizes environmental protection acceptance upon completion, ensuring that new projects meet environmental compliance requirements from the source.

The Company conducts internal environmental audits at least once a year covering all the operational locations. Non-conformities are identified through personnel interviews, document reviews, and on-site inspections, and internal auditors track rectifications until closure. Meanwhile, we actively accept surveillance audits from third-party institutions and ESG audits of the supply chain from customers, continuously improving resource utilization efficiency and pollution prevention & control.

Environmental Risk Management

The Company prioritizes environmental risk management in environmental compliance management. During the reporting year, we updated and implemented the *Environmental Factor Identification and Evaluation Procedure*, further standardizing the identification, evaluation, and hierarchical control processes of environmental factors. An environmental factor list was developed across three timeframes, three states, and eight categories, with the effectiveness of control measures for significant environmental factors regularly assessed.



Process for Identifying Environmental Factors The Company has established a comprehensive control mechanism encompassing daily inspections, environmental monitoring, and emergency response. Through regular inspections and timely maintenance of environmental protection facilities, we ensure their continuous safe and effective operation, reducing environmental risks in all aspects. Based on this, we conduct environmental monitoring of exhaust gas, wastewater, noise, and groundwater in strict accordance with the *Regulation on the Administration of Permitting of Pollutant Discharges* and the requirements of the pollutant discharge permit. We disclose relevant information as required by regulations, subjected to supervision from authorities and the public.

The Company has established a quantitative evaluation model to comprehensively score environmental factors, which are then classified into general environmental factors and significant environmental factors for differentiated management. For significant environmental factors, specialized management plans are developed, specifying responsible persons, capital investment, and completion deadlines, which are incorporated into the annual environmental target assessment. General environmental factors are managed routinely through standardized operations, specialized training, and daily inspections.



Six Dimensions for Evaluating Environmental Factor Impacts

In 2025, all production bases of the Company carried out environmental and safety risk identification and hidden hazard investigations on all fronts, covering key areas such as the operation of environmental protection facilities, solid waste management, internal compliance reviews, and the EHS system. For identified problems and hazards, all bases implemented corrective measures, and completed risk assessments and control plans, forming a closed-loop management system.

The Company has established a response mechanism for environmental emergencies. All production bases regularly identify and assess environmental risks, with the *Response Plan for Environmental Emergencies*, specialized emergency plans, and on-site disposal plans in place. As required by the regulations, all production bases conduct specialized emergency drills at least once a year for scenarios such as exhaust gas leaks, wastewater leaks, and hazardous waste leaks to enhance emergency response capabilities. In 2025, no production base incurred major administrative penalties from ecological and environmental authorities or faced criminal liability due to environmental incidents.

Environmental Protection Culture and Capacity Building

Highly valuing environmental protection and pollution prevention & control, the Company continuously strengthens the environmental awareness, knowledge, skills, and emergency response capabilities of all employees to effectively fulfill corporate environmental responsibilities. During the reporting year, the production bases organized diverse training sessions and drills on environmental laws and regulations, identification of environmental factors and risk assessment, pollution prevention & control practices, standardized management of hazardous waste, and response to environmental emergencies, enhancing employees' job performance capabilities and compliance awareness.

Index	Unit	2025	2024	2023
Number of training sessions on environmental protection and pollution prevention & control	times	31	53	43
Number of employees trained in environmental protection and pollution prevention & control	participants	1,604	2,987	3,622
Total hours of training on environmental protection and pollution prevention & control	hour	926	4,806	3,313

Green Office and Low-Carbon Operations

In response to the national carbon peak and carbon neutrality goals, Bloomage Biotech integrates green and low-carbon concepts into daily office operations and administration, improving resource utilization efficiency through digital means and fine management to reduce the environmental footprint of operations.

Energy Conservation and Fine Management	·For temperature control, the Company implements the requirements that air conditioning temperatures should not be lower than 26°C in summer and not higher than 23°C in winter. It regularly cleans and maintains air conditioning systems, and gradually applies intelligent temperature control modes. ·In lighting and equipment management, the Company implements zoned control and strengthens the "lights off when leaving, equipment powered down" policy. It cuts off power in non-essential areas during long holidays and arranges dedicated personnel for inspections and corrections to reduce energy waste.
Promotion of Paperless Operations and Resource Recycling	·The Company promotes digital office platforms. It launched an electronic signature system during the reporting year to achieve a 95% digitalization rate of internal processes, while advocating for online meetings, electronic reporting, and paperless approvals. ·For scenarios where paper use is necessary, the Company implements double-sided printing and secondary use of waste paper, and provides classified recycling bins in printing areas to enhance resource recycling levels.
Office Waste Classification and Green Facility Upgrades	·The Company manages office waste by rational classification, setting up collection points for recyclables, hazardous waste, and other waste to improve waste sorting and standardized handling. ·The Company actively promotes green initiatives in facilities. For instance, it installed safe and energy-saving solar streetlights on certain sections of roads at Jinan Production Base, reducing energy consumption while ensuring employees' travel safety.
Advocacy of Green Travel	The Company is gradually phasing out traditional fuel-powered official vehicles, prioritizing the purchase of new energy hybrid or pure electric vehicles, and adding charging pile facilities in the parking lot on the campus. It also launches a green travel initiative for employees, encouraging low-carbon commuting methods such as public transportation and carpooling to collectively reduce carbon footprints from commuting.
Environmental Culture Development	·The Company organized environmental knowledge contests and low-carbon lifestyle sharing activities during themed events such as the World Environment Day and the National Energy Conservation Publicity Week, advocating water conservation, waste classification, and reduced use of disposable products to guide employees in adopting green lifestyles through daily practices. ·During the reporting year, the Company successfully held its first-ever carbon neutrality anniversary celebration. Through small donations from 99 employees, the event achieved a reduction of 82 tons of carbon dioxide equivalent

Response to Climate Change and Energy Management

To disclose its management and actions in response to climate change in a science-based and effective way, the Company discloses its climate change risk management system and response progress in terms of governance, strategy, risk management, and metrics and targets, with reference to the *IFRS Sustainability Disclosure Standard S2: Climate-Related Disclosures* ("IFRS S2") issued by the International Sustainability Standards Board (ISSB). It continuously explores solutions to climate change issues, promoting the implementation of sustainable and low-carbon development goals with measures such as planning of emission reduction pathways, application of energy-saving technologies, and utilization of renewable energy.

Governance

To ensure effective implementation of its climate change governance efforts from strategic decision-making to execution, the Company has established a climate governance structure led by the Board of Directors, clarifying the respective responsibilities of the Board of Directors, the Management, and the execution level to advance the routine climate-related risk management.

Climate Governance Structure of Bloomage Biotech	
Board of Directors	·It reviews and makes decisions on major matters related to climate, including climate strategy, emission reduction targets and pathway planning, and climate-related risk management, and oversees emission reduction progress.
ESG Committee under the Board of Directors	·It reviews and oversees the identification and assessment of climate-related risks and opportunities, as well as the advancement and completion of key projects.
ESG Management Department	·It is responsible for daily management, policy research, and training regarding climate issues. It formulates climate strategy pathways and targets, and leads the implementation and follow-up of climate-related projects, carbon management, and information disclosure.
ESG Working Group	·It implements climate-related action plans and energy resource management requirements in accordance with the Company's climate strategy and targets, and regularly reports on action progress.

The Company has established a professional working team with expertise, industry experience, and diverse backgrounds, enhancing their functional competence through regular thematic training to advance the routine and institutionalized operation of key sustainability tasks including climate-related risk management. Meanwhile, ESG performance assessment requirements including climate change have been incorporated into the annual personal performance commitments of departments and relevant senior executives, department heads, and dedicated positions, which are linked to compensation incentives to enhance execution and implementation effectiveness.

Strategy

Bloomage Biotech has formulated a climate change strategy which has been incorporated into its sustainability strategy, advancing work related to low-carbon transition and climate resilience in all aspects. In terms of low-carbon transition, we focus on three pathways (i.e., production and operation optimization, product optimization, and supply chain optimization) to promote improvements in energy and resource efficiency, product life cycle assessment (LCA) management, and value chain carbon management. In terms of climate resilience, we improve mechanisms for addressing physical risks such as extreme weather to enhance our capabilities for guaranteeing continuous operation.

Key Strategic Pathways and Measures of Bloomage Biotech for Addressing Climate Change

Key Strategic Pathways	Strategic Initiatives	Specific Measures
Production and Operation Optimization	Improve energy and resource use efficiency in production	·Establish budgets dedicated for GHG management, and conduct GHG accounting and third-party verification ·Continuously advance technological upgrades for energy saving and energy efficiency improvements ·Deploy renewable energy facilities ·Participate in trading of green electricity in the market ·Sustain efforts in low-carbon culture development
Product Optimization	Advance R&D of sustainable products and technology	·Conduct product life cycle assessment (LCA) and product carbon footprint management ·Promote sustainable ingredient applications and packaging innovation
Supply Chain Optimization	Strengthen ESG and carbon management of supply chains	·Conduct GHG (Scope 3) accounting of value chains ·Carry out supplier self-assessment questionnaire surveys regarding GHG emissions and collect data ·Promote enhancement in the GHG management capability across the supply chain
Climate Resilience Building	Enhance climate adaptation capabilities and operational resilience	·Continuously optimize response mechanisms for physical risks such as extreme weather, keep improving emergency response systems for climate change, natural disasters, and extreme weather events, and strengthen emergency drill mechanisms and critical facility protection capabilities, so as to effectively enhance climate response capabilities during production and operation

To drive the implementation of climate change strategies, the Company focuses on key strategic pathways including production and operation optimization, product optimization, and supply chain management. With particular emphasis on critical areas such as reduction of emissions from logistics, it continuously implements concrete actions to enhance the execution efficiency of low-carbon transition and capabilities for guaranteeing continuous operation.

Optimizing Transportation Structure of International Logistics	·For international orders, the Company actively collaborates with customers to optimize transportation modes, promoting the shift from air freight to low-carbon alternatives such as ocean shipping while meeting delivery requirements, thereby reducing carbon footprint in the delivery process.
Implementing Multi-warehouse Coordination and Proximity-based Distribution	·The Company deepens multi-warehouse collaboration models such as "Fulfillment by Cloud Warehouse", shipping goods according to the "proximity principle" to shorten transportation distances and reduce energy consumption and emissions
Promoting Green Packaging	·The Company uses reusable carriers such as recyclable ice plates and insulated containers in cold chain transportation, gradually replacing disposable packaging materials to reduce waste generated
Optimizing Transportation Conditions and Modes	·The Company tests and verifies transportation conditions, and optimizes transportation conditions for certain products from "low-temperature cold chain" to "ambient temperature transportation" while ensuring the quality of such products and compliance requirements, thereby reducing energy consumption and carbon emissions in transportation

Risk Management

Bloomage Biotech has established a routine risk transmission mechanism, incorporating climate-related risk management into the corporate risk management system. Upon review and under the guidance of the Board of Directors and the ESG Committee thereunder, the ESG Management Department leads the identification and assessment of climate-related risks and opportunities, formulates response plans, and coordinates functional teams such as production, procurement, energy, and finance teams to implement them. The Company evaluates and reports on risks on a quarterly basis to ensure that potential risks can be identified and addressed in a timely manner.

Bloomage Biotech manages climate-related risks and opportunities through the following process:



·Identification: Based on its production and operation actualities, the Company systematically identifies climate-related risks and opportunities and produces a list, taking account of industry trends, domestic and international policy landscapes, and best practices as a benchmark.

	·Assessment: The Company assesses the applicability and importance of risks and opportunities based on its business operations, and comprehensively analyzes them in terms of the probability of occurrence, business impact, financial impact, and reputational impact to determine risk levels and material opportunities.
	·Monitoring: The Company continuously engages with stakeholders, and regularly reviews and updates assessment results to ensure that risks, opportunities, and response measures align with the Company's actualities.
	·Response: The Company develops and implements response plans based on identification and assessment results, including but not limited to low-carbon transition plans and adaptation measures approved by the Management, and tracks the progress and effectiveness of their implementation.

Bloomage Biotech systematically identifies climate-related risks and opportunities, taking account of business actualities and industry trends. On one hand, we incorporate climate-related physical risks and transition risks into business planning and supply chain management, and continuously strengthen our capability against risks in key areas, thus enhancing our capability for guaranteeing continuous operation. On the other hand, we seize green transition opportunities, and implement measures such as clean energy substitution, energy conservation and efficiency improvement, process optimization, and green manufacturing to reduce carbon emissions and improve resource utilization efficiency. We assess various climate-related risks and opportunities in terms of the time horizon (short term, medium term, and long term), affected value chain segment, likelihood and level of risk, and potential impact on business and finance, providing a basis for subsequent strategic choices, resource allocation, and development of action plans. The assessment results for the reporting year indicate that current climate change-related risks are generally controllable and are not expected to have a material adverse impact on our financial position, operating results, and cash flow for the next year.

Physical Risks

Risk Type	Risk Description	Risk Level	Time Horizon	Potential Impact	Response Measures
Acute Risks	Extreme precipitation	High	Short/medium/long term	·Equipment and infrastructure may be damaged, leading to decreased production efficiency and additional capital expenditures for equipment repair and replacement. ·The short-term pressure on wastewater treatment increases, the effluent discharge volume and water pollution risks are elevated, and the production stability is affected. ·Regional waterlogging and road disruptions may cause logistics obstructions and delays in raw material arrivals, affecting production continuity and order fulfillment.	·Revise and implement regulations such as the *Preparedness Plan to Respond to Natural Disasters* and the *Response Plan for Environmental Emergencies*, regularly organize flood prevention and environmental emergency drills, and improve the response mechanism for faster response. ·Optimize drainage facilities within the factory, install shut-off valves for discharge outlets, and increase stockpiles of critical flood prevention supplies.
	Tropical cyclone	Moderate	Short/medium/long term	·Logistics and supply chain disruptions may lead to failure in on-time order delivery, potentially resulting in compensation due to breach of contract and decreased customer satisfaction. ·Extreme weather deteriorates warehousing conditions, causing inventory devaluation losses.	·Supply chain resilience: Establish a pool of diversified logistics suppliers and dynamically adjust logistics plans during flood seasons and typhoon periods. ·Evaluate and purchase insurance such as property insurance to transfer potential financial loss risks.
	Extreme heat	Moderate	Short/medium/long term	·Rising cooling loads increase electricity consumption and energy costs. ·Increased temperature control pressure in warehousing and transportation elevates risks to raw material/product quality may cause scrap losses and revenue impacts. ·Higher fire protection demands and safety risks under elevated temperatures necessitate increased safety management investments and operation and maintenance costs.	·Develop the *Preparedness Plan to Respond to Natural Disasters*, and conduct regular drills for continuous improvement of the emergency response mechanism. ·Implement online temperature/humidity monitoring with out-of-limit alerts for warehousing and transportation, and improve cold chain/insulation measures. ·Strengthen fire prevention measures and maintain firefighting facilities periodically.
	River flood	Low	Short/medium/long term	·An external flood causes abnormal water inflow or backflow, heightening an operational risk and compliance pressure of the wastewater system, potentially triggering regulatory scrutiny and reputational impacts. ·Equipment and infrastructure may be damaged, leading to decreased production efficiency and additional capital expenditures for equipment repair and replacement.	·Develop the *Preparedness Plan to Respond to Natural Disasters*, and conduct regular drills for continuous improvement of the emergency response mechanism. ·Regularly inspect and reinforce flood barriers and drainage facilities, and verify drainage capacity in key areas during flood seasons to ensure steady operation under high-load conditions.
Chronic Risks	Water scarcity	Moderate	Primarily medium-to-long term (possibly short term during a drought year)	·Prolonged droughts may restrict production water quotas, directly affecting capacity utilization and revenue. ·Rising water prices lead to increased production costs.	·Continuously optimize production processes and deploy water-saving equipment, significantly improving water resource recycling rates. ·Enhance water metering and performance management, optimize production scheduling and peak-valley water usage, and improve water efficiency per unit output.
	Sea-level rise	Low	Long term	·The risk of seawater intrusion facing the production bases in coastal areas potentially causes devaluation of land and fixed assets.	·During site selection for new projects or improvement of existing facilities, thoroughly assess the risk of sea-level rise and elevate design protection standards.

Risk Type	Risk Description	Risk Level	Time Horizon	Potential Impact	Response Measures
				·Damage to coastal ports may permanently alter logistics routes and increase transportation costs.	·Regularly update climate exposure assessments for operational locations in coastal areas and dynamically adjust long-term asset allocation strategies.

Our analysis is based on two Shared Socioeconomic Pathways (SSPs) from the Intergovernmental Panel on Climate Change (IPCC), namely, SSP1-1.9 (low carbon emissions scenario) and SSP2-4.5 (high carbon emissions scenario), as detailed in the table below:

Type	Risk/Opportunity	Description	Potential Impact	Response Measures
Transition Risks	Policy & regulation	Higher carbon prices and stricter compliance requirements	·Inclusion in the carbon trading market, or intensified carbon constraints within the industry, could lead to higher costs related to allowance procurement and regulatory compliance. ·The introduction of stricter policies and regulations by China to mitigate climate change increases corporate compliance pressure and related litigation risks. ·Export products may be subject to accounting, declaration, and potential costs from border carbon mechanisms such as CBAM in the future, which could weaken the competitiveness of product prices or compress profit margins.	·Closely monitor the global market environment and changes in carbon-related laws, regulations, and policies; continuously conduct GHG inventories, verification, and carbon footprint management of products; track changes in domestic and international carbon policies and standards; and improve compliance contingency plans. ·Strengthen internal management, establish low-carbon transition targets and plans, and implement a series of actions.
	Technology	Low-carbon technology iteration	·Low-carbon technology transformation requires substantial upfront capital investment. ·Uncertainties in technology pathways and investment payback periods may lead to cost pressures and competitive risks.	·Establish dedicated R&D funds to evaluate and introduce applicable low-carbon technologies. ·Collaborate with research institutions and industry partners to advance the verification and scaled application of technologies such as green processes and bio-manufacturing.
	Market	Supply chain and demand fluctuations	·Climate factors may affect the supply stability of bio-based raw materials and drive up prices, increasing procurement costs and delivery uncertainties. · Failure to meet ESG performance or disclosure requirements of key customers for	·Strengthen ESG audits of suppliers and establish a pool of diversified suppliers to mitigate the volatility of raw material prices. ·Incorporate low-carbon and sustainability requirements into R&D and product design to expand the supply of low-carbon products and solutions.
			qualification/scoring may impact bid success and order acquisition.	
	Reputation	Stakeholders' concerns	·Insufficient information disclosure or underperformance may increase financing costs or affect financing availability. ·Failure to fulfill environmental responsibilities will damage the brand image and affect consumers' loyalty. ·If emission reduction progress falls short of expectations, fulfillment of commitments to voluntary emission reduction may increase carbon offset procurement costs.	·Disclose climate information with high quality by referencing international standards such as ISSB, actively responding to concerns from the capital market. ·Establish carbon offset procurement and utilization strategies, and strengthen due diligence of suppliers and cost management.
Opportunity	Policy	Incentive policy	·Energy conservation and emission reduction subsidies, as well as technical transformation rewards are granted.	·Actively apply for national and local green manufacturing and technical transformation projects. ·Evaluate and phase in increased usage of renewable energy such as distributed photovoltaic and biogas power.
	Market	Green finance and demand	·Instruments like green credit and sustainability-linked loans are utilized to access low-cost funding. ·Low-carbon product certification may enhance the rate of bid success, secure potential premiums or more favorable cooperation terms.	·Proactively expand green financing channels to provide financial support for low-carbon transition. ·Conduct ongoing life cycle assessments (LCA) of products, promote third-party certification, and facilitate both customer communication and practical application.
	Technology	Cost reduction and efficiency improvement	·Reduce energy and water consumption costs per unit product through industrial energy-saving technologies and resource recycling.	·Deploy high-efficiency production equipment and energy management systems to enhance energy and water efficiency, continuously reducing energy and water consumption per unit product.

Metrics and Targets

As part of its efforts to implement the concept of green manufacturing, Bloomage Biotech continuously improves its environmental management system, optimizes product design and production processes, and enhances resource utilization efficiency to reduce resource consumption and pollutant emissions.

Emission Performance

GHG Emissions of Bloomage Biotech[1]				
Indicator	**Unit**	**2025**	**2024**	**2023**

[1] The scope of statistics for Scope 1 and Scope 2 GHG emission data includes all wholly-owned operational production bases of Bloomage Biotech located within China. The GHG emissions include emissions from natural gas consumption, diesel fuel, gasoline, fugitive methane from wastewater, refrigerant charge, fire extinguishers, purchased electricity, and purchased heat. Scope 3 data include emissions from purchased goods and services, capital commodities, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, business trips, and transportation and distribution of sold products. The accounting was conducted in accordance with the requirements set forth in the *GHG Protocol: A Corporate Accounting and Reporting Standard* as well as the *ISO 14064-1:2018 Greenhouse*

GHG Emissions of Bloomage Biotech[1]					
Total GHG emissions (Scopes 1+2)	Location-based	tCO_2e	103,971.11	113,510.99	100,902.09
	Market-based	tCO_2e	97,392.40	109,785.94	/
Scope 1 emissions		tCO_2e	25,904.30	37,412.27	43,554.73
Scope 2 emissions	Location-based	tCO_2e	78,066.81	76,098.72	57,347.36
	Market-based	tCO_2e	71,488.11	72,373.66	/
GHG emissions per unit of revenue (Scopes1+2)	Location-based	tCO_2e/CNY 1 million revenue	24.76	21.14	16.61
	Market-based	tCO_2e/CNY 1 million revenue	23.19	20.44	/
Scope 3 emissions		tCO_2e	91,546.37	183,852.39	/

The Company has established GHG emission reduction targets, and commissions qualified third-party institutions to conduct carbon verifications every year. The Company implements measures such as utilization of clean energy, promotion of energy-saving technologies and process improvements to continuously reduce GHG emissions.

Target	·Strive to reduce total company-wide GHG emissions (Scopes 1 + 2) by 50% by 2030 compared to that in 2023.
Progress	·During the reporting period, the Company saw the continued increase in the usage of renewable energy and gradual expansion of its coverage. With the implementation of retrofits for energy saving and energy efficiency enhancement measures, carbon emissions at multiple main production bases, including the Jinan Production Base, shown a downward trend. Meanwhile, the Company completed life cycle assessments (LCA) of key products, with the carbon footprints of these key products showing significant reductions compared to 2023.

▶ Case: Bloomage Biotech Successfully Holds Its First-ever Carbon Neutrality Anniversary Celebration

On August 1, 2025, the first 2025 Carbon Neutrality Anniversary Celebration of Bloomage Biotech themed with "United, We Break Through" was successfully held in Jinan. The Company integrated carbon management throughout the event cycle with reference to relevant guidelines.

Preparation phase: It developed a low-carbon plan for the event, and launched a low-carbon action initiative, as well as a small donation campaign for the carbon neutrality anniversary. A total of 99 employees participated in the event, with 82 tons of carbon dioxide equivalent reduced.

Execution phase: It implemented multiple emission reduction measures, including procuring low-carbon materials, promoting "high-speed rail instead of flights" and public transportation, encouraging the "Clean Plate Campaign", and bringing personal water bottles, thereby reducing event-related emissions.

Closing phase: It compiled data on energy consumption and business travel, completed carbon emission accounting and offsetting, and obtained a carbon neutrality certificate issued by a third-party institution, achieving the goal of hosting a green event.

2025 Anniversary Celebration of Bloomage Biotech Themed with "United, We Break Through"

Low-Carbon Transformation and Energy Management

Energy Management System Improvement

Bloomage Biotech continues to strengthen energy management with the core goal of continuously improving operational energy efficiency. Through energy planning, daily management, and energy-saving improvement measures, we consistently enhance energy utilization efficiency. We have established an Energy Management Leading Group and a multi-level energy management structure to promote the systematic implementation of energy management efforts. Each production base of Bloomage Biotech has established a comprehensive whole-process energy management network covering all staff. Led by the management team and coordinated by the engineering equipment department, this network involves relevant departments, workshops, and teams, covering all critical areas and main scenarios of energy usage. Each production base formulates energy management objectives and implementation plans based on its own production characteristics, and ensures effective achievement of the objectives through process tracking and collaborative execution. During the reporting year, our Jinan Production Base and Tianjin Production Base obtained ISO 50001 Energy Management System certification.

Referring to national standards and internal management requirements, the Company has established and continuously improved its energy management system. Documents such as the *Energy Management Manual* and the *Energy Management Review Control Procedure* have been developed to enhance energy management from such aspects as technical specifications, management execution, and performance evaluation.

Energy Measurement and Statistics	·Establish an energy measurement and statistics system to regulate the procurement, warehousing, and circulation management of measuring instruments. ·Conduct regular energy measurements, and establish and maintain energy measurement registers.
Energy Alert Mechanism	·Continuously monitor energy consumption in workshops, and make comparative analysis with historical data for the same period, issuing timely alerts for out-of-limit data. ·Promote workshops to identify major energy uses, influencing factors, and key variables to optimize energy management.
Energy Review Control	·Conduct energy reviews through thematic interviews, on-site investigations, and statistical evaluations, covering unit energy utilization status, energy types and sources, energy management, and metering equipment. ·Analyze energy-saving potential and propose improvement suggestions in terms of structure process, and management.
Energy-consuming Equipment Management	·Prohibit the use of equipment explicitly eliminated by national decrees and prioritize the selection of energy-efficient products. ·Regularly maintain equipment and optimize their debugging to ensure long-term steady and efficient operation of the system, maximizing equipment performance.
Energy Conservation Awareness Training	·Launch regular energy conservation awareness campaigns to enhance employees' energy-saving awareness and job-specific energy conservation capabilities.

Identification and Management of Energy Risks

Bloomage Biotech has established a risk identification and response mechanism covering the entire energy management process, systematically identifying and analyzing internal and external factors involved in energy management. External factors mainly include laws and regulations related to energy and energy conservation, energy efficiency standards and policy requirements, as well as energy price fluctuations and energy supply situations. Internal factors mainly include production organization methods, operational status of key energy-consuming equipment and utility systems, metering and data foundations, and on-site management levels. Based on this, the Company formulates corresponding response

Gases—Part 1: Specification with Guidance at the Organization Level for Quantification and Reporting of Greenhouse Gas Emissions or Removals. During the reporting period, the total Scope 3 greenhouse gas (GHG) emissions decreased year-on-year, mainly due to the systematic structural optimization carried out by the Company around its dermatological science innovation and transformation business and nutritional science innovation and transformation business. Meanwhile, the Company is implementing low-carbon supply chain management, which has also contributed to the reduction in relevant greenhouse gas emissions. "/" indicates not applicable.

measures for risks and opportunities, and continuously tracks and updates compliance requirements as the minimum requirements for energy management.

In terms of risk identification methods, the Company conducts dynamic assessments based on on-site inspections and energy consumption/efficiency data analysis. By comparing energy consumption data, equipment operating parameters, and energy efficiency indicators, it identifies key high-energy-consuming equipment and main areas of energy consumption, monitors abnormal fluctuations, and assesses the potential of improvement for energy saving and potential risks. Key risk types of focus include production security risks caused by fluctuations in energy supply or utilities; inefficient energy consumption risks due to equipment aging, insufficient maintenance, or inadequate process optimization (such as equipment idling, insufficient waste heat utilization, or leaks); management and settlement risks arising from inaccurate metering; and waste risks resulting from inadequate management of non-production energy use.

In risk response, the Company establishes operation and maintenance standards for main energy-using processes, implements spot check and preventive maintenance mechanisms for key equipment, and continuously verifies the effectiveness of measures through on-site inspections, data tracking, and performance monitoring. In response to peak loads or supply constraints of electricity and steam, it optimizes its scheduling with peak-shifting arrangements based on its production plans, and appropriately adjusts operating parameters of key equipment to reduce load and improve efficiency without compromising product quality and process requirements. Through the above management and technical measures, it continuously reduces energy waste and improves energy utilization efficiency while ensuring production stability.

Energy Use

Energy Use of Bloomage Biotech[2]

Index	Unit	2025	2024	2023
Natural gas	cubic meter	10,060,451	13,073,453	15,686,836
Gasoline	litre	24,018	30,112	21,706
Diesel oil	litre	8,871	7,934	8,939
Purchased heat from fossil fuel	GJ	282,215.92	245,503.80	174,331.73
Purchased heat from biomass fuel	GJ	119,107.91	153,263.05	38,282.69
Total electricity consumption	kWh	90,152,911	94,746,874	70,453,123
Purchased electricity (thermal power)	kWh	65,968,824	77,625,771	66,931,210
Purchased renewable electricity	kWh	21,220,592	13,375,618	/
Total self-generated renewable electricity	kWh	2,963,495	3,745,485	3,521,913
Total energy consumption	tons of standard coal	38,312.93	42,734.83	36,811.37
Including: Clean energy consumption	tons of standard coal	7,159.09	7,398.57	1,739.05
Total energy consumption intensity	tons of standard coal /CNY 1 million revenue	9.12	7.96	6.06

Energy Conservation and Consumption Reduction Initiatives

Production bases of Bloomage Biotech analyze their energy consumption, tap into the potential of energy saving, and continuously advance energy efficiency improvement measures. The Company implements energy conservation and consumption reduction management across procurement, transportation, production, and operation. During the reporting year, we continuously enhanced scientific, fine energy utilization by focusing on key areas such as equipment energy efficiency, transportation efficiency improvement, and energy consumption monitoring. All our production bases prioritized the deployment of energy-efficient equipment during equipment replacement and procurement, preferred electric forklifts and manual hydraulic vehicles in logistics operations, and improved the transportation efficiency of raw materials, auxiliary materials, and finished products through hoists and Automated Guided Vehicles (AGVs).

Energy Conservation and Consumption Reduction Measures at Production Bases of Bloomage Biotech (Selected)

Production Bases	Specific Measures
Jinan Production Base	·It implemented projects including AI-controlled air conditioning systems, cooling tower retrofits for energy saving, and air compressor networking to enhance energy efficiency.
Tianjin Production Base	·It optimized and retrofitted production equipment by interconnecting underutilized or repetitive equipment. ·It optimized parameter settings of production equipment based on production requirements to improve operational efficiency of equipment.
Chaohu Production Base	·It conducted regular preventive maintenance and repairs on equipment to reduce failure rates and energy consumption. ·It continuously monitored energy performance parameters and operational indicators of main energy-consuming equipment to ensure rational energy use.

Optimization of Energy Structure

Bloomage Biotech accelerates the transformation of its energy structure and continuously increases the consumption of renewable energy. By constructing distributed photovoltaic (PV) systems and biogas power generation facilities, and gradually introducing purchased renewable electricity and biomass heat, the Company has continuously promoted the replacement of traditional energy sources with clean energy, achieving an equivalent emission reduction of approximately 28,224.33 tonnes of carbon dioxide equivalent (tCO_2e) in 2025.

Renewable Energy Consumption of Bloomage Biotech[3]

Index		Unit	2025	2024	2023
Renewable electricity	Purchased renewable electricity	kWh	21,220,592	13,375,618	/
	Total self-generated renewable electricity	kWh	2,963,495	3,745,485	3,521,913
	• Photovoltaic power generation	kWh	2,277,254	2,312,192	2,401,725

[2] The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. During the reporting period, energy structure adjustments and impacts from production and operational activities resulted in significant fluctuations in multiple indicators such as natural gas and gasoline. And the Company optimized the accounting caliber of total energy consumption. Based on the statistics of the original fossil fuel consumption within the production and operation boundary, the Company additionally included the consumption of clean energy within the same boundary. To enhance the comparability of data across periods, the Company has completed retrospective adjustments of relevant data for 2023 and 2024 in accordance with the unified caliber for 2025. "/" indicates not applicable.

[3] The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. During the reporting period, energy structure adjustments and impacts from production and operations and external supply of heat from biomass fuel led to significant fluctuations in multiple indicators such as renewable electricity and heat. "/" indicates not applicable.

Renewable Energy Consumption of Bloomage Biotech[3]					
	• Biogas power generation	kWh	686,241	1,433,293	1,120,188
Renewable heat	Purchased heat from biomass fuel	GJ	119,107.91	153,263.05	38,282.69

Pollutant Emissions and Waste Management

Bloomage Biotech strictly complies with pollutant prevention and control laws and regulations such as the *Law of the People's Republic of China on the Prevention and Control of Atmospheric Pollution*, the *Law of the People's Republic of China on Prevention and Control of Water Pollution*, the *Law of the People's Republic of China on the Prevention and Control of Noise Pollution*, and the *Law of the People's Republic of China on the Prevention and Control of Environment Pollution by Solid Wastes*. The Company strengthens source prevention and process control in terms of exhaust gas, wastewater, noise, and waste release management, continuously improving pollution prevention and control capabilities. It dynamically improves its internal control standards for pollutant emissions in accordance with national, local, and industry regulatory requirements, ensuring traceable emission management, controllable processes, and compliant results.

Exhaust Gas

Bloomage Biotech requires all production bases to strictly comply with laws, regulations, and standards on exhaust gas emissions. During the reporting year, the Company updated its *Exhaust Gas Management Policy* to monitor exhaust gas emissions at all production bases. The Company has established a governance structure with the Safety and Environmental Protection Management Center as the supervisory body and exhaust gas generation and management departments as the implementing bodies. It advances exhaust gas control through source reduction and end-of-pipe treatment, striving to achieve a 100% compliance rate for exhaust gas emissions. In terms of treatment measures, the Company employs processes such as dust removal, desulfurization, denitrification, isolation, water spray, and alkali spray based on exhaust gas characteristics. Dedicated personnel are assigned for daily operation and maintenance of environmental protection facilities, and qualified third-party institutions are regularly commissioned to test the emissions. During the reporting year, all exhaust gas prevention facilities maintained steady operation.

Meanwhile, the Company promotes the enhancement of exhaust gas treatment capabilities and source reduction. The efforts include the following: upgrading exhaust gas treatment facilities in factory areas, and standardizing multiple unorganized emission points for organized collection; optimizing some treatment processes from single methods to combined processes to improve treatment capacity and operational effectiveness; retrofitting internal floating roofs on the alcohol tank farms at some production bases to reduce the volatilization of volatile organic compounds (VOCs) at the source and minimize pollutant emissions.

Exhaust Gas Emission Reduction Measures of Bloomage Biotech (Selected)

Exhaust Gas Monitoring	**Xiangtan Production Base:** Monitor emissions of the base for VOCs, particulate matter, nitrogen oxides, sulfur dioxide, particulate matter, and smoke blackness on an annual basis
Exhaust Gas Purification	**Xiangtan Production Base:** ·Discharge exhaust gases through 15-meter-high exhaust stacks to improve exhaust gas collection efficiency ·Operate in Class 10,000 or higher cleanrooms to enhance the effectiveness of exhaust gas purification ·Operate within Class II biological safety cabinets, with exhaust gases filtered through ULPA filters and sterilized by UV lamps, supported by AHU purification air conditioning systems to prevent exhaust gas leakage **Tianjin Production Base:** Require all departments to replace activated carbon according to scheduled intervals to ensure the efficiency of exhaust gas purification
Odor Treatment	**Jinan Production Base:** ·Dredge and maintain biofilter beds in wastewater treatment workshops to improve the effectiveness of exhaust gas collection and treatment ·Enclose key units including equalization tanks, sumps, sludge thickening tanks, and aeration tanks to centrally collect and treat generated gases, reducing odor dispersion **Tianjin Production Base:** ·Comprehensively inspect and seal all tanks and openings in wastewater areas to prevent exhaust gas and odor diffusion

Exhaust Gas Emissions of Bloomage Biotech[4]

Index	Unit	2025	2024	2023
Sulfur oxides	ton	2.05	1.75	2.32
Nitrogen oxides	ton	3.91	6.22	7.46
Volatile organic compounds	ton	1.66	3.05	3.30

Wastewater

Bloomage Biotech actively implements national laws and regulations on wastewater management, continuously enhancing its capabilities for risk prevention and control of water environment. The Company has established and updated the *Wastewater Discharge Management Policy*, specifying compliance requirements for wastewater pollutant discharge monitoring, licensed emissions, supervision of compliant discharges, and abnormality handling.

The Company has established a wastewater discharge and treatment management system covering the entire process, with the Safety and Environmental Protection Management Center serving as the supervisory body and wastewater production and management departments as the implementing bodies. This system covers risk identification, preventive measures, emergency response, and follow-up management, ensuring continuous and steady compliance of wastewater discharge while progressively enhancing the standardization and precision of water environment management, with the goal of achieving a 100% compliance rate of wastewater discharge.

For risk identification and prevention, the Company manages by classification and regularly monitors conventional wastewater (such as domestic sewage, canteen wastewater, concentrated discharge from pure water preparation, and backwash wastewater) and accident-related wastewater (including firefighting water and chemical/hazardous waste leaks). Control of conventional wastewater is strengthened with measures like diversion of rainwater and sewage, pretreatment, and operational process management. Source control measures such as anti-corrosion, anti-seepage, diversion, and leak collection are implemented in hazardous waste storage areas and chemical storage zones, with pollution treatment facilities and pipeline networks regularly inspected. In case of potential non-compliant discharge or emergencies, the Company constructs or improves facilities such as emergency ponds and main rainwater discharge interceptors, while developing corresponding wastewater pollution contingency plans and organizing drills. It implements measures like diking, emergency collection, external monitoring coordination, and compliant disposal during the incidents. After the incidents, it keeps track of and monitors them to drive closed-loop rectification of hidden risks.

Regarding facility deployment and operational management, the Company's main production bases have self-built wastewater treatment systems where industrial wastewater is treated to meet standards before discharge. For bases connected to wastewater treatment systems of the industrial parks, pretreatment and discharge controls are implemented according to park requirements, with ongoing coordination and communication maintained with the parks. The Company implements a multi-tiered monitoring mechanism of "online monitoring + routine testing + third-party verification", and commissions qualified third-party institutions for scheduled routine monitoring, creating multiple safeguards to ensure steady effluent compliance and long-term system operation.

All production bases monitor wastewater quality following the process of "sampling—testing—verification and reporting—abnormality handling", focusing on such indicators as Chemical Oxygen Demand (COD), Ammonia Nitrogen (NH3-N), and Suspended Solids (SS). Test results are documented and promptly reported to the Safety and Environmental Protection Department for discharge compliance assessment and operation control. In case of abnormal fluctuations, retesting, root cause analysis, and corrective actions are initiated per internal protocols, with treatment processes and operational parameters adjusted when necessary to prevent non-compliant discharge risks. In case of non-compliant discharge risks arising at the bases connected to wastewater treatment systems of the industrial parks, such bases promptly coordinate with the parks to take interception measures under emergency procedures, diverting wastewater to emergency facilities within the parks for further compliant treatment before discharge, minimizing the impact on the external environment.

[4] The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. The Company monitors, collects, and treats air pollutant emissions in compliance with regulatory requirements, including emissions such as particulate matter that are not materially significant in information disclosure. During the reporting period, the Company's improvements in environmental protection facilities and adjustments in production and operations resulted in significant fluctuations in most pollutant emission data.

While strengthening compliant discharge, the Company promotes wastewater resource utilization. Reclaimable water streams (such as steam condensate) are reused to improve water utilization efficiency. Synergies with downstream treatment facilities are explored to comprehensively utilize certain high-concentration waste liquids (e.g., as carbon sources in treatment processes), reducing source treatment loads and enhancing resource recovery while ensuring compliance.

As an enterprise engaged in the manufacturing of pharmaceutical-grade products, related products (hyaluronic acid and its derivatives) may enter wastewater treatment systems during container cleaning and other processes before discharge. Test results show compliance with discharge regulations. Given the non-toxic nature of the products, lack of bioactivity, and suitability as food ingredients, they pose no substantive negative impact on the environment or human health.

Wastewater Discharge of Bloomage Biotech[5]

Index	Unit	2025	2024	2023
Total volume of wastewater discharged	10,000 tons	174.60	171.54	123.85
Chemical oxygen demand	ton	86.53	102.52	54.01
Ammonia nitrogen	ton	1.11	0.80	2.03
Total phosphorus	ton	1.28	1.04	0.79
Total nitrogen	ton	8.64	11.23	10.10

Noise

In strict compliance with noise management laws and regulations, and referring to national and local standards such as the *Emission Standard for Industrial Enterprises Noise at Boundary*, Bloomage Biotech ensures that production noise meets environmental emission standards, reducing and preventing noise pollution and hazards. We implement measures such as sound insulation, vibration reduction, noise reduction, and sound absorption for production equipment to lower noise emissions, proactively select low-noise equipment, and optimize the layout of high-noise equipment. Besides, we formulate noise monitoring plans and detect noise every year.

Waste

Upholding the green development concept, Bloomage Biotech implements comprehensive waste control and resource utilization at all production bases. We have established internal regulations including the *General Industrial Solid Waste Management Policy* and the *Hazardous Waste Management Policy* to ensure the traceability and tracking of, and accountability for waste. Following the principle of "prevention first, combined with control" and the "three simultaneous" provisions, the Company has established a hierarchical waste management system with the Safety and Environmental Protection Management Center as the supervisory body and waste generation and management departments as the implementing bodies. This system, which covers general industrial solid waste, domestic waste, and hazardous waste, defines supervision and daily management responsibilities, enabling standardized full-process waste control.

In 2025, Jinan Production Base of the Company promoted a pilot project for general solid waste reduction, and set waste reduction targets. By implementing measures for key process optimization, including extending blowing time to reduce the moisture content of filter residue and improving dehydration processes to decrease the moisture content and yield of sludge, we achieved and exceeded the set targets.

Targets	Plant 1 of Jinan Production Base: ≥1% reduction in filter residue per unit of pharmaceutical-grade HA product; Plant 2: ≥5% reduction in unit sewage sludge.
Target Completion Status	Plant 1 of Jinan Production Base: ≥6% actual reduction in filter residue per unit of pharmaceutical-grade HA product; Plant 2: ≥10% actual reduction in unit sewage sludge.

The Company strengthens waste management control measures, ensuring standardized full-process waste management in terms of source reduction, collection by classification, standardized storage, compliant transportation and disposal, and register management.

Management Phase	Solid Waste	Hazardous Waste
Source Reduction	·Optimize production processes, improve product quality and yield, and reduce solid waste generation. ·Reduce the moisture content and yield of sludge through process optimization to decrease solid waste generation.	·Recycle cleaning solutions to reduce chemical consumption and lower hazardous waste generation. ·Strengthen pollution prevention requirements in production scheduling, and ensure simultaneous operation of treatment facilities and main facilities to reduce process risks.
Collection by Classification	·Define classification standards based on the *Directory of National Hazardous Wastes* and characteristics of general industrial solid waste, and collect non-hazardous waste by classification (general solid waste, domestic waste, and food waste).	·Collect and separately manage hazardous waste by classification to avoid mixed storage.
Standardized Storage	·Categorize general industrial solid waste into recyclable waste and other industrial solid waste. Recyclable waste is centrally processed by the waste repository of the Company, while other industrial solid waste is stored in storage sites for general solid waste. ·Post graphic symbols of environmental protection indicating corresponding solid waste categories, and store waste by classification and zone. ·Strictly enforce storage site requirements to ensure environmental protection standards regarding solid waste, including "prevention of scattering, loss, leakage, and rain exposure", prohibiting open-air storage.	·Establish dedicated hazardous waste storage rooms with zoned areas for items such as laboratory heavy metal waste liquids, general waste liquids, waste reagent bottles, spent activated carbon, and waste engine oil. ·Storage rooms must maintain cool ventilation, comply with safety regulations, remain isolated from ignition sources, and be subject to management by assigned personnel. ·Prevent contact or mixing of incompatible hazardous wastes, and strictly prohibit open-air storage.
Compliant Transportation and Disposal	·Entrust units with corresponding qualifications for transportation and disposal, and verify the business licenses, environmental impact assessment documents, pollution discharge permits, and other qualifications of the disposal units. ·Domestic waste is transported by units with clearance capacity to locations designated by the government to prevent random dumping.	·Entrust units with hazardous waste business permits and hazardous goods transportation qualifications for transportation and disposal. ·Standardize inbound/outbound records and handover management.
Register Management	·Implement the information-based register management throughout the process, covering electronic management registers for the entire process of generation, storage, transfer, and final disposal.	·Implement the transfer manifest system, and establish electronic registers to ensure the traceability and ease of querying of each batch of hazardous waste.

The Company continuously conducts waste management training and awareness campaigns to strengthen employees' awareness of "reduction, resource utilization, and harmlessness". Main production bases of the Company actively carry out various training sessions and practical activities to promote the implementation of waste management requirements.

Waste Training Sessions and Practical Activities of Bloomage Biotech (Selected)

Chaohu Production Base: conducted the "Training on Laboratory Waste Liquid Disposal Knowledge" to enhance laboratory personnel's standardized operational capabilities in classification, storage, and disposal of waste liquids.

[5] The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. During the reporting period, the Company's improvements in environmental protection facilities and adjustments in production and operations resulted in significant fluctuations in most pollutant emission data.

Tianjin Production Base： regularly conducted specialized training on hazardous waste and general solid waste management to improve employees' compliance awareness and site management.

Jinan Production Base： organized thematic awareness campaigns to enhance environmental management personnel's cognitive and practical capabilities in solid waste reduction and resource utilization.

Waste Release of Bloomage Biotech[6]

Index	Unit	2025	2024	2023
Total waste discharged	ton	7,102.82	12,204.44	10,923.55
General industrial waste	ton	5,492.61	10,521.68	9,599.45
Hazardous waste	ton	87.94	144.22	85.01
Domestic waste	ton	889.10	1,184.42	581.09
Food waste	ton	633.17	354.12	658.00
Recycled waste	ton	3,304.38	7,125.01	7,331.00
Hazardous waste emission intensity	ton/CNY 1 million revenue	0.02	0.03	0.01
Non-hazardous waste emission intensity	ton/CNY 1 million revenue	1.67	2.25	1.78

Resource Utilization and Circular Economy

Water Management

Relying on municipal water supply systems, Bloomage Biotech provides water for all office and production activities, covering production processes, cooling system replenishment, boiler water feeding, environmental protection facility operation, and daily life needs. To strengthen water resource management, the Company has formulated and implemented the *Regulations on Energy and Energy Conservation & Consumption Reduction Management*, specifying hierarchical water metering and strengthening whole-process monitoring and data support. The Energy Management Leading Group organizes, manages, and coordinates water resource usage and energy conservation efforts. The Engineering Equipment Department serves as the competent department for water management. At the production units of each level, the first persons of departments, workshops, and teams responsible for production respectively act as responsible persons for energy management at their respective levels, forming an energy management network covering the entire production base to ensure efficient water resource utilization and coordinated achievement of energy-saving targets.

In 2025, Bloomage Biotech set water conservation targets, defining improved water efficiency as the core direction. It continued to advance water conservation management by increasing the recycling rate of condensate, optimizing production processes and taking other measures. All production bases systematically implemented water conservation and consumption reduction solutions centered on the principles of "rational metering, efficient water use, and resource recovery" to ensure effective achievement of targets. In the reporting year, the Company successfully achieved its water conservation targets as scheduled.

Water Conservation Strategies and Consumption Reduction Practices of Bloomage Biotech (Selected)

Water Conservation and Consumption Reduction Strategies	Specific Practices
Rational Metering	**Hainan Base:** Regularly monitored purified water source quality to ensure metering accuracy. **Tianjin Base:** Analyzed energy usage weekly and monthly to promptly address water consumption fluctuations and losses. **Jinan Base:** Monitored water balance, with metering and data analysis for each water consumption unit.
Efficient Water Use	**Dongying Base:** Newly installed a purified water distribution system to enhance water utilization efficiency. **Hainan Base:** Regularly inspected water supply pipelines to identify and eliminate water wastage such as water running overflowing, dripping and leaking. **Jinan Base:** Launched a water conservation initiative to encourage all employees to save water.
Resource Recycling	**Tianjin Base:** ·Recycled primary concentrated water for reuse of purified water. ·Recovered steam generated during alcohol distillation and conveyed it as condensate to workshops for recycling. **Hainan Base:** Modified purified water concentrate discharge to the cooling pond for water resource reuse, reducing direct tap water consumption for cooling.

▶ Case: Circulation Retrofit of Heat Medium Water Reduces Water Resource Consumption

After the drying phase in the "Three-in-One" production process of Bloomage Biotech, equipment needs to be cooled for discharge. Before the retrofit, cooling involved discharging hot heat medium water and replenishing with cold water, consuming several tons of fresh water per operation and resulting in significant water wastage. To address this, the Company installed plate heat exchangers in the heat medium water loop and interconnected them with the chilled water system within the plant. After the retrofit, heat medium water circulated in a closed loop during cooling, exchanging heat with chilled water via plate heat exchangers for cooling. The process needs no discharge and replenishment, thereby reducing fresh water consumption and drainage losses during cooling. The project achieved closed-loop cooling without discharge or replenishment, lowering fresh water usage, associated water costs and softening treatment expenses, and saving energy.

▶ Case: Replacement of Water Softener Resin Enhances Water Production Efficiency, Conserves Resources and Reduces Consumption

Due to resin aging in water softeners of Bloomage Biotech, the water output capacity of the equipment decreased, increasing regeneration frequency and causing additional water and chemical consumption. To address this issue, we replaced the resin material and performed restorative maintenance during the overhaul period. After the replacement, the operational efficiency of the water softener improved, with regeneration frequency reduced by approximately 50% compared to pre-retrofit levels, saving about 3,250m³ of water annually and reducing water treatment costs by approximately CNY 19,700, while decreasing resource consumption during equipment operation.

Water Resource Consumption of Bloomage Biotech[7]

Index	Unit	2025	2024	2023
Total water consumption	10,000tons	182.58[8]	163.83	149.33
Water use intensity	ton/CNY 1 million revenue	434.80	305.04	245.77

Packaging Material Management

Bloomage Biotech strictly complies with domestic green packaging policy requirements including the *Law of the People's Republic of China on Product Quality*, the *Food Safety Law of the People's Republic of China*, the *Drug Administration Law of the People's Republic of China*, the *Regulations on the Supervision and Administration of Cosmetics*, the *Regulations on the Supervision and Administration of Medical Devices*, and the *Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Wastes*. The Company keeps an eye on green packaging policies and industry trends, and advances the management and improvement of packaging materials and design in line with business characteristics.

Guided by circular economy principles, the Company implements practices focused on packaging material reduction and recyclability while ensuring product safety, quality, and compliance requirements are met. We optimize packaging structures and material usage, and enhance the adaptability of recyclable and reusable design. We also explore the application of renewable and biodegradable materials where feasible, and pay attention to the full lifecycle impact of

[6] The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. During the reporting period, the Company's improvements in environmental protection facilities and adjustments in production and operations resulted in significant fluctuations in most waste release data.

[7] The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China.

[8] During the reporting period, the Company's overall water consumption increased, primarily due to the commissioning of new production capacity and the operation of newly constructed supporting facilities.

packaging materials. With these measures, we progressively reduce the environmental burden of packaging.

Reducing Packaging Material Usage	Promoting Recycling and Circularity	Applying Sustainable Materials
While meeting functional requirements for product protection, compliance, user experience, etc., we optimize structures and specifications to reduce unnecessary packaging material usage, thereby lowering resource consumption and environmental impact at the source.	We design recyclable packaging to improve packaging recyclability, while trialing the use of recycled materials in packaging, such as recycled polyethylene terephthalate (rPET) and recycled cartons, to promote resource circularity.	Considering product safety and regulatory requirements, we explore the use of alternative materials like renewable and biodegradable options where feasible, gradually reducing reliance on virgin petroleum-based plastics.

Reducing Packaging Material Usage

While ensuring packaging functionality, Bloomage Biotech continuously takes measures to mitigate the environmental impact of packaging materials. By reducing packaging weight, optimizing packaging structures and processes, and utilizing low-carbon materials, we are committed to advancing packaging material lightweighting to alleviate environmental pressure of packaging at the source.

Packaging Structure Optimization and Reduction	·We advanced packaging lightweighting and material optimization to reduce resource consumption and environmental impact. By implementing reduced-layer packaging design, eliminating unnecessary intermediate layers or outer boxes, and developing corrugated lamination processes, we effectively reduced corrugated paper and paper usage by over 20% while ensuring protective performance of packaging. This resulted in an annual reduction of approximately 50 tons in raw material consumption and also a decrease of about 30 tons in packaging waste. ·BIOHYALUX brand under Bloomage Biotech reduced raw material waste from custom mold development through standardized packaging molds, and adopted lightweight acrylic materials to lower overall energy consumption during warehousing and transportation, further reducing carbon emissions.  **Optimization of BIOHYALUX Product Packaging**
Packaging Material Substitution	·In raw material production and packaging workshops, the replacement of polyethylene plastic bags with material buffer tanks saved 12,251 polyethylene plastic bags in 2025. ·We substituted plastic film sealing with dispensing methods in packaging to reduce plastic usage. ·We promoted the use of biodegradable or compostable plant fiber materials (bagasse) for inserts of single-use boxes to replace traditional inner trays made of plastic, reducing virgin plastic consumption by approximately 25 tons annually.
Low-carbon Materials	·We updated 1ml plungers and boosters for pre-filled syringes by adopting hot runner molds. This project is expected to reduce PC injection molding waste by about 1 ton annually, corresponding to a carbon emission reduction of approximately 3 tons of CO_2 equivalent[9]. ·We utilized biodegradable or compostable plant fiber materials for inserts of single-use boxes to decrease virgin plastic usage.
Packaging Reduction	We used lightweight penicillin bottles to achieve a 30% weight reduction compared to traditional products.

▶ Case: Application of Low-Carbon Bubble Films in Cloud Warehouses Reduces Carbon Emissions from Packaging Materials

To mitigate the environmental impact of packaging materials in e-commerce fulfillment, Bloomage Biotech piloted replacing protective inner packaging materials for C-end shipments in multiple cloud warehouses with a low-carbon eco-friendly bubble film (RW eco-formula). While meeting protective performance and usage requirements, this material reduces carbon emission intensity per unit of material compared to conventional solutions. During the reporting year, the low-carbon bubble film was applied across multiple cloud warehouses and SKUs, achieving scaled implementation.

▶ Case: Corrugated Lamination Process R&D Project Drives Single-use Packaging Lightweighting and Recyclability Upgrade

The Company initiated the development of a sustainable-based "corrugated lamination" packaging process upon approval, enabling the replacement of solid grayboards of traditional rigid boxes with high-strength corrugated core layers through material and structural innovation. This achieves lightweight and easy recyclability while meeting packaging protection and appearance presentation requirements. The project prioritizes recyclable systems in material selection and enhances load-bearing performance through structural design. meanwhile, validation methods such as DOE optimization and environmental adaptability testing are employed to ensure the new solution can be adapted to existing production lines for mass production. Within the project scope, evaluations indicate this solution can reduce raw material usage per box by approximately 20%, decrease box weight by about 10%-20%, and lower carbon emissions per box by around 20%, while maintaining required packaging compression resistance.

▶ Case: Bloomage Biotech Implements Reusable Packaging Design to Establish Green Cycle for Cream Products

Bloomage Biotech actively practices green design concepts by introducing reusable packaging solutions for cream products. Through standardized design, the same outer box is compatible with refill cores for the entire cream series, extending packaging lifespan and reducing frequent disposal of outer boxes due to product changes. Meanwhile, minimalist packaging is adopted for refill cores, significantly reducing the usage of single-use plastics and auxiliary materials.

Currently, we have launched refill design for several flagship brands:

BIOHYALUX Elasticity Filler Anti-Wrinkle Essence Cream 50g (with refill)

BIOHYALUX INFIHA Barrier Repairing Light Cream 50g (with refill)

BIOHYALUX INFIHA Barrier Repairing Nourishing Cream 50g (with refill)

QuadHA Skin Dynamic Youth Cream 40g (Nourishing Version) (with refill)

QuadHA Skin Dynamic Youth Cream 40g (with refill)

QuadHA Energize Regenerating Eye Cream 20g (with refill)

MedRepair Multi-Element Concentrated Repair Essence Cream (with refill)

Refill Packaging Design for Flagship Brands

Promoting Recycling and Circularity

Upholding sustainable development principles, Bloomage Biotech fully considers post-consumer recycling scenarios during packaging design, prioritizing easily recyclable mono-materials and upgrading packaging for multiple products. Concurrently, the Company systematically advances recycling programs for discarded packaging and scrapped products by category, gradually establishing more efficient recycling and resource utilization mechanisms to enhance the circularity of packaging materials and facilitate the implementation of a green closed-loop system.

▶ Case: "Empty Single-use Ampoule Recycling Program" of BIOHYALUX Illuminates Beauty of Circularity

As a pioneer in China's single-use ampoule serum category, BIOHYALUX brand under Bloomage Biotech launched its "Empty Single-use Ampoule Recycling Program" in 2020 to explore pathways for cosmetic packaging recycling. Collected empty

[9] It is calculated based on a carbon footprint of approximately 3 tons of CO_2 equivalent per ton of PC material.

ampoules are sorted before sent to recycling plants, where they are transformed through resource utilization into recycled products such as frisbees, flowerpots, and art installations. Currently, this recycling program has expanded to include empty single-use ampoules from non-BIOHYALUX brands. Consumers can submit recycling applications via the "BIOHYALUX Official Mall" mini-program and receive "Ampoule Credits" upon approval, redeemable for benefits including single-use serums, skincare samples, and medical aesthetic treatments. During the reporting year, the program achieved 48,000 redemption instances, recycling 6.4207 million BIOHYALUX ampoules (68.86% of the total) and 2.9033 million ampoules from other brands (31.14% of the total). We recycled a total of 21.2767 million empty single-use ampoules from BIOHYALUX brand and 3.8527 million from other brands, promoting packaging recycling and public engagement in low-carbon practices.

Annual Empty Single-use Ampoule Recycling Plan of BIOHYALUX

▶ Case: Empty Bottle Recycling Plan-Giving Bottles A "New" Life

QuadHA brand under Bloomage Biotech partnered with offline stores for the "Empty Bottle Recycling Plan—Giving Bottles A 'New' Life" campaign, where consumers return empty bottles to stores to exchange for items, advancing packaging recycling and circularity.

Empty Bottle Recycling Plan—Giving Bottles A "New" Life

Applying Sustainable Materials

Bloomage Biotech continuously advances green packaging upgrades, prioritizing renewable and recyclable materials including Post-Consumer Recycled (PCR) plastics, molded pulp inserts, and FSC-certified paper to reduce the usage of virgin petroleum-based plastics and reliance on fossil resources.

▶ Case: Skincare Brands Fully Adopt FSC-Certified Eco-Paper

Skincare brands under Bloomage Biotech use FSC-certified paper for outer boxes of products, ensuring traceable paper sourcing from well-managed, ecologically friendly forests that deliver social benefits and economic sustainability. Sustainable packaging is enhanced through prioritized use of renewable, traceable raw materials.

Outer Box of a Product of a Skincare Brand under Bloomage Biotech

Procurement of Packaging Materials by Bloomage Biotech				
Indicator	Unit	2025[10]	2024	2023
Total purchase volume of packaging materials	Ton	3,006.41	8,494.23	5,270.00
Procurement volume of FSC-certified paper packaging materials	ton	160.72	1,635.00	846.00

Biodiversity Assessment

Adhering to the bottom line of biodiversity conservation in its production and operations, Bloomage Biotech continuously identifies, monitors, and mitigates potential impacts of its operational activities on the surrounding ecological environment. The Company assesses potential risk sources by considering factors such as the scope of impact, probability of occurrence, and severity of harm, and formulates and implements corresponding prevention and control measures. Meanwhile, it integrates the concept of biodiversity conservation into product development, manufacturing, and raw material procurement processes. Leveraging its technological advantages in synthetic biology, it strives to reduce the potential impact of products throughout their life cycle on biodiversity and promote sustainable development.

Biodiversity Conservation Measures of Bloomage Biotech (Selected)		
Bottom Line Protection Measures	Project planning and design stage	We conduct environmental impact assessments in accordance with the law and implement necessary ecological protection measures during construction.
	Daily production and operation stage	We regularly assess biodiversity and investigate surrounding ecosystems and species of flora and fauna. The Company has assessed biodiversity, with results indicating no nature reserves, scenic areas, national and local key protected wild plants, or rare or endangered wild animals within a 1 km radius of the plant site. Provided that environmental protection facilities are operating properly and effectively, and measures such as the testing and disinfection of foreign items are implemented, the operational activities are not expected to have significant negative impacts on biodiversity. The Company will continue to conduct relevant assessments and prudently manage biodiversity risks.

During the reporting year, the Company assessed biodiversity at its Jinan Production Base as a pilot initiative. The assessment team investigated the ecological environment surrounding the area where the production base is located, and assessed and controlled risk sources such as environmental pollution and invasive species, with no significant negative impacts identified.

[10] During the reporting year, the Company conducted systematic structural optimization focusing on its innovative transformation businesses in dermatological science and nutritional science. As a result, the total procurement volume of packaging materials and the procurement volume of FSC-certified paper packaging materials both decreased compared with previous years.

04

Talent Development and Community Engagement

Bloomage Biotech adheres to a people-centered philosophy of sustainable development, viewing its responsibilities to employees and to communities as an integrated whole that mutually reinforces one another. Internally, we are committed to creating an equal, diverse, inclusive, and safe workplace. Through a comprehensive, lifecycle-oriented development system, we support employees' lifelong growth while systematically managing occupational health and safety to safeguard their physical and mental well-being. Externally, we rely on the "In Cloud" public welfare campaign to actively fulfill our corporate citizenship responsibilities, integrating technology, art, and philanthropy to give back to society. Through coordinated internal and external efforts, we strive to achieve synergistic progress in employee development, community prosperity, and corporate sustainability.

Fair Employment and Employee Rights

We strictly adhere to the principle of equal employment and place respect for and protection of human and labor rights at the core of our operations and management. We adopt management measures, such as standardizing recruitment and hiring practices, improving employment policies, and strictly upholding ethical standards to continuously safeguard the fundamental and lawful rights of all employees.

Compliant Employment

We take the *Universal Declaration of Human Rights* as our guiding principle and strictly comply with labor laws and regulations in China and other regions where we operate, including the *Labor Law of the People's Republic of China* and the *Labor Contract Law of the People's Republic of China*. We also actively refer to international social responsibility standards such as SA8000, ISO 26000, and the Ethical Trading Initiative (ETI), incorporating relevant requirements into our *Employee Handbook* and internal management policies. We treat all employees fairly and equitably regardless of race, social status, nationality, gender, age, disability, marital status, religious belief, cultural background, or other differences. We strictly prohibit child labor, forced labor, and any form of discrimination, harassment, or abuse, and are committed to fostering a safe, equal, and respectful workplace.

In recruitment and separation management, including termination and resignation, we implement standardized management practices, including but not limited to the following measures:

Employee Recruitment	·**Openness and Fairness:** We conduct all recruitment activities in accordance with our *Recruitment Management System*, adhering to the principles of openness and fairness. We strictly prohibit any form of discrimination or favoritism based on ethnicity, religion, disability, gender, marital status, or any other factor. ·**Standardized and Transparent Procedures:** We have established a comprehensive recruitment process covering job requisition submission, approval, job posting, resume screening, interviews and assessments, background checks, and hiring decisions to ensure a standardized and transparent process and merit-based recruitment. ·**Rigorous and Compliant Review:** With the informed consent of candidates, we strictly verify their identity information to prevent child labor, identity fraud, and potential conflicts of interest. ·**Flexible and Controlled Mechanism:** For urgent, unplanned, or specialized talent needs, we implement a strictly supervised special approval process to ensure controlled procedures while enabling timely recruitment and appropriate job fit.
Employee Separation Management	·**Respect for Voluntary Resignation:** In cases where employees voluntarily terminate their labor contracts, we fully respect their decision and handle resignation procedures in accordance with relevant regulations. ·**Priority for Internal Placement:** During workforce adjustments, we prioritize internal reassignment and job transfers to retain talent to the greatest extent possible, reduce employee turnover, and enhance organizational stability. ·**Lawful and Compliant Dismissal:** Where termination of an employment contract is necessary, we strictly comply with the *Labor Contract Law of the People's Republic of China*, and communicate with employees in advance regarding the reasons for termination and subsequent arrangements. We provide severance payment in accordance with the law, and support employees' reemployment through career counseling, training recommendations, and internal transfer opportunities.

While maintaining the stability of our core teams, we actively fulfill our social responsibilities by exploring diverse employment models and creating more job opportunities in emerging sectors. We continue to increase hiring in areas such as livestreaming e-commerce, content marketing, and digital operations, creating a range of emerging roles including AI Agent engineers, private domain operations specialists, and content operations specialists. Meanwhile, we actively explore diverse employment models and provide various forms of flexible employment opportunities. Through sound management mechanisms, we safeguard the lawful rights and benefits of flexible workers and promote a virtuous cycle between corporate development and job creation.

As of the end of the reporting period, we employed 3,699 people, all of whom are covered by duly executed labor contracts. All employees were adults aged 18 or above. No incidents of child labor or forced labor occurred, and there were no cases involving debt bondage, human trafficking, or other practices that seriously violate human rights standards.

Diversity and Inclusion

We are committed to fostering a diverse, equitable, and inclusive work environment and firmly believe that differences in gender, ability, background, and experience enrich our teams with broader perspectives and creativity. We provide equal opportunities for career development to all employees and actively leverage the unique strengths of our workforce's diverse backgrounds in our operations.

In 2025, we further enhanced our diversity, inclusion, and anti-discrimination management system. Topics including opposition to discrimination and harassment, and the prohibition of forced labor and abusive practices, have been incorporated into our *Employee Onboarding Guide* and induction training, ensuring that every new employee completes relevant awareness training upon joining. With our policies and systems, we continuously strengthened targeted support and rights protection for various employee groups. We respected the ethnic cultures and religious beliefs of all staff, built a diversified talent system, and implemented non-discriminatory policies and measures, effectively safeguarding the equal rights and personal dignity of every employee.

Multicultural Integration	·We fully respect the cultural traditions and dietary habits of employees from different ethnic backgrounds, and actively integrate this respect into our daily operations and employee care initiatives. For example, our cafeterias offer a variety of dining options designed to accommodate diverse dietary needs. ·We embrace an open and inclusive employment philosophy, actively attracting international talent to enhance organizational vitality and strengthen our global perspective. As of 2025, we employed 11 expatriate staff from various countries.
Support for Post-retirement Rehiring	·We have established the *Management Regulations on Post-Retirement Rehiring*, providing a platform for experienced senior professionals to continue contributing their expertise. In 2025, we had 2 post-retirement rehired employees.
Employment Promotion for Persons with Disabilities	·Our recruitment practices explicitly prohibit discrimination. We continuously create suitable job opportunities for persons with disabilities and improve accessibility facilities to safeguard their legitimate rights and interests. In 2025, we employed 11 employees with disabilities. We ensured that their compensation exceed the local minimum wage standard, and we provided them with all statutory social benefits in compliance with national regulations, including pension, medical, unemployment, work-related injury, and maternity insurance, as well as a housing provident fund.

Indicator		Headcount in 2025 (persons)	Proportion (%)
Gender Structure	Male	1,961	53.01%
	Female	1,738	46.99%
Age Structure	Aged 30 or below	1,588	42.93%

Indicator		Headcount in 2025 (persons)	Proportion (%)
	Aged 31 to 50	2,041	55.18%
	Aged 51 or above	70	1.89%
Job Level	Ordinary employees	3,532	95.49%
	Middle management	162	4.37%
	Senior management	5	0.14%
Education Background	Below bachelor's degree	1,732	46.82%
	Bachelor's degree	1,383	37.39%
	Master's degree	552	14.92%
	Doctoral degree	32	0.87%

Key Performance

- In 2025, the proportions of female employees at Bloomage Biotech were as follows:
- Proportion of female employees of the total number of employees: 46.99%
- Proportion of female employees in senior management: 20.00%
- Proportion of female employees in middle management: 41.36%
- Proportion of female employees in R&D staff: 61.98%

Employee Compensation and Rights

We continuously refine our employee compensation and benefits systems. By establishing robust policies, providing favorable working conditions, and maintaining open channels for communication and grievance reporting, we foster a work environment built on respect, fairness, and collaboration.

Employee Compensation

We adhere to the principle of equal pay for equal work and continuously enhance our *Compensation Management System* and *Performance Management System*. Our compensation practices are guided by the principles of paying for the position and performance, and maintaining openness, fairness, and transparency. We ensure that salaries are paid in full and on time, and we provide each employee with a detailed payroll statement, enabling them to clearly understand their salary composition, bonuses, and various benefits.

Our compensation structure consists of a fixed base salary, with performance-linked variable pay as the core incentive. Overtime wages are paid in accordance with legal requirements. We have also established a range of allowances and subsidies to effectively respond to employees' daily and special needs. Furthermore, each year, considering current rates in the job market and the overall compensation budget, we implement dynamic salary adjustments based on employee performance ratings. This process is moderately weighted in favor of high-performing and high-potential talent, continuously enhancing our compensation competitiveness and organizational vitality.

To enhance the motivational function of compensation, we will continue to optimize our income distribution structure, ensuring that pay is closely aligned with employee contributions and performance outcomes. We have established a cascading mechanism that translates strategic goals into organizational performance metrics, which are then cascaded down to individual employee performance objectives. This ensures a clear line of sight from strategy to execution, driving effective implementation. In terms of performance appraisal, we have developed a robust indicator system grounded in principles of fairness, compliance, and incentive. Organizational performance focuses on key business indicators, strategic initiatives, and exceptional items, while employee performance focuses on business targets, personal development goals, and corresponding bonus or deduction items, forming a systematic performance management system with clear direction. We set differentiated appraisal cycles based on the characteristics of different roles. For example, R&D positions are assessed through a combination of project-based and annual reviews, while supply chain positions undergo quarterly and annual reviews, enhancing the rationality and effectiveness of evaluations.

To ensure that our incentive mechanisms are precisely aligned with the Company's strategy and business development needs, we updated the bonus incentive plans for our front-line business and R&D platforms during the year. This initiative strengthens the relevance and effectiveness of our incentives, fully stimulating the creativity and execution of our core teams. At the same time, we maintain an equity incentive plan to attract and retain outstanding talent, promoting the long-term, shared development of both the Company and the employees.

Employee Rights and Interests

We place high importance on and resolutely safeguard the legitimate rights and interests of all employees. We strictly prohibit all forms of forced labor and protect employees' rights to rest and leave, participate in trade unions, freedom of association, and collective bargaining. Through open, inclusive, and transparent internal communication mechanisms, we continuously enhance our employees' sense of fulfillment.

We explicitly prohibit any form of forced labor or abusive practices, including sexual coercion, sexual assault, threats, body searches, mistreatment, humiliation, exploitation, or harassment. Through our policies, we clearly define employee rights and delineate boundaries for manager conduct. We have established grievance mechanisms, with dedicated departments responsible for investigating and addressing concerns and conducting ongoing supervision to ensure fair and compliant handling.

In terms of working hours and leave management, we have formulated the *Attendance and Leave Management System* and strictly implement standard working hours and comprehensive working hour calculation systems. By implementing a well-designed multi-shift system covering different time periods, and based on different job functions, we flexibly configure standard working hours, comprehensive working hours, and flexible working arrangements such as staggered shifts. This approach effectively balances operational needs with employees' personal lifestyles, safeguarding employees' legitimate rights to rest and leave while maintaining business and production order.

We are committed to fostering a transparent, efficient, and diversified organizational communication environment. Through institutionalized feedback channels, normalized democratic participation, and robust protection of employee rights, we continuously enhance organizational health and employees' sense of belonging. To ensure orderly and efficient communication, we have established both online and offline daily communication channels and clearly defined communication conduct guidelines:

Standardized Communication Channels	·We follow the principle of "prioritizing communication within the reporting line, supplemented by cross-level communication". For daily work matters, employees should first communicate with their direct supervisor. If an issue remains unresolved or requires escalation, employees may communicate through written formats such as email or Feishu, ensuring clear and traceable processes.
Healthy Communication Environment	·We advocate a communication culture based on mutual respect and factual accuracy, prohibiting any form of offensive language, personal attacks, or dissemination of false information. When raising work-related concerns, employees must base their feedback on facts and provide constructive suggestions.
Responsible Information Sharing	·We require that all information shared through our communication channels is accurate, complete, and timely. Concealing key information or maliciously creating information asymmetry is strictly prohibited. Individuals who cause adverse consequences due to information concealment or misrepresentation will be held accountable in accordance with relevant regulations.

We have established a multi-tiered employee feedback mechanism, encompassing face-to-face communication channels such as employee meetings and departmental gatherings, as well as various feedback channels including email and online suggestion boxes, enabling two-way communication. We conduct regular anonymous employee satisfaction surveys to systematically understand employee perceptions and needs across five dimensions: job responsibilities, management processes, work environment, career development, and compensation and benefits. At the same time, we actively involve employees in shaping our policies and procedures. Important policies are published on internal platforms for broad employee consultation, safeguarding employees' right to information and participation.

We fully respect and protect, in accordance with the law, employees' legitimate rights to freedom of association and collective bargaining. Without prejudice to legality, we do not interfere with the establishment, operation, or management of collective bargaining, facilitating communication between labor and management. Trade unions have been established in accordance with the law at all our production bases and operate in compliance with the *Trade Union Management System*. These unions actively represent employee voices, participate in democratic management, and safeguard employees' legitimate rights and interests. Through various welfare and care initiatives, they contribute to building harmonious and stable labor relations.

Reporting and Complaints

To safeguard the legitimate rights and privacy of our employees, we have established strictly confidential and anonymous channels for reporting complaints and concerns. Employees can safely and anonymously report issues such as policy violations, workplace misconduct, and safety hazards. All reports shall be investigated and handled independently and impartially. Whistleblower information is strictly protected, and all forms of retaliation are prohibited.

Additionally, in our *Code of Business Conduct for Employees*, we explicitly require employees to protect the Company's interests. If employees become aware of any conduct that violates company policies or may harm the Company's interests, they can promptly report the matter to their direct supervisor, department head, responsible executive, or the relevant functional departments.

Complaint Channel

E-mail address: hr@bloomagebiotech.com

Employee Development and Growth

At Bloomage Biotech, we regard our people as the core driver of corporate growth. We continuously enhance our career development pathways, training systems, and performance incentive mechanisms to provide comprehensive support for employee growth.

Talent Acquisition and Assessment

We have planned talent development from a strategic perspective and established an efficient talent recruitment and management mechanism. Through data-driven forecasting of talent needs and strategic partnerships with external recruitment agencies, we have built a talent pool of qualified candidates covering technical, managerial and other professional fields.

Our recruitment strategy integrates both online and offline channels, leveraging internal and external resources. Online, we utilize major job platforms, our corporate website, and university partnerships to attract talent broadly, engaging with graduating students through virtual career fairs and interactive sessions. Offline, we actively participate in campus recruitment events and industry seminars to expand our reach.

We have established long-term strategic partnerships with leading academic institutions including Peking University, Tsinghua University, and Jiangnan University. Through initiatives such as university-industry collaboration bases, we secure early access to outstanding young talent. Meanwhile, we encourage employee referrals and continuously activate and nurture our candidate pool through ongoing database management.

Our assessment process employs a diversified approach to talent selection. We have developed a comprehensive evaluation system combining professional assessments, situational simulations, and multi-round interviews to thoroughly evaluate candidate capabilities, ensuring strong alignment with our strategic talent needs.

Talent Development and Growth

We view our people as the core driver of organizational development and are committed to building a systematic and diversified talent development and growth system. Guided by the strategic principles of "tiered development, career-long support, and multi-channel career pathways", we provide employees across different functions and levels with clear career progression opportunities and sustained growth support through structured promotion and rotation mechanisms, customized development programs, and integrated online and offline learning platforms.

By Rank	We have established differentiated development systems tailored to junior, middle, and senior managers, as well as key professional talent.
By Function	We have defined clear career pathways across various functions, including R&D, professional tracks, and management.
By Execution	Through targeted initiatives such as key position talent development programs and internal promotion mechanisms, we are building a sustainable talent pipeline to ensure a robust supply of talent to support the Company's long-term development.

Employee Training

We have established a tiered and function-specific training system covering all employees across their entire career journey. Focusing on key areas including corporate culture and policies, general skills, professional capabilities, and leadership, we have designed differentiated development programs and learning pathways for four key groups: new hires, managers, professional/R&D staff, and employees in critical positions. This approach aims to provide systematic learning resources to enhance the managerial and professional skills of employees at all levels, supporting talent development aligned with job requirements and empowering the Company's growth.

Training for New Employees	·We conduct a series of training programs for newly hired employees. By developing an onboarding learning roadmap, we help new employees gain a comprehensive and in-depth understanding of our business operations and immerse themselves in our corporate culture. Training sessions include policy briefings and hands-on system training, with aim to enhance work efficiency and help new colleagues integrate quickly into their teams. In 2025, over 400 sessions were attended by newly hired regular employees.
Training for Managers	·Based on the competency requirements for managers and business development needs, we have designed and implemented development programs for managers at different levels, as well as programs for developing potential future leaders. Courses include *Leadership and Role Awareness*, *Task Planning and Execution*, *Coaching and Developing Employees*, and *Team Building and Succession Planning*, systematically enhancing managers' leadership skills and change management capabilities.
Training for Professional/R&D Staff	·In line with the professional competency requirements for each function and role, we have developed corresponding learning roadmaps, establishing a progressive capability-building system from foundational to advanced levels. Through weekly online professional knowledge sharing sessions (with an average weekly participation of 354 employees in 2025), we continuously cultivate the skills of core talent across various professional domains.
Training for Employees in Critical Positions	·Guided by the core principles of "precise selection, support for growth, emphasis on practical application, and role-readiness", we have built a closed-loop, full-cycle development system. This process involves identifying critical positions across the Company, defining talent criteria for these positions, conducting talent reviews to determine development priorities and objectives, designing customized development plans, and performing talent assessments to ensure readiness for placement. Through these phased steps, we systematically nurture and deploy talent for critical positions.

Employee Training Overview 2025 of Bloomage Biotech[11]

Indicator		Unit	2025	2024	2023
Average training hours of employees		hour	34.72	22.83	26.61
Average training hours by rank	General staff	hour	35.96	25.84	18.49
	The Management	hour	23.46	32.52	38.52
Average training hours by gender	Male	hour	41.28	29.17	22.19
	Female	hour	23.37	24.16	23.15

Meanwhile, we actively leverage and integrate high-quality external resources, maintaining stable partnerships with renowned universities, professional training institutions, and industry think tanks. We regularly introduce cutting-edge programs and support employees in participating in external certifications and high-level industry exchange activities, broadening their professional perspectives and industry insights. In 2025, we continued to invest resources in enhancing workforce capabilities, with total annual employee training expenditure reaching CNY 598,100 and an employee training coverage rate of 100%.

Career Development Pathways and Promotion Mechanism

During the reporting period, we formulated the *Employee Development and Promotion Mechanism*, systematically upgrading our employee promotion and talent rotation systems. The upgrading focus on building diversified career pathways, establishing precise evaluation systems, facilitating horizontal talent mobility, and ensuring fairness and transparency. These initiatives aim to address the limitations of traditional single-path management promotions, one-dimensional talent assessment methods, and constrained development approaches, creating a more flexible and equitable talent development ecosystem.

We have established three career development tracks for employees, i.e., the management track, the professional track, and the R&D track. Employees may pursue vertical progression within their chosen tracks or horizontal rotation across different tracks, providing multiple development pathways that align employee growth with our strategic objectives as closely as possible. At the same time, we have implemented a standardized promotion process covering nomination, review, approval, public notification, and a 3 to 6-month probationary assessment period. Promotion results are publicly announced within appropriate scopes based on rank, ensuring process transparency and openness.

In terms of talent development, we have established a multi-dimensional cultivation system incorporating mentorship

[11] Due to statistical scope and data availability constraints, only data related to AI training and new employee training are disclosed during the reporting period.

guidance, rotational assignments, and individual advancement support, continuously refining our employee development model.

Mentorship and Guidance	·**Mentorship Program:** We have established an internal coaching mechanism, providing employees with professional advisory and guidance support. ·**Regular Knowledge Sharing:** We conduct regular meetings to encourage communication and learning among employees, facilitate the sharing of best practices, and enable employees to independently access required training resources.
Experiential and Practical Learning	·**On-the-job Training:** Employees are matched with positions suited to their individual capabilities to accumulate practical skills and management experience through hands-on work. ·**Job Rotation Mechanism:** Based on the characteristics of job category transition, priorities for horizontal rotation, and qualification requirements for various positions, employees may pursue transition and development within their career development paths, with no fixed duration for rotation assignments.
Support for Learning	·**Personal Development:** We provide learning subsidies to encourage employees to pursue advanced degrees or professional certifications, supporting their efforts to obtain relevant qualifications and credentials.

To support continuous learning and career development, we adhere to our internal *Benefits Management System*, providing professional qualification training programs and educational advancement opportunities for all employees (including part-time and contract workers). The system clearly defines reimbursement provisions for academic advancement and subsidy support for obtaining professional certifications, offering learning subsidies at varying amounts based on rank to comprehensively motivate employees to enhance their professional capabilities and educational qualifications. In 2025, we invested a total of CNY 313,100 in subsidies for academic degrees and professional certifications. This year, in recognition of our ongoing exploration and development of talent pathways, we received several prestigious accolades in talent development and employer branding:

The 3rd China Human Resources Venus Awards
AI+HR Practice Pioneer Award

Liepin
Outstanding Employer Award (Beijing Region)

Zhaopin
Best Employer Award

Boss Zhipin
King's Boat-Most Talent-Friendly Employer Award

Employee Care and Benefits

Adhering to a people-centered approach, we have established a comprehensive benefits system that includes both statutory benefits and supplementary ones. Through diverse care initiatives, we strive to enhance our employees' sense of fulfillment, happiness, and belonging. All major production bases have signed *Collective Labor Agreements* with enterprise trade unions, covering fundamental principles such as diversity and anti-discrimination and anti-harassment. These agreements also address matters including working hours, wages, occupational safety and health, women's rights, employee insurance and benefits, and staff training, providing institutional support for the protection of employee rights and interests.

In terms of statutory benefits, we strictly comply with national laws and regulations. In accordance with our *Leave and Attendance Management System* and *Benefits Management System*, we make full contributions on behalf of employees to social insurance (including medical, pension, unemployment, work-related injury, and maternity insurance), and the housing provident fund. Additionally, employees enjoy various statutory leave benefits, including paid annual leave, sick leave, marriage leave, maternity leave, parental leave, nursing leave, paternity leave, and bereavement leave.

In terms of supplementary benefits, to enhance employee welfare and satisfaction, we provide a range of additional benefits for all regular employees. For care and wellness, we offer commercial insurance and annual physical examinations, complemented by supplementary health insurance and online physician consultation services. These benefits effectively alleviate employees' difficulties in accessing medical care and addressing medication queries. They can also guide appropriate specialist selection and provide health counseling to help relieve physical and mental stress. For financial benefits, we provide transportation subsidies, assistance with work residence permit applications, and discounts on company products, supporting work-life balance of employees on all fronts.

We regularly organize activities such as holiday celebrations, employee appreciation events, and team-building events, as well as continue to enhance the comfort of office environment through human-centered design to create a good organizational atmosphere that is dynamic, enjoyable, and harmonious.

▶ Case: Celebrating 25 Years of Shared Journey - Bloomage Biotech Holds 25th Anniversary Events

In August 2025, to celebrate our 25th anniversary and strengthen team cohesion, Bloomage Biotech held a series of anniversary events. Through interactive activities such as puzzle challenges and ring toss games, the events effectively stimulated team vitality and collaborative spirit. The subsequent "Two-Line Tour of Jinan City" facilitated cross-departmental interaction, fostering a harmonious atmosphere and creating vibrant shared memories for this significant corporate milestone.

2025 Anniversary Celebration of Bloomage Biotech Themed with "United, We Break Through"

▶ Case: Responding to Employee Needs with Care and Commitment

To understand the perspectives and development needs of young employees, the Jinan Production Base of Bloomage Biotech launched the evening school program themed with "Bloomage Biotech Night Talks" in mid-October, organizing no fewer than four themed sessions monthly. Through diverse and engaging activities, the program creates an interactive platform for young employees, enriching their spare time. Through ongoing communication, we promptly address concerns and resolve questions,

enabling young employees to feel the sincere care of the Party organization within the Company's development journey.



"Bloomage Biotech Night Talks" Themed Event

▶ Case: Responding to Employee Needs with Care and Commitment

To address the practical needs of employees' families, the Jinan Production Base launched a family parenting consultation program, inviting professionals to conduct over 20 guidance sessions on parent-child relationships. For employees whose children are preparing for the senior high school or college entrance examinations, the base thoughtfully organized the study tour program themed with "Bloomage Biotech Kids". Employees' children were invited to step into the R&D center and production workshops, experiencing firsthand the corporate culture and technological innovation. Customized gifts were presented to the children, further enhancing their sense of involvement, strengthening employees' sense of belonging, and aligning them with the Company's goals for growth.

"Bloomage Biotech Kids" Themed Study Tour Program

Key Performance
• In 2025, the coverage rate reached 100% for statutory social insurance and housing provident fund contributions for employees
• In 2025, the coverage rate reached 100% for annual physical examinations for employees

Key Performance
• In 2025, the coverage rate stood at 100% for supplementary medical insurance and physical examinations provided by the Company for employees
• In 2025, 176 family members of employees were covered under the supplementary commercial medical insurance

Work Safety and Occupational Health Protection

Bloomage Biotech strictly complies with relevant national laws and regulations, including the *Work Safety Law of the People's Republic of China* and the *Law of the People's Republic of China on Prevention and Control of Occupational Diseases*. We have established and continuously improved a systematic, standardized environmental, health, and safety (EHS) management system. Through robust governance structures, effective prevention mechanisms, efficient emergency response, and rigorous closed-loop improvement processes, we safeguard employee safety and health in all aspects.

Work Safety Management System

We prioritize the health and safety of our employees, contractors, and related parties. Adhering to the principles of "prevention with continuous improvement", we have built a safety management system with clear accountabilities and effective operations, ensuring the comprehensive implementation of all occupational health and safety requirements.

During the reporting period, in alignment with the latest compliance requirements, we updated and released several core policies, including the *Emergency Rescue Management System*, the *EHS Inspection and Hazard Investigation and Management System*, the *EHS Training and Education Management System*, and the *Contractor EHS Management System*. These updates ensure that safety management is governed by clear guidelines, further enhancing the completeness and adaptability of our policy framework. As of the end of the reporting period, all production bases in Jinan, Tianjin, and Dongying had obtained ISO 45001 Occupational Health and Safety Management System certification. Regular internal audits and management reviews are conducted to ensure the effective operation of the system.

Each production base has established a Work Safety Committee, chaired by the base director. These committees are responsible for coordinating safety management at their respective bases, setting safety objectives and priorities, and monitoring implementation. We have also established a centralized Safety and Environmental Protection Management Center, responsible for developing, maintaining, and supervising the EHS management system.

We have implemented a comprehensive work safety management system covering contractors, suppliers, and dispatched workers. All production bases are required to conduct rigorous qualification reviews during contractor onboarding and sign safety management agreements. Upon entering the facility, all personnel must conduct on-site operations in accordance with our Special Operations Management System and other relevant policies, undergo standardized safety training and assessments, and receive safety briefings before commencing work. During operations, we designate safety supervisors, implement safety measures, and require the operation supervisor, responsible departments and the Safety and Environmental Protection Department to conduct multi-level on-site supervision, ensuring consistent safety management standards across all bases and establishing closed-loop safety control from start to finish.

All production bases have implemented an entire personnel responsibility system for work safety, which decomposes annual safety objectives level by level to subsidiaries, departments, workshops and individuals. Its implementation is promoted through regular meetings, and coordination & performance appraisals. Through safety culture initiatives, ongoing monitoring, and regular internal and external audits, we consolidate and validate safety management outcomes. We also conduct post-incident reviews and analyses to drive continuous improvement of the management system.

Key Performance
• In 2025, Bloomage Biotech's total investment in work safety and occupational health amounted[12] to CNY 8.0427 million. Investment in employee work safety liability insurance was CNY 98,400, and the coverage rate of work safety liability insurance for relevant positions[13] reached 100%.
• In 2025, the purchase rate reached 100% for work-related injury insurance for employees at all production bases of Bloomage Biotech.

Work Safety and Emergency Response

We have systematically established and operated a dual prevention mechanism comprising safety risk classification & control and hazard identification & elimination. With ongoing work safety training and annual internal & external safety audits, we continuously update our risk registers and implement control measures, achieving standardized closed-loop

[12] The statistical scope covers Bloomage Biotech Group, including all expenditures on occupational health and safety. These expenditures include safety-related expenditures, physical examinations for employees, occupational health examinations, testing of occupational disease hazards, and investment in employee work safety liability insurance and work-related injury insurance.

[13] This item is not a mandatory requirement for the industry to which Bloomage Biotech belongs.

management across all production processes. Through these systematic management initiatives throughout the year, we fulfilled all work safety objectives.

Work Safety Management

Through hazard identification, assessment, and implementation of control measures, we continuously conduct hazard investigations to reduce work safety risks, prevent personal injury and health damage incidents, and effectively safeguard employee safety and health.

We strictly adhere to process safety design standards, closely monitoring parameters including temperature, pressure, and flow rates throughout production operations, and conducting regular maintenance and inspection of process equipment to ensure safe operation. During the year, we further strengthened upstream control and on-site protection throughout the equipment lifecycle. When acquiring new equipment, we prioritized inherently safer designs that incorporated safety features like interlocks, emergency stops, and audible-visual alarms. In view of mechanical injury risks such as collision, entanglement and clamping of moving equipment, special assessments were carried out and protective devices were improved accordingly. We also identified risk points across job-specific workplace scenarios and optimized tooling and work methods, for example, by adding protective covers and improving feeding platforms. These measures reduced personnel exposure risks while improving operational efficiency and convenience. For special operations such as hot work and confined space operations, we strictly enforced pre-operation approval requirements and on-site monitoring during operations. Operators must hold valid special operation certifications and complete specialized safety training. Emergency supplies were equipped on site, and the "Three Nos" operations (operations conducted without approval, certification, or monitoring) are strictly prohibited.

In terms of laboratory safety management, we have formulated and strictly implemented a series of policies including the *Laboratory Management Measures for the Company-wide R&D Platforms*, which specify standard operating procedures for chemicals, biological materials and experimental equipment. To reduce laboratory safety risk exposure, we have taken the following measures including risk identification and control, proper segregation and compliant disposal of hazardous chemicals, provision and supervision of personal protective equipment, regular maintenance of laboratory equipment, and the appointment of safety officers to formulate emergency plans and organize drills.

Regular Hazard Identification and Control

All production bases of Bloomage Biotech have established the dual prevention mechanism and conduct annual reviews to ensure its effectiveness. Specific measures include maintaining risk registers and hazard identification records, and conducting regular inspections covering comprehensive, seasonal, special, holiday, and routine checks. Hazards identified are promptly assessed and rectified in accordance with the *Management System for Safety Inspections and the Investigation and Treatment of Hidden Dangers*. Rectification progress is notified to employees via our internal OA (Office Automation) system to ensure process transparency and full participation. For the safety management of contractors and suppliers, we strictly enforce the *Contractor EHS Management System*, implementing closed-loop management covering qualification review, pre-entry safety briefings and training, and whole-process supervision of operations to mitigate risks associated with external personnel. In 2025, the Safety and Environmental Protection Management Center organized two rounds of safety audits and inspections across all production bases and R&D platforms.

Emergency Response Mechanism

To effectively respond to emergencies, we have established standardized EHS incident classification and response procedures, covering categories including workplace accidents, occupational disease incidents, on-site traffic accidents, food poisoning, and unexpected environmental incidents. The department involved must report incidents to the Safety and Environmental Protection Management Center immediately after occurrence, and activate the corresponding emergency response plan according to the incident level. We have also established an Emergency Leadership Group and a standing Emergency Management Office, with on-site emergency response coordination teams established within each business unit, ensuring unified command, rapid response, and effective handling during emergencies to minimize losses.

For occured EHS incidents, we have established a full-process closed-loop management process from investigation to rectification and implementation. We adhere to the "Four No Releases" incident handling principle. An investigation team, led by the Safety and Environmental Protection Management Center or the department with EHS responsibilities, completes investigations within specified timeframes and issues reports analyzing root causes and defining responsibilities and corrective measures. The department involved must implement all corrective requirements, with the Safety and Environmental Protection Management Center responsible for tracking and verification. Upon completion of the rectification, the Center shall establish incident files containing investigation reports, rectification reports, and training records. Regular incident statistical analysis is conducted, transforming lessons learned into continuous optimization of management systems, truly achieving closed-loop EHS management and long-term improvement.

Safety Training and Emergency Drills

In accordance with the *EHS Training and Education Management System*, we have established a tiered and function-specific safety training system covering all employees. We strictly implement a three-tier safety education program at the company, department, and team levels, ensuring that new employees, contractors, and visitors receive appropriate safety briefings and training before entering the premises. Training content is closely aligned with actual production activities, covering areas including laws and regulations, operating procedures, hazard identification, emergency response, and safety considerations for new processes, technologies, materials, and equipment. Training is delivered through diverse formats, including expert lectures, case study analyses, online learning, and hands-on practical exercises. We have established a rigorous training evaluation mechanism that incorporates attendance and pass rates into performance assessments, fostering a shift in employee safety mindset from "safety required of me" to "safety wanted by me".

In terms of emergency response capabilities, we conduct annual emergency drills across all production bases and office locations in accordance with safety emergency plans, helping employees translate safety knowledge into practical on-the-job skills. In conjunction with "Work Safety Month" activities, we organize themed publicity and education campaigns centered on the principle of "prioritizing safety, emphasizing prevention, and taking an integrated approach to risk management". Through initiatives such as digital display promotions, educational video screenings, and targeted discussion sessions, we continuously cultivate a safety culture. Additionally, we engage fire safety and industry experts to conduct specialized skills training, organizing hands-on drills with fire extinguishers, fire blankets, and fire hydrants to effectively enhance employees' practical response capabilities. These activities also encourage employees to participate in identifying workplace hazards, promoting the implementation of safety responsibilities and the cultivation of safe behaviors.

In 2025, a total of 847 safety training and education sessions were conducted across all production bases, reaching 18,162 participants.

Safety Drills at Production Bases

Occupational Health and Safety Incident Reporting

We have established multiple accessible reporting channels for occupational health and safety incidents. All production bases utilize digital tools including Feishu's Snap feature, suggestion boxes, and work group platforms, to enhance reporting efficiency. Formal procedures, such as the *Safety Reporting and Whistleblowing Management System*, support both named and anonymous reporting. All employees may report directly to their line managers or on-site HSE officers (Health, Safety and Environment). Every report received is subject to standardized documentation and investigation procedures, with corresponding incentive and accountability measures implemented to ensure corrective actions are taken.

Occupational Health and Safety Overview 2025 for Bloomage Biotech Employees

Index	Unit	2025	2024	2023
Number of work-related deaths	person	0	0	0
Number of work-related injuries	incidents	4	0	3
Workdays lost due to work-related injuries	day	392	0	53
Lost Time Injury Frequency Rate (LTIFR)	%	0.52	0	0.32

Chemical Safety Management and Control

We strictly comply with relevant laws and regulations such as the *Work Safety Law of the People's Republic of China*, and the *Regulations on the Safety Administration of Hazardous Chemicals*. We have established and continuously improved internal systems including the *Hazard Identification and Assessment System*, the *Highly Toxic Chemicals Management System*, the *Chemicals Management System*, and the *Precursor Chemicals and Explosive-Prone Chemicals Management System*. We require that all activities involving chemicals at our production bases (including procurement, storage, requisition, use, handling, and disposal, as well as operations involving precursor and explosive chemicals) must strictly adhere to these policies and be subject to standardized controls. Furthermore, we implement rigorous chemical risk identification, assessment, and emergency management procedures, integrating them into daily operations to minimize the consequences of any incidents.

Risk Identification and Assessment	·**Basic Chemical Risk Identification:** We collect complete information on all chemicals used, including specific components, physicochemical properties, and clear hazard information (e.g., health hazards such as skin corrosion/irritation, respiratory irritation, and environmental hazards such as toxicity to aquatic life). ·**Environmental Risk Assessment:** We conduct specialized assessments in accordance with the *HJ 611-2011 Technical Guidelines for Environmental Impact Assessment of Pharmaceutical Construction Projects*. This encompasses identification of hazardous substances and major hazard installations, investigation of incidents at similar facilities, determination of risk sources, risk prediction, development of targeted prevention and control measures, and preparation of comprehensive emergency plans. ·Biological Evaluation: In accordance with the GB/T 16886 series of standards, we conduct physicochemical information collection for medical devices/components, data gap analysis, and toxicological risk assessment, performing equivalence assessments when necessary.
Emergency Response Procedures	·**Chemical Spill Response:** In the event of a spill, all non-essential personnel are immediately evacuated. Emergency responders must wear appropriate professional protective equipment, including positive-pressure respirators and acid/alkali-resistant protective clothing. ·**Emergency Response for Personnel Health:** We have developed detailed health first-aid protocols covering emergency procedures for different exposure scenarios, ensuring sound and effective responses. ·**Incident Reporting and Drills:** Following an incident, responsible personnel at the second and third-tier departments must immediately report to their superior department and the Risk Control Management Department. We also conduct regular hazardous chemical emergency drills to enhance employees' ability to respond to emergencies. ·**Post-incident Evaluation and Improvement:** Upon conclusion of each incident response, we organize dedicated post-incident reviews to analyze causes and evaluate response effectiveness. Based on these reviews, we update emergency plans, optimize protective resource allocation, and refine training content, forming a closed-loop management process.

Occupational Health Protection

We firmly believe that excellent safety performance and comprehensive employee well-being stem not only from systematic safety assurance but also from a strong safety culture and proactive health management. We integrate systematic occupational health protection with safety culture development, safeguarding employees' physical and mental well-being through policies, personal protection, and health care initiatives.

We strictly comply with relevant laws and regulations, including the *Law of the People's Republic of China on the Prevention and Control of Occupational Diseases*, and have developed the *Occupational Health Management System* and the *Management System for Personal Protective Equipment*. Additionally, we conduct regular identification and assessment of occupational hazard factors in the workplace, and engage qualified third-party agencies for on-site sampling and testing to continuously verify the effectiveness of hazard control measures, ensuring that employees work in a safe and healthy environment.

Engineering Controls	·We employ a combination of engineering measures including isolation, segregated operations, ventilation, dust removal, noise reduction, and enclosed and piped production equipment, to reduce employee exposure to occupational hazard factors.
Personal Protective Equipment (PPE) Provision and Management	·We provide employees with PPE that meets national standards, including earplugs/earmuffs, safety helmets, masks, and gas masks, and supervise proper usage. ·We conduct regular and ongoing inspections and maintenance of PPE, with damaged or ineffective items promptly replaced and records properly retained. ·For high-risk positions, we enhance protection by optimizing operation methods and reasonably shortening exposure duration, reducing occupational health risks at the source.
Occupational Health Training and Education	·We organize regular specialized occupational health training for all employees, disseminating knowledge on occupational disease prevention and enhancing employees' health protection awareness and self-care capabilities. For employees exposed to occupational disease hazards, pre-job, on-the-job and post-employment occupational health examinations are conducted. Employees are informed of the examination results and health recommendations, enabling dynamic monitoring of health changes.
Equipment and Operational Safety Support	·We strengthen mechanical equipment safety management, conducting planned maintenance and condition inspections (e.g., quarterly maintenance) to reduce occupational health risks such as noise and leakage caused by equipment abnormalities, thereby improving on-site safety.

Beyond traditional occupational disease prevention, we also address musculoskeletal disorders resulting from repetitive operations. We continuously promote automation initiatives to replace manual labor and the application of auxiliary handling equipment at all production bases. For example, we have introduced robotic arms for palletizing operations in Chaohu and Hainan, and utilize AGVs (Automated Guided Vehicles) or manual carts to replace manual heavy lifting, reducing employees' physical strain and repetitive operation risks.

In 2025, we achieved our annual occupational health protection objectives, with overall performance meeting expectations and demonstrating positive progress. Key achievements include:

- Compliance rate for occupational hazard factor testing: 100%
- Occupational health examination coverage: 100%
- Completion rate for the design, construction, and commissioning of occupational disease prevention facilities in new, modified, and expanded projects: 100%

Community Care and Contribution

Bloomage Biotech firmly believes that a company's sustainable development is inseparable from the prosperity of the communities in which it operates. Through our long-standing "In Cloud" public welfare campaign, we continuously explore opportunities in rural revitalization, healthcare access, and cultural preservation. We are committed to empowering local industries through technology, enhancing community well-being, and improving the lives of rural residents.

▶ Case: Supporting Rural Revitalization with Technology - the Chinese Pear Story

Bloomage Biotech, taking the Chinese pear (Pyrus ussuriensis Maxim) – a species endemic to Linxia Prefecture, Gansu Province – as the core link, completed five years of dedicated R&D efforts and launched Runlanxin, a science-based skincare brand, in 2025 leveraging synthetic biology technology.

The story of this brand began with the Company's attention to the Chinese pear (Pyrus ussuriensis Maxim), a unique plateau fruit native to Linxia, during a public welfare project. This ancient species is not only a key carrier of Linxia's regional farming culture, but also demonstrates remarkable resilience in the harsh plateau environment of drought and intense UV radiation. Yet it has long faced the dilemma of insufficient development and utilization, a short industrial chain, and low added value, with its resource advantages never effectively translated into industrial value. To address this challenge, the Company actively responded to the national rural revitalization strategy and explored a sustainable development path of "Technology Empowerment + Industry-Driven Farmer Support". Through in-depth development of the Chinese pear via microbial biomimetic fermentation technology, the Company successfully developed the highly active ingredient "Chinese Pear Ferment Extract", which significantly enhances the concentration and diversity of the fruit's natural active components, transforming this characteristic plateau agricultural product into a high value-added biotech raw material.

In terms of the implementation of industrial transformation, two cosmetic ingredients developed from the Chinese pear have completed filing with the National Medical Products Administration (NMPA), namely Pyrus ussuriensis Maxim Powder (NMPA Filing No. 20250042) and Hanseniaspora uvarum/Pyrus ussuriensis Maxim Ferment Filtrate (NMPA Filing No. 20250051). Leveraging the core antioxidant and anti-photoaging properties of these ingredients, the Company developed the Runlanxin brand with the core philosophy of "Rooted in Place, in Sync with Nature", created targeted skincare solutions tailored to the arid, high-UV environment of Northwest China, and brought Linxia's distinctive plateau resources into the public consumer market through science-based skincare products.

Leveraging a multi-faceted framework of "Cultural Promotion, Technology Empowerment and Industrial Transformation", the

Company has developed a sustainable cooperation model of "R&D in the East, Transformation in the West" and "Markets in the East, Bases in the West", pioneering an innovative approach to technology-enabled rural revitalization. This model has effectively addressed the widespread challenge facing unique local resources in remote regions: high-quality produce fails to command premium prices, paired with underdeveloped deep processing capabilities. With industrial development as its core vehicle, the initiative has not only driven the broad spread of Linxia's distinctive local culture and intangible cultural heritage, but also delivered a step-change in agricultural product added value via biotechnology. This has spurred the upgrading of local industries and steady income growth for farming households, ultimately delivering the coordinated development of cultural preservation and economic revitalization, and forging a replicable, sustainable path for business for good and inclusive common development.

Runlanxin Product Line

▶ Case: 15 Years of "In Cloud" Public Welfare Campaign: A Longstanding Commitment from Cultural Preservation to Industrial Synergy

In December 2025, "In Cloud" public welfare campaign, a public welfare brand of Bloomage Biotech, celebrated its fifteenth anniversary milestone with the charity exhibition and performance themed with "Discover Gansu: The Bloom of Life" at the Beijing Times Art Museum. The event brought together intangible cultural heritage inheritors from across Gansu, presenting over a dozen forms of indigenous art. Through a stage language combining strength with subtlety, the performances captured Gansu's unique cultural character, at once majestic and delicate. Since its launch in 2011, this campaign has covered a cumulative total of over 170,000 kilometers through its on-the-ground operations. It has built deep connections with more than 400 inheritors of ethnic culture and intangible cultural heritage from 41 ethnic groups. Through the showcase and promotion of intangible cultural heritage art, the campaign has continuously raised public awareness and recognition of the preservation and inheritance of China's ethnic culture.

Charity Exhibition and Performance Themed with "Discover Gansu: The Bloom of Life"

Beyond our business operations, we are deeply committed to public welfare initiatives and social responsibility. We actively engage in community care, rural revitalization, support for women and children, promotion of sports and wellness, and public education in science, delivering meaningful social impact through diverse, professionally executed programs that reflect our commitment to giving back.

▶ Case: Multi-Faceted Public Welfare Initiatives Drive Community Development at Jinan Production Base

In 2025, Bloomage Biotech actively fulfilled our corporate citizenship responsibilities through sustained investment in social welfare initiatives, including material donations, establishment of special funds, and charitable activities. In response to the national call for East-West collaboration, we donated over CNY 1.0213 million in materials to the Women's Federations of Linxia Prefecture and Linxia County in Gansu Province. These funds are dedicated to supporting local women's and children's development, strengthening the development of community-level women's federation organizations, and enabling care services. For localized public welfare efforts, our Jinan Production Base, under the guidance of the Jinan High-tech Zone Charity Federation, established the "Bloomage Special Charitable Fund" focusing on key areas such as educational support and rural revitalization, planning and implementing a series of charitable programs. Throughout the year, the base also organized four "Charity Sale" events, encouraging employee participation and channeling collective goodwill toward positive impact.

Jinan Production Base Donates to Linxia and Establishes Charitable Fund

▶ Case: QuadHA Champions Sports & Wellness Initiatives with Professional Care

QuadHA, a brand under Bloomage Biotech, actively champions sports and wellness initiatives while advancing public health literacy. By supporting athletic events and implementing health-focused programs, it promotes an active lifestyle and advocates for scientifically grounded health concepts. In the realm of sports and wellness, it has sponsored a total of 28 outdoor events, placing "energy" at the core of its mission, empowering athletes to push their limits and encouraging science-based approaches to fitness and healthy living. On the health and professional front, it focuses on health advocacy and industry knowledge sharing. It has contributed over 340,600 product units to hospital health services, industry association exchanges, and public health experience initiatives. Through these efforts, the brand leverages its professional expertise to champion health aesthetics and elevate public health awareness.

QuadHA Supports Sports & Wellness Activities and Public Science Education

▶ Case: Caring Through Innovation: Bloomage Biotech's Support for Persons with Disabilities

Bloomage Biotech has long believed that a company's value derives from society and should be returned to society. On occasions such as the National Day of Helping Persons with Disabilities and the International Day of Persons with Disabilities, we have carried out a series of care activities in local communities, translating our professional health expertise into genuine warm support for persons with disabilities. At these events, the attentive service and sincere interactions of our volunteer teams were widely appreciated by individuals with disabilities and their families within the community.

Bloomage Biotech participated in the "Care Without Limits" Public Welfare Initiative Series

▶ Case: Bringing Warmth to Neighbors in Need: Bloomage Biotech's Winter Charity Initiative

Bloomage Biotech actively participated in the community care initiative organized by the Wangjing Sub-district Disability Persons' Federation in Beijing's Chaoyang District. Our employee volunteers visited local communities, delivering thoughtfully prepared care packages to families with special needs. Each package contained not only practical daily essentials but also our signature wellness products, offering tangible care tailored to residents' winter needs. Through face-to-face conversations and warm interactions, our volunteers shared health knowledge and genuine concern, demonstrating corporate social responsibility through meaningful action and contributing to a more compassionate and inclusive community.

Bloomage Biotech Winter Charity Initiative for Persons with Disabilities

National Employment Assistance Month & Chinese New Year Charity Event Organized at Bajiao Sub-district, Shijingshan District, Beijing

Supported Employment Base Establishment & Chinese New Year Appreciation Event Organized at Yanshan Xingcheng Sub-district, Fangshan District, Beijing

Disability Employment Support Initiative Organized at Guangwai Sub-district, Xicheng District, Beijing

Employment Support Initiatives of Bloomage Biotech

Index of Indicators

SSE Sustainability Report Disclosure Guidelines

Dimension	Disclosure Topics	Section/Index
Environmental	Response to climate change	Response to Climate Change and Energy Management
	Pollutant Emissions	Pollutant Emissions and Waste Management
	Waste Management	Pollutant Emissions and Waste Management
	Ecosystem and Biodiversity Conservation	Biodiversity Assessment
	Energy Utilization	Response to Climate Change and Energy Management
	Water Utilization	Resource Utilization and Circular Economy
	Circular Economy	Resource Utilization and Circular Economy
Social	Rural Revitalization	Community Care and Contribution
	Social Contribution	Community Care and Contribution
	Innovation-Driven Development	R&D Innovation
	Ethics in Technology	R&D Innovation
	Supply Chain Security	Sustainable Supply Chain Management
	Equal Treatment of Small and Medium-sized Enterprises	During the period, the Company's balance of accounts payable (including notes payable) remained under CNY 30 billion, accounting for less than 50% of total assets. Furthermore, no instances of overdue payments to SMEs were identified. Therefore, this topic is not applicable.
	Product and Service Safety and Quality	Quality Management, Pharmacovigilance and Adverse Reactions, Chemical Ingredient Management, Customer Services and Rights Protection
	Data Security and Client Privacy Protection	Intelligent Technology Empowerment and AI Security
	Employees	Fair Employment and Employee Rights, Employee Development and Growth, Employee Care and Benefits, Work Safety and Occupational Health Protection
Governance Related to Sustainable Development	Due Diligence Investigation	Sustainable Development Management System, Compliance and Internal Control Risk Management
	Stakeholder Engagement	Stakeholder Engagement and Double Materiality Assessment
	Anti-Commercial Bribery and Anti-Corruption	Business Ethics
	Anti-Unfair Competition	Business Ethics

GRI Index

GRI Standard	Disclosure	Section
GRI 2: General Disclosures	2-1 Organizational details	About This Report, About Bloomage Biotech
	2-2 Entities included in the organization's sustainability reporting	About This Report
	2-3 Reporting period, frequency and contact point	About This Report
	2-4 Restatements of information	ESG Key Performance Tables
	2-5 External assurance	/
	2-6 Activities, value chain and other business relationships	About This Report, Sustainable Supply Chain Management
	2-7 Employees	Fair Employment and Employee Rights, Employee Development and Growth, Employee Care and Benefits, Work Safety and Occupational Health Protection
	2-8 Workers who are not employees	Work Safety and Occupational Health Protection, Sustainable Supply Chain Management

GRI Standard	Disclosure	Section
	2-9 Governance structure and composition	Corporate Governance
	2-10 Nomination and selection of the highest governance body	Corporate Governance
	2-11 Chair of the highest governance body	Corporate Governance
	2-12 Role of the highest governance body in overseeing the management of impacts	Corporate Governance
	2-13 Delegation of responsibility for managing impacts	Corporate Governance
	2-14 Role of the highest governance body in sustainability reporting	Sustainable Development Management System
	2-15 Conflicts of interest	Business Ethics
	2-16 Communication of critical concerns	Stakeholder Engagement and Double Materiality Assessment
	2-17 Collective knowledge of the highest governance body	Corporate Governance
	2-18 Evaluation of the performance of the highest governance body	Corporate Governance
	2-19 Remuneration policies	Corporate Governance
	2-20 Process to determine remuneration	Corporate Governance
	2-21 Annual total compensation ratio	/
	2-22 Statement on sustainable development strategy	Sustainable Development Management System
	2-23 Policy commitments	Corporate Governance, Sustainable Development Management System, Compliance and Internal Control Risk Management, Business Ethics, Network Information Security and Data Privacy, Environmental Compliance Management, Employee Development and Growth
	2-24 Embedding policy commitments	Corporate Governance, Sustainable Development Management System, Compliance and Internal Control Risk Management, Business Ethics, Network Information Security and Data Privacy, Environmental Compliance Management, Employee Development and Growth
	2-25 Processes to remediate negative impacts	Compliance and Internal Control Risk Management, Network Information Security and Data Privacy, R&D Innovation, Quality Management, Environmental Compliance Management, Response to Climate Change and Energy Management, Pollutant Emissions and Waste Management, Work Safety and Occupational Health Protection
	2-26 Mechanisms for seeking advice and raising concerns	Compliance and Internal Control Risk Management, Network Information Security and Data Privacy, R&D Innovation, Quality Management, Environmental Compliance Management, Response to Climate Change and Energy Management, Pollutant Emissions and Waste Management, Work Safety and Occupational Health Protection
	2-27 Compliance with laws and regulations	Corporate Governance, Sustainable Development Management System, Compliance and Internal Control Risk Management, Business Ethics, Network Information Security and Data Privacy, Environmental Compliance Management, Employee Development and Growth
	2-28 Membership associations	Stakeholder Engagement and Double Materiality Assessment
	2-29 Approach to stakeholder engagement	Stakeholder Engagement and Double Materiality Assessment
	2-30 Collective bargaining agreements	Fair Employment and Employee Rights
GRI 3: Material Topics	3-1 Process to determine material topics	Stakeholder Engagement and Double Materiality Assessment
	3-2 List of material topics	Stakeholder Engagement and Double Materiality Assessment
	3-3 Management of material topics	Stakeholder Engagement and Double Materiality Assessment
GRI 201: Economic Performance	201-1 Direct economic value generated and distributed	Economic Performance
	201-2 Financial implications and other risks and opportunities due to climate change	Response to Climate Change and Energy Management
	201-3 Defined benefit plan obligations and other retirement plans	Employee Care and Benefits
	201-4 Financial assistance received from government	/
GRI 202: Market Presence	202-1 Ratios of standard entry level wage by gender compared to local minimum wage	Fair Employment and Employee Rights, Social Performance
	202-2 Proportion of senior management hired from the local community	Corporate Governance, Fair Employment and Employee Rights
GRI 203: Indirect Economic Impacts	203-1 Infrastructure investments and services supported	/
	203-2 Significant indirect economic impacts	Community Care and Contribution
GRI 204: Procurement Practices	204-1 Proportion of spending on local suppliers	/
GRI 205: Anti-corruption	205-1 Operations assessed for risks related to corruption	Business Ethics
	205-2 Communication and training about anti-corruption policies and	Business Ethics

GRI Standard	Disclosure	Section
	procedures	
	205-3 Confirmed incidents of corruption and actions taken	Business Ethics
GRI 206: Anti-Competitive Behavior	206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices	Business Ethics
GRI 207: Tax	207-1 Approach to tax	/
	207-2 Tax governance, control, and risk management	/
	207-3 Stakeholder engagement and management of concerns related to tax	/
	207-4 Country-by-country reporting	/
GRI 301: Materials	301-1 Materials used by weight or volume	Resource Utilization and Circular Economy
	301-2 Recycled input materials used	Resource Utilization and Circular Economy
	301-3 Reclaimed products and their packaging materials	Resource Utilization and Circular Economy
GRI 302: Energy	302-1 Energy consumption within the organization	Response to Climate Change and Energy Management, Resource Utilization and Circular Economy
	302-2 Energy consumption outside of the organization	Response to Climate Change and Energy Management, Resource Utilization and Circular Economy
	302-3 Energy intensity	Response to Climate Change and Energy Management, Resource Utilization and Circular Economy
	302-4 Reduction of energy consumption	Response to Climate Change and Energy Management, Resource Utilization and Circular Economy
	302-5 Reductions in energy requirements of products and services	Response to Climate Change and Energy Management, Resource Utilization and Circular Economy
GRI 303: Water and Effluents	303-1 Interactions with water as a shared resource	Resource Utilization and Circular Economy
	303-2 Management of water discharge-related impacts	Pollutant Emissions and Waste Management
	303-3 Water withdrawal	Resource Utilization and Circular Economy
	303-4 Water discharge	Pollutant Emissions and Waste Management
	303-5 Water consumption	Resource Utilization and Circular Economy
GRI 304: Biodiversity	304-1 Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas	Biodiversity Assessment
	304-2 Significant impacts of activities, products and services on biodiversity	Biodiversity Assessment
	304-3 Habitats protected or restored	Biodiversity Assessment
	304-4 IUCN Red List species and national conservation list species with habitats in areas affected by operations	Biodiversity Assessment
GRI 305: Emissions	305-1 Direct (Scope 1) GHG emissions	Response to Climate Change and Energy Management
	305-2 Energy indirect (Scope 2) GHG emissions	Response to Climate Change and Energy Management
	305-3 Other indirect (Scope 3) GHG emissions	Response to Climate Change and Energy Management
	305-4 GHG emissions intensity	Response to Climate Change and Energy Management
	305-5 Reduction of GHG emissions	Response to Climate Change and Energy Management
	305-6 Emissions of ozone-depleting substances (ODS)	/
	305-7 Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant air emissions	Pollutant Emissions and Waste Management
GRI 306: Waste	306-1 Waste generation and significant waste-related impacts	Pollutant Emissions and Waste Management
	306-2 Management of significant waste-related impacts	Pollutant Emissions and Waste Management
	306-3 Waste generated	Pollutant Emissions and Waste Management
	306-4 Waste diverted from disposal	Pollutant Emissions and Waste Management
	306-5 Waste directed to disposal	Pollutant Emissions and Waste Management
GRI 308: Supplier Environmental Assessment	308-1 New suppliers that were screened using environmental criteria	Sustainable Supply Chain Management
	308-2 Negative environmental impacts in the supply chain and actions taken	Sustainable Supply Chain Management
GRI 401: Employment	401-1 New employee hires and employee turnover	Social Performance
	401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees	Employee Care and Benefits
	401-3 Parental leave	Employee Care and Benefits
GRI 402: Labor/Management Relations	402-1 Minimum notice periods regarding operational changes	/
GRI 403: Occupational Health and Safety	403-1 Occupational health and safety management system	Work Safety and Occupational Health Protection
	403-2 Hazard identification, risk assessment, and incident investigation	Work Safety and Occupational Health Protection
	403-3 Occupational health services	Work Safety and Occupational Health Protection
	403-4 Worker participation, consultation, and communication on occupational health and safety	Work Safety and Occupational Health Protection

GRI Standard	Disclosure	Section
	403-5 Worker training on occupational health and safety	Work Safety and Occupational Health Protection
	403-6 Promotion of worker health	Work Safety and Occupational Health Protection
	403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	Work Safety and Occupational Health Protection
	403-8 Workers covered by an occupational health and safety management system	Work Safety and Occupational Health Protection
	403-9 Work-related injuries	Work Safety and Occupational Health Protection
	403-10 Work-related ill health	Work Safety and Occupational Health Protection
GRI 404: Training and Education	404-1 Average hours of training per year per employee	Employee Development and Growth
	404-2 Program for upgrading employee skills and transition assistance programs	Employee Development and Growth
	404-3 Percentage of employees receiving regular performance and career development reviews	Employee Development and Growth
GRI 405: Diversity and Equal Opportunity	405-1 Diversity of governance bodies and employees	Fair Employment and Employee Rights
	405-2 Ratio of basic salary and remuneration of women to men	Fair Employment and Employee Rights
GRI 406: Non-discrimination	406-1 Incidents of discrimination and corrective actions taken	Fair Employment and Employee Rights
GRI 407: Freedom of Association and Collective Bargaining	407-1 Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk	Fair Employment and Employee Rights
GRI 408: Child Labor	408-1 Operations and suppliers at significant risk for incidents of child labor	Sustainable Supply Chain Management, Fair Employment and Employee Rights
GRI 409: Forced or Compulsory Labor	409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor	Sustainable Supply Chain Management, Fair Employment and Employee Rights
GRI 410: Security Practices	410-1 Security personnel trained in human rights policies or procedures	Work Safety and Occupational Health Protection
GRI 411: Rights of Indigenous Peoples	411-1 Incidents of violations involving rights of indigenous peoples	/
GRI 413: Local Communities	413-1 Operations with local community engagement, impact assessment, and development programs	Community Care and Contribution
	413-2 Operations with significant actual and potential negative impacts on local communities	Community Care and Contribution
GRI 414: Supplier Social Assessment	414-1 New suppliers that were screened using social criteria	Sustainable Supply Chain Management
	414-2 Negative social impacts in the supply chain and actions taken	Sustainable Supply Chain Management
GRI 415: Public Policy	415-1 Political contributions	/
GRI 416: Customer Health and Safety	416-1 Assessment of the health and safety impacts of product and service categories	Customer Services and Rights Protection
	416-2 Incidents of non-compliance concerning the health and safety impacts of products and services	Customer Services and Rights Protection
GRI 417: Marketing and Labeling	417-1 Requirements for product and service information and labeling	Customer Services and Rights Protection
	417-2 Incidents of non-compliance concerning product and service information and labeling	Customer Services and Rights Protection
	417-3 Incidents of non-compliance concerning marketing communications	Customer Services and Rights Protection
GRI 418: Customer Privacy	418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data	Customer Services and Rights Protection

IFRS S2 Recommended Disclosure Index

Suggested Disclosure		Section
Governance	The governance body (which can include the board of directors, a committee, or an equivalent governing body) or individual responsible for overseeing climate-related risks and opportunities	Response to Climate Change and Energy Management
	The role of the Management in the governance processes, controls, and procedures for monitoring, managing, and overseeing climate-related risks and opportunities	Response to Climate Change and Energy Management
Strategy	Climate-related risks and opportunities that could reasonably be expected to affect the entity's prospects	Response to Climate Change and Energy Management
	The current and anticipated effects of climate-related risks and opportunities on the entity's business model and value chain	Response to Climate Change and Energy Management
	The effects of climate-related risks and opportunities on the entity's strategy and decision-making, including information about its climate-related transition plan	Response to Climate Change and Energy Management
	The effects of climate-related risks and opportunities on the entity's financial position, financial performance, and cash flows for the reporting period, and the anticipated effects on the entity's financial position, financial performance, and cash flows over the short, medium,	Response to Climate Change and Energy Management

Suggested Disclosure		Section
	and long term, with considerations given to how climate-related risks and opportunities are included in the entity's financial planning	
	The resilience of the entity's strategy and its business model to climate-related changes, developments, and uncertainties, with consideration given to the climate-related risks and opportunities identified by the entity	Response to Climate Change and Energy Management
Risk Management	The processes and related policies used by the entity for identifying, assessing, prioritizing, and monitoring climate-related risks	Response to Climate Change and Energy Management
	The processes used by the entity for identifying, assessing, prioritizing, and monitoring climate-related opportunities, including information on whether and how the entity uses climate-related scenario analysis to identify climate-related opportunities	Response to Climate Change and Energy Management
	The extent to which the processes for identifying, assessing, prioritizing, and monitoring climate-related risks and opportunities are integrated into the entity's overall risk management process, and how they are integrated and communicated	Response to Climate Change and Energy
Metrics and Targets	Information related to cross-industry metric categories	Environmental Performance
	Industry-specific metrics related to specific business models, activities, or other common characteristics of the industries in which the entity operates	Environmental Performance
	The goals set by the entity to mitigate or adapt to climate-related risks or capitalize on climate-related opportunities, and any goals required by law or regulation, including the metrics used by the governance body or the Management to measure progress against these goals	Environmental Performance

GHG Verification Statement

BUREAU VERITAS

Bureau Veritas Certification

Greenhouse Gases Verification Opinion

is awarded to

BLOOMAGE BIOTECHNOLOGY CORP., LTD.

Bureau Veritas Certification (Beijing) Co., Ltd. was engaged to conduct an independent verification of the greenhouse gases (GHG) emissions reported by BLOOMAGE BIOTECHNOLOGY CORP., LTD. for the period stated below. This verification opinion applies to the related information included within the scope of work described below.

Boundaries covered by the verification:

- Verification site name: BLOOMAGE BIOTECHNOLOGY CORP., LTD.
- Verification site address:

  No.678 Tianchen St.,High-Tech Development Zone, Jinan, Shandong Province, China（BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan No.1 Factory Zone）

  No.3333, Middle of Century Avenue, High-Tech Development Zone, Jinan, Shandong Province, China（BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan No.2 Factory Zone）

  No.2001, Dazheng Road, High-Tech Development Zone, Jinan, Shandong Province, China（BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan No.3 Factory Zone）

  No.1 Zhinuhe Road, Dongying District, Dongying City, Shandong Province, China（DONGYING FIRST BIOCHEM INDUSTRIAL Co., Ltd. Dongying Company）

  No.33, Fangyi Road, Central District,Tianjin Economic and Technological Development Zone, Tianjin City, China（BLOOMAGE BIOTECH(TIANJIN) Co., Ltd. Tianjin Company）

  No.8 Zhenxing Road, Chaohu Economic Development Zone, Anhui Province, China（ANHUI LEMEIDA BIOTECHNOLOGY Co., Ltd. Chaohu Company）

  No.33 Ankang Street, Mei'an Science and Technology New City, Xiuying District, Haikou City, Hainan Province, China (BLOOMAGE BIOTECH(HAINAN) Co., Ltd. Hainan Company)

  Room 1013-1016, 10th Floor, Building 1, Innovation and Entrepreneurship Center, No. 31 Dongfeng Road, Xiangtan Economic and Technological Development Zone, Xiangtan City, Hunan Province, China (BLOOMAGE BIOTECH(XIANGTAN) Co., Ltd. Xiangtan Company)
- Reporting period covered: 01/01/2025 to 31/12/2025

Organizational boundaries: Activities and facilities of Jinan No.1 Factory Zone、Jinan No.2 Factory Zone、Jinan No.3 Factory Zone、Dongying Company、Tianjin Company、Chaohu Company、Hainan Company 、Xiangtan Company of BLOOMAGE BIOTECHNOLOGY CORP., LTD. under operational control approach.

Reporting boundaries: Direct GHG emissions generated in production of bioactive material, medical terminal products, functional skincare products, etc and related management activities within the organizational boundaries, as well as significant indirect greenhouse gases emissions.

Emissions data verified under reporting boundaries:

- Category 1: Direct GHG emissions: 25,904.30 tCO_2e
- Category 2: Indirect GHG emissions from imported energy (location-based): 78,066.81 tCO_2e

  Indirect GHG emissions from imported energy (market-based): 71,488.11 tCO_2e
- Category 3: Indirect GHG emissions from transportation: 14,347.85 tCO_2e
- Category 4: Indirect GHG emissions from products used by organization: 77,198.53 tCO_2e

BUREAU VERITAS

Bureau Veritas Certification

- Category 5: Indirect GHG emissions associated with the use of products from the organization: Non-significant indirect emissions and not quantified
- Category 6: Indirect GHG emissions from other sources: Non-significant indirect emissions and not quantified

  Total quantified emissions(location-based): 195,517.49 tCO_2e

  Total quantified emissions(market-based): 188,938.78 tCO_2e

Limitations and exclusions: Excluding other non-significant indirect GHG emissions

GHG verification protocol used to conduct the verification:

- ISO 14064-1:2018 Greenhouse gases - Part 1: Specification with guidance at the organization level for quantification and reporting of greenhouse gas emissions and removals
- ISO 14064-3:2019 Greenhouse gases - Part 3: Specification with guidance for the verification and validation of greenhouse gas statements

Level of assurance:

- Reasonable assurance

GHG verification methodology:

- Interview for relevant personnel;
- Review of the documentary evidence;
- Evaluation of the methodology and information systems for data collection, aggregation, analysis and review;
- Audit of sampled sites and data to verify source.

Verification conclusion:

Based on the verification process and findings, the GHG emission data in the GHG inventory report from BLOOMAGE BIOTECHNOLOGY CORP., LTD. is in compliance with ISO 14064-1:2018 Greenhouse gases - Part 1: Specification with guidance at the organization level for quantification and reporting of greenhouse gas emissions and removals.

Statement of independence, impartiality and competence:

Bureau Veritas Group is an independent professional services company that specializes in Quality, Health, Safety, Social and Environmental management with over 190 years' history in providing independent assurance services.

No member of the verification team has a business relationship with BLOOMAGE BIOTECHNOLOGY CORP., LTD. and its directors or managers beyond that required by this assignment. We conducted this verification independently and to our knowledge there has been no conflict of interest.

Bureau Veritas Group has implemented a Code of Ethics across the business to maintain high ethical standards among staff in their day-to-day business activities.

Lead verifier: Carbon HU
No.: EMICN100857A
Version No.: No.1

Verification date: 31/03/2026
Issue date: 15/04/2026

Signed on behalf of
Bureau Veritas Certification (Beijing) Co., Ltd.

Certification body address: Room 02, 9 / F, West Office Building 1, Oriental Economic and Trade City, Oriental Plaza, No.1 East Chang'an Street, Dongcheng District, Beijing, China. 100738
Further clarifications regarding the verification scope of this opinion may be obtained by consulting the organization.
To check this opinion validity please call: +86 10 59683663

ESG Key Performance Tables

Environmental Performance[14]

Indicators			Unit	2025	2024	2023
GHG[15]	Total GHG emissions (Scopes 1 and 2)	Location-based	tCO2e	103,971.11	113,510.99	100,902.09
		Market-based	tCO2e	97,392.40	109,785.94	/
	GHG emissions per unit of revenue (Scopes 1 and 2)	Location-based	tCO2e/CNY 1 million	24.76	21.14	16.61
		Market-based	tCO2e/CNY 1 million	23.19	20.44	/
	Scope 1 emissions		tCO2e	25,904.30	37,412.27	43,554.73
	Scope 2 emissions	Location-based	tCO2e	78,066.81	76,098.72	57,347.36
		Market-based	tCO2e	71,488.11	72,373.66	/
	Scope 3 emissions		tCO2e	91,546.37	183,852.39	/
Energy[16]	Natural gas		cubic meter	10,060,451	13,073,453	15,686,836
	Gasoline		litre	24,018	30,112	21,706
	Diesel oil		litre	8,871	7,934	8,939
	Purchased electricity (thermal power)		kWh	65,968,824	77,625,771	66,931,210
	Purchased renewable electricity		kWh	21,220,592	13,375,618	/
	Self-generated renewable electricity	Total amount	kWh	2,963,495	3,745,485	3,521,913
		Photovoltaic electricity generation	kWh	2,277,254	2,312,192	2,401,725
		Biogas electricity generation	kWh	686,241	1,433,293	1,120,188
	Purchased heat from fossil fuels		GJ	282,215.92	245,503.80	174,331.73
	Purchased heat from biomass fuel		GJ	119,107.91	153,263.05	38,282.69
	Total energy consumption[17]		tons of standard coal	38,312.93	42,734.83	36,811.37
	Including: Clean energy consumption		tons of standard coal	7,159.09	7,398.57	1,739.05
	Total energy consumption intensity		tons of standard coal/CNY 1 million revenue	9.12	7.96	6.06
Water[18]	Total water consumption		10,000 tons	182.58	163.83	149.33
	Water use intensity		ton/CNY 10,000 revenue	434.80	305.04	245.77
Packaging Materials[19]	Total purchase volume of packaging materials		ton	3,006.41	8,494.23	5,270.00
	Purchase volume of FSC-certified paper packaging materials		ton	160.72	1,635.00	846.00
Waste[20]	Total waste discharged		ton	7,102.82	12,204.44	10,923.55
	General industrial waste		ton	5,492.61	10,521.68	9,599.45
	Hazardous waste		ton	87.94	144.22	85.01
	Domestic waste		ton	889.10	1,184.42	581.09
	Food waste		ton	633.17	354.12	658.00
	Recycled waste		ton	3,304.38	7,125.01	7,331.00
	Non-hazardous waste emission intensity		ton/CNY 1 million revenue	1.67	2.25	1.78
	Hazardous waste emission intensity		ton/CNY 1 million revenue	0.02	0.03	0.01
Exhaust Gas[21]	Sulfur oxides		ton	2.05	1.75	2.32
	Nitrogen oxides		ton	3.91	6.22	7.46
	Volatile organic compounds		ton	1.66	3.05	3.30
Wastewater	Total volume of wastewater discharged		10,000 tons	174.60	171.54	123.85
	Chemical oxygen		ton	86.53	102.52	54.01

[14] The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. "/" indicates not applicable.

[15] Scope 1 and Scope 2 greenhouse gas emissions include emissions from the consumption of natural gas, diesel, gasoline, fugitive methane from wastewater, refrigerant charging, fire extinguishers, purchased electricity and purchased heat. Scope 3 emissions include emissions from purchased goods and services, capital goods, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, business trips, and transportation and distribution of sold products. The accounting was conducted in accordance with the *GHG Protocol: Corporate Accounting and Reporting Standard for Greenhouse Gases* and *ISO 14064-1:2018 Greenhouse Gases—Part 1: Specification with Guidance at the Organization Level for Quantification and Reporting of Greenhouse Gas Emissions or Removals*. During the reporting period, the total Scope 3 greenhouse gas emissions decreased year-on-year, mainly due to the systematic structural optimization carried out by the Company around its dermatological science innovation and transformation business and nutritional science innovation and transformation business. Meanwhile, the Company is carrying out low-carbon supply chain management, which has also had an impact on relevant greenhouse gas emissions.

[16] During the reporting period, the Company continued to optimize its energy mix. Meanwhile, driven by adjustments in production and operational activities, the consumption of natural gas, gasoline, and purchased electricity decreased significantly.

[17] During the reporting period, the Company optimized the accounting caliber of this indicator. Based on the statistics of the original fossil fuel consumption within the production and operation boundary, the Company additionally included the consumption of clean energy within the same boundary. To enhance the comparability of data across periods, the Company has completed retrospective adjustments of relevant data for 2023 and 2024 in accordance with the unified caliber for 2025.

[18] During the reporting period, the Company's overall water consumption increased, primarily due to the commissioning of new production capacity and the operation of newly constructed supporting facilities.

[19] During the reporting year, the Company conducted systematic structural optimization focusing on its innovative transformation businesses in dermatological science and nutritional science. As a result, the total procurement volume of packaging materials and the procurement volume of FSC-certified paper packaging materials both decreased compared with previous years.

[20] During the reporting period, the Company's improvements in environmental protection facilities and adjustments in production and operations resulted in significant fluctuations in most waste emission data.

[21] During the reporting period, the Company's improvements in environmental protection facilities and adjustments in production and operations resulted in significant fluctuations in most exhaust gas emission data.

Indicators		Unit	2025	2024	2023
	demand (COD)				
	Ammonia nitrogen	ton	1.11	0.80	2.03
	Total phosphorus	ton	1.28	1.04	0.79
	Total nitrogen	ton	8.64	11.23	10.10
Training on Environmental Protection and Pollution Prevention and Control	Number of training sessions	times	31	53	43
	Number of employees trained	participants	1,604	2,987	3,622
	Total training duration	hour	926	4,806	3,313

Social Performance[22]

Indicators			Unit	2025	2024	2023
Employment	Total number of employees		person	3,699	4,444	4,655
	Number of employees by gender	Male	person	1,961	2,268	2,344
		Female	person	1,738	2,176	2,311
	Number of employees by age	Aged 30 or below	person	1,588	2,205	2,568
		Aged 31 to 50	person	2,041	2,172	2,017
		Aged 51 or above	person	70	67	70
	Number of employees by rank	Senior management	person	5	8	8
		Middle management	person	162	193	663
		General staff	person	3,532	4,243	3,984
	Number of employees by geographic location	Mainland China	person	3,688	4,428	4,637
		Regions or countries outside Mainland China (including Hong Kong, Macao, and Taiwan)	person	11	16	18
Employee Diversity	Number and proportion of women in management	Female senior management (executives)	person	1	4	4
		Proportion of women in senior management	%	20.00	50.00	50.00
		Female middle management (above the manager level)	person	67	80	328
		Proportion of women in middle management	%	41.36	41.45	49.47
	Number and proportion of R&D	Number of R&D employees	person	860	920	926
		Proportion of R&D employees	%	23.25	20.70	19.87
		Number of female R&D employees	person	533	577	576
		Proportion of female R&D employees	%	61.98	62.72	62.20
	Number of employees by physical condition	General staff	person	3,688	4,427	4,643
		Disabled employees	person	11	17	12
	Number of employees by ethnic group	Number of employees of ethnic minorities	person	104	120	131
		Number of employees of non-ethnic minorities	person	3,595	4,324	4,524
	Number of employees by education background	Doctor's degree and Professor	person	32	43	36
		Master's degree	person	552	633	654
		Bachelor's degree	person	1,383	1,699	1,712
		Below bachelor's degree	person	1,732	2,069	2,253
Employee Turnover Rate	Total employee turnover rate		%	29.30	28.75	28.46
	Turnover rate by gender	Male	%	24.92	26.80	-
		Female	%	34.03	30.76	-
	Turnover rate by age	Aged 30 or below	%	33.85	38.51	-
		Aged 31 to 50	%	25.40	18.00	-
		Aged 51 or above	%	23.36	17.52	-
	Turning rate by region	Mainland China	%	29.28	28.75	-
		Regions or countries outside Mainland China (including Hong Kong, Macao, and Taiwan)	%	37.04	29.41	-
Employee Training	Average training hours by gender	Male	hour	41.28	29.17	22.19
		Female	hour	23.37	24.16	23.15
	Average training hours by rank	The Management	hour	23.46	32.52	38.52
		General staff	hour	35.96	25.84	18.49
	Total number of employees trained		%	100	100	100
	Average training hours of employees		hour	34.72	22.83	26.61
	Total investment in employee training		CNY 10,000	253.01	267.25	506.57
Employee Development	Proportion of employees receiving performance appraisals		%	100	100	100
Internal	Total number of promotions		person	231	322	/

[22] The symbol "-" indicates that the item is not counted, while the symbol "/" indicates that the item is not applicable.

Indicators			Unit	2025	2024	2023
Promotion	Internal promotion rate		%	6.24	7.25	/
	Number of promotions by gender	Number of male employees promoted internally	person	118	114	/
		Proportion of male employees promoted internally	%	51.08	35.40	/
		Number of female employees promoted internally	person	113	208	/
		Proportion of female employees promoted internally	%	48.92	64.60	/
	Number of promotions by rank	senior management	person	2	4	/
		Proportion of senior management promoted internally	%	0.87	1.24	/
		Middle management	person	9	25	/
		Proportion of middle management promoted internally	%	3.90	7.76	/
	Number of promotions by age	Aged 30 or below	person	88	172	/
		Aged 31 to 50	person	142	147	/
		Aged 51 or above	person	1	3	/
Employee Compensation	Unadjusted average gender pay gap[23]		%	-8.75	-7.71	-
	Ratio of average wages by gender		%	91.96	92.84	-
	Median wage ratio by gender		%	77.07	78.46	-
Employee Benefits	Proportion of employees' social security contributions		%	100	100	100
	Supplementary medical insurance coverage rate for regular employees		%	100	100	100
	Physical examination coverage rate for regular employees		%	100	100	100
Employee Health and Safety	Occupational health and safety training	Number of occupational health and safety training sessions	times	839	1,755	640
		Number of employees trained on occupational health and safety	participants	18,105	34,080	16,675
		Safety education coverage rate for suppliers, contractors, etc.	%	100	100	100
		Total hours of occupational health and safety training	hour	2,810	36,629	23,533
	Work-related injury incidents	Number of work-related injuries	incidents	4	0	3
		Number of work-related deaths	person	0	0	0
		Number of working days lost due to work-related injuries	day	392	0	53
		Lost time injury frequency rate (LTIFR)	%	0.52	0	0.32
	Investment in occupational health and safety	Total investment	CNY 10,000	804.27	1,082.22	935.05
		Investment in employee safety liability insurance	CNY 10,000	9.84	13.52	13.76
	Safety audit	Internal safety audit rate	%	100	100	100
		Rectification rate of safety audit	%	100	100	100
Intellectual Property	Cumulative number of intellectual property rights	Cumulative number of invention patents authorized	item	464	392	296
		Cumulative number of design patents authorized	item	96	73	58
		Cumulative number of utility model patents authorized	item	131	122	98
		Cumulative number of trademark rights authorized	item	5,569	5,057	4,346
		Cumulative number of software and copyright authorizations	item	121	113	100
		Cumulative number of invention patents applied to main business	item	464	392	296
	Cumulative number of intellectual property authorizations by region	Cumulative number of domestic patent authorizations	item	667	572	445
		Cumulative number of overseas patent authorizations	item	24	15	7
		Cumulative number of domestic trademark	item	4,538	4,180	3,749

[23] Unadjusted average gender pay gap = (average male pay - average female pay) ÷ average male pay x 100%. Ratio of average wages by gender is the difference in average hourly wages between full-time male employees and full-time female employees, expressed as a ratio of male/female. Median wage ratio by gender is the difference in median hourly wages between full-time male employees and full-time female employees, expressed as a ratio of male/female.

Indicators			Unit	2025	2024	2023
		authorizations				
		Cumulative number of overseas trademark authorizations	item	1,031	877	597
	Annual number of intellectual property rights	Annual number of invention patent authorizations	item	72	96	87
		Annual number of design patent authorizations	item	23	15	16
		Annual number of utility model patent authorizations	item	9	24	12
		Annual number of trademark right authorizations	item	512	711	585
		Annual number of software and work copyright authorizations	item	8	13	17
		Annual number of invention patents authorized for main business	item	72	96	87
	Annual number of property intellectual property authorizations by region	Annual number authorizations of domestic patent	Items	95	127	112
		Annual number of overseas patent authorizations	Items	9	8	3
		Annual number of domestic trademark authorizations	Items	358	431	530
		Annual number of overseas trademark authorizations	Items	154	280	55
Suppliers	Total number of suppliers		entities	489	1,339	712
	Number of suppliers by region	Mainland China	entities	480	1,333	601
		Hong Kong, Macao, and Taiwan, China	entities	1	1	2
		Overseas countries or regions	entities	8	5	109
	Signing rate of compliance commitment letters of suppliers of production materials		%	100	100	94
Cybersecurity	Network and data security violations		incidents	0	0	0

Indicators		Unit	2025	2024	2023
Social Welfare	Total investment in public welfare	CNY 10,000	102.13	960.96	/

Governance Performance

Indicators		Unit	2025	2024	2023
Board Composition and Governance Overview	Number of directors	person	9	9	9
	Number of female directors in the Board	person	2	3	3
	Proportion of female directors in the Board	%	22.22	33.33	33.33
	Number of independent directors in the Board	person	3	3	3
	Proportion of independent directors in the Board	%	33.33	33.33	33.33
	Number of directors with industry experience in the Board	person	2	5	5
	Number of directors with risk management experience in the Board	person	2	6	6
	Number of directors with financial management experience in the Board	person	4	3	3
	Proportion of independent directors in the Audit Committee	%	66.67	100	100[24]
	Proportion of independent directors in the Nomination Committee	%	66.67	66.67	66.67
	Proportion of independent directors in the Remuneration and Assessment Committee	%	66.67	66.67	66.67
	Proportion of independent directors in the Strategy Committee	%	20	20	20
	Proportion of independent directors in the ESG Committee	%	66.67	66.67	66.67
	Number of the Board meetings held	times	8	5	6
	Number of the shareholders' meetings held	times	2	2	1
	Number of meetings of each committee	times	13	10	7
Special Training on	Number of compliance training sessions	times	9	3	6

[24] On December 29, 2023, the Company held the 10th Meeting of the Second Board of Directors and approved the *Proposal on Adjusting Members of the Audit Committee of the Second Board of Directors*. Upon adjustment, 100% of the Audit Committee members are independent directors.

Indicators		Unit	2025	2024	2023
Corporate Governance	Rate of personnel in key positions covered by compliance training	%	100	100	100
	Number of anti-bribery training sessions	times	1	4	2
	Rate of personnel in key positions covered by anti-bribery training	%	100	100	100

Economic Performance

Indicators	Unit	2025	2024	2023
Operating revenue	CNY 100 million	41.99	53.71	60.76
Net income attributable to parent	CNY 100 million	2.92	1.74	5.93
Total R&D investment	CNY 100 million	4.72	4.66	4.46
Proportion of R&D investment in operating revenue	%	11.24	8.68	7.35